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ABSTRACT 
Heart failure is a very common medical condition with significant mortality and 
morbidity. Patients hospitalised with heart failure are at high risk of death in the short 
term and patients with chronic heart failure in the community are also at a high risk of 
death in the medium to long term. It is difficult to accurately identify those at a higher 
risk of death as current methods of risk stratification lack both sensitivity and 
specificity. The available treatments for prevention of sudden death in patients with 
heart failure such as Implantable Cardioverter Defibrillators (ICD) are expensive and 
do not abolish the risk of sudden death completely. Hence it is necessary to improve 
risk stratification methods in patients with heart failure and identify factors predicting 
mortality in those patients with ICD protection. 
 
This thesis first describes a series of studies examining the clinical factors that predict 
increased risk of short-term mortality in patients with a recent hospitalisation for 
heart failure. These include examination of patient demographics, clinical history and 
examination, blood tests, electro-cardiographic and echo-cardiographic variables and 
medication.  Based on these variables, I have formulated a simple scoring system to 
predict short term mortality in hospitalised patients with heart failure. This score was 
validated in a prospective study of contemporary heart failure population with a 
recent hospital admission. The relationship of cholesterol and risk of death in heart 
failure was examined in detail. 
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Then, the utility of Holter monitoring and signal averaged electro cardiograms 
(SAECG) for risk stratification were examined based on the prognostic value of 
abnormalities found by these tests in patients with chronic heart failure. 
Finally patients with heart failure deemed at high risk of sudden death and had ICDs 
implanted were studied and factors predicting shocks and mortality were identified. 
Two separate studies were done, first in population who had ICDs mainly for 
secondary prevention and the second in patient population who had ICDs exclusively 
for primary prevention. 
From these studies, I have identified those clinical characteristics that are associated 
with high risk of death in patients with acute and chronic heart failure and those 
associated with death in patients with heart failure after ICD implantation. 
 
 
 
 
 
 
 
 
 4 
 CONTENTS  
Page no 
 List of Figures 13 
 List of Tables 16 
Chapter 1 Introduction 19 
1.1 Epidemiology of heart failure 19 
1.2 Mortality in heart failure 19 
1.3 Mode of death in heart failure 19 
1.3.1 Frequency of sudden death versus progressive heart failure 
death 
20 
1.3.2 Functional status and mode of death 20 
1.3.3 Predicting sudden cardiac death (SCD) in heart failure 21 
1.3.4 Risk prediction models in acute heart failure 22 
1.4 Current treatment of heart failure and impact on mode of death 22 
1.5 Implantable Cardioverter Defibrillators (ICD) 23 
1.6 Need for risk stratification 24 
1.7 Outline of this thesis 25 
1.7.1 Euro Heart Failure Survey 25 
1.7.2 Euro Heart Failure Risk Score 25 
1.7.3 Hull Life Lab programme 26 
1.7.4 ICDs in heart failure  26 
Chapter 2 Review of risk prediction models in acute heart failure derived 
from large heart failure registries 
27 
 5 
2.1 Introduction 27 
2.2 EFFECT model 28 
2.3 ADHERE model 31 
2.4 OPTIMIZE-HF model 33 
2.5 Summary 36 
Chapter 3 Methods of investigations, data handling and statistics 39 
3.1  Clinical investigations 39 
3.1.1 Electrocardiography (ECG) 39 
3.1.2 Signal averaged ECG 40 
3.1.2.1 Recording and analysis of SAECG 40 
3.1.2.2 Criteria for late potential 41 
3.1.3 Holter monitoring 41 
3.1.4 Echocardiography 42 
3.1.5 Biochemical and haematological investigations 42 
3.2 Statistical methods 43 
3.2.1 General data handling 43 
3.2.2 Standard normal distribution 43 
3.2.3 Missing values handling 43 
3.2.4 Logistic regression 44 
3.2.4.1 Predictive modelling 44 
3.2.4.2 Output from logistic regression 44 
3.2.4.3 Advantages and limitations of logistic regression 44 
3.2.5 Bootstrapping 45 
 6 
3.2.6 Log linear analysis 46 
3.2.7 Poisson Regression 46 
3.3 Summary 46 
Chapter 4 Predictors of short term mortality in heart failure – Insights 
from  the Euro Heart Failure Survey 
47 
4.1 Introduction 47 
4.2 Euro heart failure survey 47 
4.3 Methods 48 
4.3.1 Study population 48 
4.3.2 Clinical investigations 48 
4.3.2.1 ECG 48 
4.3.2.2 Echocardiography 49 
4.3.2.3 Blood tests 49 
4.3.3 Statistical analysis 49 
4.4 Results 50 
4.4.1 Death 50 
4.4.2 Clinical investigations 50 
4.4.3 Univariate analysis 51 
4.4.4 Multivariable analysis 51 
4.4.5 Derivation of risk score 54 
4.5 Discussion 60 
4.6 Limitations 64 
4.7 Conclusions 65 
 7 
Chapter 5 Validation of Euro Heart Failure score in a contemporary heart 
failure population 
      66 
5.1 Introduction 66 
5.2 Aim 66 
5.3 Patients and Methods 66 
5.4 Results 68 
5.5 Discussion 70 
5.6 Limitations 71 
5.7 Conclusions 71 
Chapter 6 Cholesterol level and risk of death in heart failure – A review 
of literature about the cholesterol paradox 
72 
6.1 Introduction 72 
6.2 Statins in coronary heart disease 72 
6.3 Statins in heart failure 73 
6.4 Pleiotropic effects of statins in patients with heart failure 74 
6.4.1 Beyond lipid lowering 74 
6.4.2 Anti-oxidant properties 74 
6.4.3 Anti-inflammatory actions 74 
6.4.4 Statin and apoptosis 79 
6.4.5 Left Ventricular function 79 
6.4.6 Anti-arrhythmic properties 80 
6.5 Advanced heart failure and cholesterol 80 
6.5.1 Reverse Epidemiology 81 
 8 
6.6 Statins and Coenzyme Q10 83 
6.7 Drug interactions 83 
6.8 Recent randomised trials of statin therapy in heart failure 84 
6.9 Conclusions 85 
Chapter 7 Cholesterol level and risk of death in heart failure –  The 
findings from Euro Heart Failure Survey                                      
87 
7.1 Introduction 87 
7.1.1 Cholesterol levels in heart failure 87 
7.1.2 Causes of low cholesterol in heart failure 87 
7.1.3 Role of statin therapy in heart failure 87 
7.2 Aims 88 
7.3 Methods 88 
7.4 Results 88 
7.4.1 Cholesterol levels 88 
7.4.2 Mortality and cholesterol level 90 
7.4.3 Cholesterol level and left ventricular systolic dysfunction 94 
7.5 Discussion 97 
7.6 Limitations 98 
7.7 Conclusions 98 
Chapter 8 ECG as a predictor of severity of heart failure – Relationship 
between repolarisation abnormalities on the surface 
electrocardiogram and severity of left ventricular systolic 
dysfunction – a report from the Euro Heart Failure survey.             
       99 
 9 
8.1 Background 99 
8.2 QT prolongation 99 
8.3 Aims 100 
8.4 Methods 100 
8.4.1 ECG analysis 101 
8.4.2 Echocardiography 102 
8.4.3 Data Analysis 102 
8.5 Results 103 
8.6 Discussion 108 
8.7 Conclusions 109 
Chapter 9 The utility of Signal Averaged ECG in risk stratification of Heart 
failure patients 
110 
9.1 Introduction 110 
9.2 Hypotheses 111 
9.3 Patients and methods 111 
9.3.1 12 lead ECG 112 
9.3.2 Signal averaged ECG 112 
9.3.2.1 Recording technique 112 
9.3.2.2 Criteria to define presence of late potentials 113 
9.3.3 Statistical analysis 113 
9.4 Results 114 
9.4.1 12 - lead ECG 114 
9.4.2 SAECG 121 
 10 
9.4.2.1 QRS duration on SAECG 121 
9.4.2.2 Late potentials on SAECG 125 
9.4.3 NT-pro BNP 127 
9.5 Discussion 127 
9.6 Limitations 136 
9.7 Conclusions 136 
Chapter 10 Relation between prevalence of arrhythmias on Holter 
monitoring and risk of death in patients with heart failure.         
137 
10.1 Background 137 
10.2 Holter monitoring in Heart Failure 138 
10.3 Aims 139 
10.4 Study population and methods 139 
10.5 Statistical methods 140 
10.6 Results 140 
10.7 Discussion 145 
10.8 Limitations 147 
10.9 Conclusions 147 
Chapter 11 Predictors of shocks and mortality in heart failure patients 
with Implantable Cardioverter-Defibrillators (ICDs) – all 
indications 
     148 
11.1 Introduction 148 
11.2 Aims 149 
11.3 Study population 149 
 11 
11.4 Methods 149 
11.5 Results 150 
11.5.1 Shocks 154 
11.5.1.1 Appropriate shocks 154 
11.5.1.2 Inappropriate shocks 155 
11.5.1.3 NYHA class and outcome 155 
11.5.2 Mortality 157 
11.6 Discussion 157 
11.7 Limitations 162 
11.8 Conclusions 162 
Chapter 12 ICDs for primary prevention – Factors associated with shocks 
and mortality in contemporary heart failure population. 
163 
12.1 Introduction 163 
12.2 Study population 163 
12.3 Aims 163 
12.4 Methods 164 
12.5 Results 164 
12.6 Discussion 171 
12.7 Limitations 172 
12.8 Conclusions 172 
Chapter 13 Improving the prognosis of heart failure – A review of the 
multi-disciplinary  approach to reduce mortality       
173 
13.1 Background 173 
 12 
13.2 Post-mortem studies in sudden death 173 
13.3 Hospitalised patients with acute decompensation of heart 
failure 
174 
13.4 Mechanistic approaches to the prevention of common causes of 
sudden death 
174 
13.4.1 Reducing sudden vascular death 176 
13.4.2 Reducing sudden arrhythmic death 176 
13.4.3 Cardiac Resynchronisation therapy (CRT) 177 
13.4.4 Implantable Cardioverter-Defibrillators 177 
13.5 Prevention of sudden death in patients with asymptomatic 
LVSD (ALSVD) 
178 
13.6 Heart failure with a normal left ventricular ejection fraction 180 
13.7 Reducing mortality in hospitalised patients with acute 
decompensated heart failure 
181 
13.7.1 Medical therapy 181 
13.7.2 Other devices in heart failure management (excl CRT/CRT-D) 181 
13.8 Developing the most effective strategy to reduce mortality 182 
Chapter 14 Conclusions 183 
 Acknowledgements 187 
 Publications from this thesis  189 
 Appendix 192 
 References 194 
 13 
                                               LIST OF FIGURES 
 Title Page no 
2.1 Predictors of in hospital mortality in the ADHERE registry – Mortality 
in derivation (D) and validation (V) cohorts. 
34 
2.2 The relationship between serum creatinine (SCr) and systolic blood 
pressure (SBP) as measured at hospital admission and in-hospital 
mortality in the OPTIMIZE –HF model. 
37 
3.1 ECG intervals 40 
4.1 Relation between cholesterol level and mortality 56 
4.2 Mortality related to cholesterol level in patients on lipid lowering 
drugs. 
57 
4.3 Relation between Euro Heart Failure Risk Score and mortality at 12 
weeks of hospital admission 
58 
6.1 Relation between cholesterol level and mortality in a cohort of 114 
patients with chronic heart failure, followed up to 3 years. 
82 
7.1 Distribution of cholesterol level in Euro Heart Failure Survey 89 
7.2 Relation between cholesterol level in quintiles and mortality within 
each quintile. 
92 
7.3 Mortality related to cholesterol level in patients on lipid lowering 93 
 14 
drugs 
7.4 Relation between cholesterol level and LV systolic dysfunction 95 
7.5 Relation between cholesterol level, LV systolic dysfunction and 
mortality 
96 
8.1 ECG intervals 101 
8.2 Relation between QRS and severity of left ventricular systolic 
dysfunction (LVSD) 
105 
8.3 Relation between QTc and severity of left ventricular systolic 
dysfunction (LVSD) 
105 
8.4 Relation between JTc and severity of left ventricular systolic 
dysfunction (LVSD) 
106 
9.1 Kaplan – Meier curve showing the relation between QRS duration (in 
tertiles) on 12 lead ECG and survival. 
120 
9.2 Bland – Altman plot showing correlation between QRS measured from 
12 lead ECG and filtered QRS measured from SAECG 
122 
9.3 Relation between severity of LV dysfunction and filtered QRS duration 
on Signal Averaged ECG.  
123 
9.4 Kaplan – Meier survival graph showing the relation between filtered 
QRS duration (in tertiles) and mortality within 5 years. 
124 
 15 
9.5 Kaplan – Meier plot showing lack of association between presence of 
late potentials on SAECG and survival. 
126 
9.6 Relation between severity of LVSD and prevalence of late potentials 
on SAECG 
128 
9.7 Relation between NT-pro BNP level and severity of LV systolic 
dysfunction on echocardiography 
129 
9.8 Kaplan - Meier survival graph showing the relation between NT pro – 
BNP level (in tertiles) and mortality within 5 years 
130 
9.9 Relation between presence of late potentials on SAECG and NT-pro 
BNP level.   
131 
9.10 Correlation between filtered QRS on SAECG and NT-pro BNP level. 132 
12.1 Kaplan – Meier survival plot showing the relation between serum 
creatinine and survival after ICD implantation. 
170 
13.1a Adjudicated causes of death in autopsied patients with a sudden 
mode of death before and after autopsy was used to determine cause 
of death. 
175 
13.1b Relation of acute coronary findings to mode of death  175 
 
 
 
 16 
LIST OF TABLES 
 Title  Page no 
2.1 The multivariable predictors of 30 day and 1 year mortality in the 
EFFECT model. 
29 
2.2 EFFECT Risk Scoring system 30 
2.3 Predictors of mortality in OPTIMIZE-HF model 35 
4.1 Univariate Analysis by binary logistic regression predicting mortality 
within 12 weeks of admission with heart failure 
52 
4.2 Multivariable analysis by binary stepwise logistic regression 
predicting mortality within 12 weeks of admission with heart failure. 
55 
 
4.3 Euro Heart Failure Score and mortality 59 
5.1 Euro Heart Failure Survey score 67 
5.2 Reason for hospital admission 68 
5.3 Details of medication 68 
5.4 Frequency distribution of Euro Heart Failure Survey score and death 
in this study population 
69 
6.1 Trials of statins and heart failure 75 
7.1 Cholesterol levels (mmol/l), treatment and survival 89 
7.2 Survival vs Lipid lowering treatment and mean cholesterol levels 90 
7.3 Relation between cholesterol levels in quintiles and mortality 91 
8.1 ECG variables related to severity of LVSD 104 
 17 
8.2 QRS and QTc prolongation predicting moderate or severe LVSD 107 
9.1 Patient characteristics of survivors compared with those who had 
died by 5 years of follow up. 
115 
9.2 Univariate predictors of mortality 117 
9.3 Multivariable predictors of mortality 118 
9.4 Relation between ECG intervals and presence of significant LVSD  119 
9.5 Relation between ECG intervals and survival at 5 years 119 
9.6 Relation between death and presence of late potentials  125 
10.1 Patient characteristics and LV function 141 
10.2 Prevalence of arrhythmias on holter monitoring 142 
10.3 Differences in clinical characteristics between patients who survived 
or died at 2 years 
143 
10.4 Univariate predictors of mortality 144 
10.5 Multivariable predictors of mortality 144 
11.1 Indications for ICD 151 
11.2 Baseline patient characteristics 152 
11.3 Details of benefit and harm from ICD 154 
11.4 Univariate predictors of appropriate shocks 156 
 18 
11.5 Univariate predictors of inappropriate shocks  156 
11.6 Univariate predictors of mortality 158 
12.1 Baseline clinical characteristics 166 
12.2 Details of reoperation after ICD implantation 168 
12.3 Complications managed conservatively 168 
12.4 Relation between ECG rhythm (prior to ICD implantation), beta 
blocker therapy and outcome 
169 
12.5 Relation between creatinine level (in quartiles) and mortality 169 
12.6 Causes of inappropriate shocks 170 
 
 
 
 
 
 
 
 
 
 
 
 19 
CHAPTER 1. INTRODUCTION 
1.1 EPIDEMIOLOGY OF HEART FAILURE 
The life-time risk of developing heart failure is one in five with little evidence of variation 
in prevalence between industrialised countries in Europe and North America.[1, 2] Heart 
failure affects 1-2% of the population, causes about 5% of medical admissions amongst 
adults and complicates a further 10-15%.[3, 4] Heart failure is usually due to left 
ventricular systolic dysfunction (LVSD) secondary to ischaemic heart disease or dilated 
cardiomyopathy. Many cases have preserved LV systolic function with clinical signs of 
heart failure. This is a poorly understood but common phenomenon, especially in elderly 
women with stiff hypertrophied ventricles.[5] The mechanism is believed to be due to 
diastolic dysfunction and it can be paroxysmal.[6] Lack of understanding may reflect the 
fact that the problem is predominantly vascular rather than cardiac in origin. 
1.2 MORTALITY IN HEART FAILURE 
Heart failure has a poor prognosis.  One third or more of patients will die within 6 months 
of diagnosis and the annual mortality amongst 6 month-survivors is 10-15%.[7] Patients 
with heart failure due to left ventricular systolic dysfunction have a worse prognosis. In 
the CHARM study, patients with LVSD had an annual mortality of 9% whereas those with 
preserved LV systolic function had an annual mortality of only 4%.[5, 7-10]  
1.3 MODE OF DEATH IN HEART FAILURE 
Most patients with heart failure will die suddenly or from progressive heart failure. More 
patients with left ventricular systolic dysfunction will die suddenly before developing heart 
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failure rather than dying subsequent to a diagnosis of heart failure.[11] The risk of dying 
from progressive heart failure is particularly high in the early period after diagnosis with 
over half of all progressive heart failure deaths in the first six months occurring within one 
month after diagnosis.[12] Sudden death has generally been perceived to be primarily an 
arrhythmic problem. Whilst this is usually the case, a substantial proportion could be due 
to other causes such as stroke or myocardial infarction. Acute myocardial infarction is 
associated with sudden cardiac death due to an arrhythmia and is also likely to precipitate 
a worsening in progressive heart failure and subsequent death. [13, 14] 
1.3.1 Frequency of sudden death versus progressive heart failure death 
Randomised clinical trial data showed that in general, sudden death constituted 50% of all 
deaths, progressive heart failure death accounting for 30% and the rest being non cardiac 
deaths, although this was not consistent.[15-23]  
1.3.2 Functional status and mode of death 
The relative importance of these modes of death varies with functional class. Patients in 
NYHA class II are more likely to die suddenly rather than progressing to end-stage heart 
failure, whereas patients with NYHA class III or IV are likely to die of progressive 
deterioration of pump failure (i.e. from a low cardiac output). In the CONSENSUS-I trial 
heart failure patients with NYHA IV symptoms had progressive heart failure as the mode 
of death in 65% of cases.[24] In the RALES study which recruited patients with severe 
symptoms in the prior six months, approximately 50% of all deaths were due to 
progressive heart failure.[25]  
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1.3.3 Prediction of sudden cardiac death (SCD) in heart failure 
Predicting sudden death in CHF patients remains a big challenge.[26-29] There is no 
reliable variable which can accurately predict the risk of sudden death. [30] Several risk 
variables (non sustained ventricular tachycardia, heart rate variability, left ventricular 
ejection fraction, ECG markers etc) have been shown to predict the risk of SCD in various 
studies done mainly in post myocardial infarction patients.[31-40] As a result, a number of 
tests have been developed but the relatively low positive predictive accuracy of these 
tests adversely affects their usefulness.[41, 42] At best, alone or in combination, these 
tests reach a positive predictive accuracy of 30%. Although this may not be a problem 
when low-cost, effective therapy free from adverse effects is possible; unfortunately this 
is not the case. Moreover many of these studies were done in the pre optimal treatment 
era when most patients were not on beta blockers and many not on ACE inhibitors.  SPECT 
(single photon emission computed tomography) has been proposed recently as a risk 
stratifying tool in patients with left ventricular ejection fraction > 35%.[43, 44] 
A study by Huikuri et al, has found that these arrhythmia risk variables, particularly the 
autonomic and standard ECG markers, have limited predictive power in identifying 
patients at risk of sudden death after acute myocardial infarction, in the beta blocking 
era.[45] It is not known whether this is applicable to all heart failure patients. Other 
studies have previously found these methods useful. It is necessary to establish whether 
these methods are useful in risk stratification for heart failure patients in the current era 
of optimal treatment with beta blockers and ACE inhibitors. 
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Recently, imaging of the cardiac sympathetic innervation with 123I-mIBG imaging has been 
found to be helpful in assessing the extent of myocardial injury and remodelling 
associated with ischemic and nonischemic cardiomyopathy, thus identifying the substrate 
associated with SCD.[46]  The criteria for clinical use are being developed and this may 
emerge as useful tool for risk stratification in the near future. 
1.3.4 Risk prediction models in acute heart failure 
In contrast to risk prediction in patients with chronic heart failure where there are 
extensive data, the prediction of risk of death during hospitalisation for acute heart failure 
has not received the same amount of attention. There are several reasons which include 
lack of consistent definition of acute decompensated HF, limited prospective data and use 
of different statistical techniques to analyse these data. Hence the available evidence in 
this area is largely derived from major heart failure registries around the world. In the 
following chapter risk prediction tools derived from three large worldwide registries of 
patients hospitalised with heart failure are reviewed. 
1.4 CURRENT TREATMENT OF HEART FAILURE AND IMPACT ON MODE OF DEATH 
Standard treatment for heart failure due to left ventricular systolic dysfunction includes 
angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), 
beta-blockers and aldosterone antagonists. The use of ACEI and beta blockers in patients 
with heart failure is associated with a reduction in deaths due to both sudden death and 
progressive heart failure.[20, 22, 47, 48] Similarly, aldosterone antagonists have been 
reported to reduce both progressive heart failure death and sudden death. [18, 25] The 
use of device therapies such as implantable-cardioverter defibrillators have been reported 
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to reduce the risk of sudden death.[49-51] Cardiac resynchronisation therapy reduces the 
incidence of both sudden death and progressive heart failure deaths.[52] 
1.5 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD) 
Large multi centre trials (MADIT, MUSTT & AVID) have shown that Implantable 
Cardioverter Defibrillators (ICD) are beneficial in patients at high risk of sudden cardiac 
death (SCD) i.e. with a history of myocardial infarction and reduced systolic LV 
function.[53] ICD therapy was shown to prolong life in this high risk population with heart 
failure. Although all of these trials included a significant number of patients with heart 
failure, they did not address specifically the role of ICD in heart failure patients. However, 
the SCD-HeFT study demonstrated a 7.2% absolute decrease in mortality after 5 years in 
heart failure patients who had ICD, when compared to those treated with 
amiodarone.[54] 
Despite these advancements in drug and device therapy, there has been no major impact 
on sudden death. A survey from USA showed that there was only a minor decline in the 
absolute number of sudden cardiac deaths in the 1990s (unselected population), despite a 
large increase in the number of ICD implants over the same time.[55] Despite 25 years of 
technical advances in ICD therapy, ICD-unresponsive SCD remains a problem and pooled 
analysis of randomised trials indicates a crude rate of ICD-unresponsive SCD of 5%, which 
comprises about 30% of cardiac deaths.[56] Meta-analyses of RCTs showed that ICD 
therapy is associated with a relative risk reduction of SCD of approximately 60%, far less 
than the greater than 90% efficacy that many expect.[57] A critical appraisal by an expert 
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group suggested that the scientific community might have overestimated the benefits of 
ICD.[58] 
1.6 NEED FOR RISK STRATIFICATION 
ICDs prolong life but are expensive. Analyses from 8 randomised trials showed that the 
use of an ICD was projected to add between 1.01 and 2.99 quality-adjusted life-years 
(QALY) and between US$68,300 and US$101,500 in cost.[59] It is likely that no more than 
one patient in 10 will have a life-saving defibrillation over a 2-3 year period, as the annual 
rate of appropriate shock therapy in the SCD-HeFT trial was 5.1%[60]. In other words 90 
out of 100 patients receiving a device do not benefit and may be harmed. In the same 
trial, the median survival after an appropriate shock was only 168 days.[61] Hence the ICD 
prolonged life only by 6 months.  
With increasing numbers of patients surviving a myocardial infarction but left with LV 
systolic dysfunction, potential candidates for ICD therapy constitute a large population. 
Hence, patient selection is now a major issue and it is important to identify those patients 
at a higher risk of death, hence more likely to derive benefit from ICDs. Inappropriate 
patient selection is likely to cause more harm due to ICD.  
In patients who are at high risk of death despite having an ICD are more likely to benefit 
from a palliative medical management rather than from the ICD. In other words an ICD 
would not prolong life in these patients although it is indicated as per guidelines. A 
retrospective study of device therapy in end stage heart failure found that CRT-D 
implantation in heart failure patients needing inotropes, did not improve survival.[62, 63] 
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In patients at the other end of the spectrum (i.e. at a very low risk of death) an ICD is likely 
to result in harm and should be avoided. 
1.7 OUTLINE OF THIS THESIS 
Based on the above principles, I have conducted a series of experiments as detailed in the 
following chapters.  
1.7.1 Euro Heart Failure Survey 
The Academic Cardiology Department at the University of Hull holds the core data 
collected from the Euro Heart Failure Survey. I had utilised these data to  
 identify factors predicting mortality in patients hospitalised with heart failure, 
  study the utility of Electrocardiogram (ECG) to detect and determine the severity 
of left ventricular dysfunction and  
 study the relation between cholesterol and risk of death. 
1.7.2 Euro Heart Failure Risk Score 
Based on the above studies, I had formulated the Euro Heart Failure Risk score to estimate 
the risk of death in patients hospitalised with heart failure using few simple clinical 
variables. I then examined the applicability of this score to a contemporary population by 
conducting a study in the Liverpool Heart and Chest Hospital in the year 2010. 
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1.7.3. Hull Life Lab programme 
The Hull LifeLab® is a large, longitudinal epidemiologically-based cohort study of patients 
with heart failure. Patients in this cohort receive optimal medical diagnosis and therapy 
and attend for regular follow-up visits with regular investigation including symptoms, signs 
and quality of life score, physical examination, ECG, Echo and neuro-endocrine 
measurements such as brain natriuretic peptide. These patients were recruited to 
undergo 24 hour ECG monitoring and Signal Averaged ECG recordings. I then examined 
the relation between the abnormalities on these tests and mortality. 
1.7.4. ICDs in Heart Failure 
Finally I have studied patients who had ICDs and identified those factors that were 
associated with increased risk of mortality. Two separate groups were studied; the first 
group had ICDs mainly for secondary prevention and the second group for primary 
prevention. 
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CHAPTER 2. REVIEW OF RISK PREDICTION MODELS IN ACUTE HEART 
FAILURE DERIVED FROM LARGE HEART FAILURE REGISTRIES 
2.1. INTRODUCTION 
Heart failure (HF) is a serious condition, a leading cause of hospitalisation in persons older 
than 65 years and is associated with significant morbidity and mortality. Although there 
has been reduction in in-hospital mortality over the last 15 years, there has not been any 
major improvement in 30 day mortality and hospital re-admission rates have 
increased.[64, 65] The huge impact of hospitalisations due to heart failure on health care 
systems has led to research to identify those patients who are at high risk in order to 
target them for intense therapy or move on to palliative care if appropriate. 
There are lot of data in the literature regarding those factors which are associated with 
higher risk of mortality in outpatients with chronic heart failure. These variables include 
demographic characteristics, clinical severity of HF, ventricular function, ventricular 
dyssynchrony, renal function, haematology, neuro-hormonal activation, pulmonary 
function, and hemodynamics.  However the prediction of risk of death during 
hospitalisation for acute heart failure has not received the same amount of attention. 
There are several reasons which include lack of consistent definition of acute 
decompensated HF, limited prospective data and use of different statistical techniques to 
analyse these data. Hence the available evidence in this area is largely derived from major 
heart failure registries around the world. In this chapter, risk prediction tools derived from 
three large worldwide registries of patients hospitalised with heart failure are reviewed. 
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2.2 EFFECT MODEL 
The Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study was a 
retrospective study of 4031 community based patients presenting with heart failure at 
multiple hospitals in Canada between 1997 and 2001.[66] The patients included were 
those newly admitted with a primary diagnosis of heart failure and the study excluded 
those who had developed heart failure complicating the hospital admission. The 
derivation cohort comprised of 2024 patients and the validation cohort had 1407 patients. 
The multivariable predictors of 30 day and 1 year mortality are given in table 2.1. A heart 
failure risk scoring system was derived from these variables (table 2.2).  Patients with very 
low-risk scores (< 60) had a mortality rate of 0.4% at 30 days and 7.8% at 1 year. Patients 
with very high-risk scores (>150) had a mortality rate of 59% at 30days and 78.8% at 1 
year. 
This is a simple model meant to give guidance for health care providers during the early 
stages of hospitalisation with heart failure. It is based on simple clinical observations 
which could be readily obtained in the community; age, blood pressure and respiratory 
rate. Blood tests consisted of simple biochemistry comprising blood urea nitrogen and 
serum sodium concentration. It should be noted that this model is independent of 
ventricular function, as echocardiography is not immediately available in many settings. 
The EFFECT model takes into consideration of the co-morbidities which include dementia, 
cirrhosis, chronic obstructive airways disease, cerebrovascular disease and cancer. 
Dementia and cirrhosis score more points than other co-morbidities. 
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Table 2.1: The multivariable predictors of 30 day and 1 year mortality in the EFFECT 
model.* 
Variable 
30 day model 1 year model 
OR (95% CI) P value OR (95% CI) 
P 
value 
Age, y (per 10-unit increase) 1.7 (1.45–1.99) < .001 1.61 (1.45-1.77 < .001 
Systolic BP, mm Hg  
(per 10-unit increase) 
0.84 (0.8-0.88) < .001 0.88 (0.85-0.9) < .001 
Respiratory rate, breaths/min 
(per 5-unit increase) 
1.23 (1.12-1.36) < .001 1.15 (1.08-1.24) < .001 
Sodium < 136 mEq/L 1.53 (1.14–2.05) .005 1.46 (1.19-1.80) <.001 
Hemoglobin < 10g/dl NA NA 1.37 (1.05-1.78) .02 
Urea Nitrogen, mg/dl 
(per 10-unit increase) 
1.55 (1.42-1.71) <.001 1.49 (1.39-1.60) <.001 
Cerebrovascular disease 1.43 (1.03-1.98) .03 1.36 (1.08-1.71) .01 
Dementia 2.54 (1.77-3.65) <.001 2.00 (1.47-2.72) <.001 
Chronic obstructive pulmonary 
disease 
1.66 (1.22-2.27) .002 1.41 (1.13-1.75) .003 
Hepatic cirrhosis 3.22 (1.08-9.65) .04 5.80(2.23-15.11) <.001 
Cancer 1.86 (1.28-2.70) .001 1.85 (1.4-2.43) <.001 
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Table 2.2: EFFECT Risk Scoring system.* 
Variable 
No  of points 
30 - day score 1- year score 
Age, y + Age (in years) + Age (in years) 
Respiratory rate/m 
(min 20; max 45) 
+ Rate /m + Rate /m 
Systolic BP (mm Hg) 
>180  
160 – 179 
140 – 159 
120 – 139 
100 – 119 
90 – 99 
<90 
 
-60 
-55 
-50 
-45 
-40 
-35 
-30  
 
-50 
-45 
-40 
-35 
-30 
-25 
-20 
Urea nitrogen  
(maximum 60 mg/dl) 
+ level (in mg/dl) + level (in mg/dl) 
Sodium <136 meq/l +10 +10 
Cerebrovascular disease +10 +10 
Dementia +20 +15 
Chronic obstructive 
pulmonary disease 
+10 +10 
Hepatic cirrhosis +25 +35 
Cancer +15 +15 
Hemoglobin <10g/dl NA +10 
* Reproduced with permission from Journal Reprints/Permissions, AMA (ref:15764). 
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The EFFECT model is unique that it not only predicts in-hospital and short term mortality, 
but also intermediate term mortality at 1 year. However, this model is not very specific to 
heart failure as too much emphasis is given for the co-morbidities,  which themselves 
indicate poor prognosis even when they are considered on their own. The other 
disadvantage is that the main determinant of adverse prognosis in heart failure, i.e. the 
severity of LV systolic dysfunction is not included. Thus the EFFECT model predicts adverse 
outcome based on the “general” health status of heart failure patients rather than based 
the actual severity of heart failure. 
2.3 ADHERE MODEL 
The Acute Decompensated Heart Failure National Registry (ADHERE) model is based on 
data collected from 65,275 patient episodes of hospitalisation with a primary diagnosis of 
acute decompensated HF in 263 hospitals across the USA.[67] This model is intended as a 
“clinical risk prediction tool” for in-hospital mortality. 
The predictors of in-hospital mortality were determined from an initial derivation cohort 
consisting of 33,046 hospitalisations and a validation cohort consisting of subsequent 32, 
229 hospitalisations. The mean age was 72.5 years and 52% were female. 58% had 
coronary artery disease. 46% had preserved left ventricular systolic function. In-hospital 
mortality was similar in both the derivation (4.2%) and validation (4.0%) cohorts.  
These data were subjected to classification and regression tree (CART) analysis. This is an 
empirical statistical technique based on recursive partitioning analysis helpful in setting up 
clinical decision rules. Using this technique, 39 clinical variables were analysed. The best 
single predictor of mortality was high levels of blood urea nitrogen (BUN) (15.35 mmol/l) 
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followed by low systolic blood pressure (SBP <115 mm Hg) on admission and then by high 
levels of serum creatinine (> 243 µmol/l). On multivariate logistic regression analysis, BUN 
level, SBP, heart rate and age were the most significant mortality risk predictors.  
The final “tree” generated by the CART analysis is given in figure 2.1 with mortality rates 
from derivation and validation cohorts indicated. The branch points in this tree permit 
patient stratification into 5 risk groups (low, intermediate 1, 2, & 3 and high). The 
mortality risk varied accordingly from 2.1% to 21.9% with statistically significant 
differences between all groups except between intermediate risk groups 2 and 3. 
The ADHERE model has shown that three simple admission clinical and laboratory 
variables, namely systolic blood pressure, blood urea nitrogen and serum creatinine can 
readily stratify patients into groups at low, intermediate and high risk for in-hospital 
mortality. It should be noted that 2 of the 3 variables are based on renal function. 
Although 39 variables including demographics, clinical and lab data such as qualitative left 
ventricular ejection fraction were included, they did not improve the predictive accuracy. 
The complex multivariable model which also included age and heart rate improved the 
prediction only marginally.  
In summary, the renal function (BUN and creatinine) and hemodynamic status (SBP) were 
the two main determinants of in hospital mortality. These findings are in line with several 
other studies demonstrating the association of poor outcome in patients with heart failure 
and renal impairment. Although left ventricular function has been shown to predict 
mortality in other studies, it did not offer any incremental risk discrimination over renal 
function and SBP. Thus ADHERE CART analysis provides a practical, user – friendly and 
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bedside risk prediction tool. However, the disadvantage is that this model relies only on 
two parameters (renal function and blood pressure), one of which is highly influenced by 
the dosage of concomitant heart failure medication. Thus a patient who was on maximal 
dosage of beta blocker and ACEI is likely to have a better prognosis but may be marked as 
having higher risk due to a lower SBP. 
2.4 OPTIMIZE-HF MODEL 
OPTIMIZE-HF (Organised Program to initiate Lifesaving Treatment in Hospitalised Patients 
with Heart Failure) was a national hospital based registry and quality improvement 
program conducted in 259 hospitals across the USA in 2003-2004.[68] It used a web based 
registry data collection tool with process-of-care interventions that promoted evidence 
based therapy for eligible patients. Patients were enrolled if they were 18 years of age or 
older and the primary reason for admission was new or worsening heart failure or if they 
developed significant HF symptoms during hospitalisation. 
48,612 patients were enrolled with a mean age of 73 years. 52% were women. 46% had 
ischaemic aetiology and LVSD was present in 49%. In-hospital mortality was 3.8%. 
Eighteen predictors of mortality were identified (table 2.3) and these included age, heart 
rate, systolic BP, serum sodium, serum creatinine and presence of LVSD. Presence of co-
morbidities such as chronic obstructive pulmonary disease (COPD), peripheral vascular 
disease (PVD) and liver disease increased the risk of death. A risk prediction nomogram 
has been derived from the multivariable model and this is available on the OPTIME-HF 
website. From this nomogram, a score is calculated which is directly associated with the 
probability of in-hospital mortality.  
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Figure 2.1: Predictors of in hospital mortality in the ADHERE registry – Mortality in 
derivation (D) and validation (V) cohorts. 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from Journal Reprints/Permissions Department, American 
Medical Association (ref:15764) 
 
 
BUN < 43 mg/dl 
Mortality = 2.68% (D) / 2.83% (V) 
 
BUN > 43 mg/dl 
Mortality = 8.98% (D) / 8.35% (V) 
 
Total Hospitalisation Episodes 
Derivation cohort (D) = 33406 
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SBP > 115 mm Hg 
 Low risk  
2.14% (D) / 2.31% (V) 
 
 
SBP < 115 mm Hg 
 Intermediate risk 3 
5.49% (D) / 5.67% (V) 
SBP > 115 mm Hg 
Intermediate risk 2 
6.41% (D) / 5.63% (V) 
SBP < 115 mm Hg 
 
15.28 % (D) / 15.3% (V) 
Sr Cr < 2.75 mg/dl 
Intermediate Risk 1 
12.42% (D) / 13.23% (V)
  
Sr Cr > 2.75 mg/dl 
High Risk 
21.94% (D) / 19.76% (V) 
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Table 2.3: Predictors of in-hospital mortality from OPTIMIZE-HF model* 
Variable OR 95% CI p value 
Serum Creatinine: per 0.3 mg/dl increase upto 3.5 
mg/dl 
1.18 1.16 – 1.20 < 0.0001 
Systolic BP: per 10 mm Hg increase up to 160 0.83 0.80 - 0.86 < 0.0001 
Age: per 10-yr increase 1.34 1.26 – 1.41 < 0.0001 
Heart rate: per 10bpm increase between 65-110bpm 1.18 1.13 – 1.24 < 0.0001 
Sodium: per 3 mEq/l decrease  < 140 mEq/l 1.15 1.10 – 1.20 < 0.0001 
Sodium: per 3 mEq/l decrease  > 140 mEq/l 0.87 0.78 – 0.97 0.0100 
HF as primary cause of admission 0.72 0.60 – 0.88 0.0011 
Liver disease 2.33 1.43 – 3.80 0.0007 
Prior CVA / TIA 1.37 1.19 – 1.58  <0.0001 
Peripheral vascular disease 1.32 1.13 – 1.54 0.0003 
Diastolic BP: per 10-mm Hg increase up to 100 mm Hg 0.90 0.85 – 0.95 0.0003 
Hyperlipidemia 0.80 0.71 – 0.91 0.0009 
Smoker within past year 0.70 0.58 – 0.85 0.0004 
No known HF before this admission 0.65 0.51 – 0.85 0.004 
African American 0.71 0.57 – 0.87 0.0009 
LVSD 1.28 1.13 – 1.46 0.0002 
Chronic obstructive pulmonary disease 1.19 1.04 – 1.35 0.0120 
ACE inhibitor at admission 0.84 0.75 – 0.95 0.0056 
Beta-blocker at admission 0.77 0.68 – 0.87  <0.0001 
*Reproduced with permission from Copyright Clearance Centre, Elsevier Limited (licence 
no: 2577231225188). 
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A CART analysis showed that SBP, serum creatinine (SCr), age and heart rate as the most 
discriminative variables for predicting in-hospital mortality. In-hospital mortality increased 
by 18% for every 0.3mg/dl increase in serum creatinine and by 34% for every 10-year 
increase in age. There was 17% reduction in in-hospital mortality with each 10-mm Hg 
increase up to 160 mm Hg. Figure 2.2 shows the relationship between SBP and SCr 
measured at admission and in-hospital mortality.  
In addition, a few important observations were noted in this study. As with the EFFECT 
model, presence of co morbidities was predictive of mortality. However diabetes was not 
significantly associated with excessive risk and hyperlipidemia was associated with lower 
risk. Patients who were on ACE inhibitor or beta-blocker had a lower risk of in-hospital 
mortality.  
The main disadvantages of this model are that it contains several variables and the need 
to consult the normogram to calculate the risk. Hence it is more complex than the other 
two models discussed earlier. However unlike other two models, it is comprehensive and 
combines the physiological variables and co morbidities with the presence of LVSD. 
2.5 SUMMARY 
A variety of risk prediction tools are available to predict mortality of patients hospitalised 
with heart failure. These are based on large heart failure registries and pooled trial data. 
These tools suggest that mortality can be predicted reasonably well with simple clinical 
data and routine investigations. 
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Figure 2.2: The relationship between serum creatinine (SCr) and systolic blood pressure 
(SBP) as measured at hospital admission and in-hospital mortality in the OPTIMIZE –HF 
model.* 
 
 
*Reproduced with permission from Copyright Clearance Centre, Elsevier Limited (licence 
no: 2577231225188) 
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However these models do have some limitations. These include oversimplification of a 
complex pathophysiology and inability to differentiate clearly between those who will 
improve with aggressive treatment and those likely to die irrespective of whatever 
therapeutic measures being undertaken. None of these models are specific to heart 
failure patients as they are based on the overall well being / sickness of the patients and 
are influenced by the co-morbidities. Hence the results could be similar if these models 
were applied to any patient population with an acute medical illness. 
Around half of those included in these models had preserved LV systolic function and this 
reflects the inconsistency between clinical diagnosis of heart failure and objective 
assessment of LV systolic function. Many patients might have had diastolic dysfunction 
which is hard to establish or right heart failure, although it cannot be excluded that some 
were misdiagnosed as having heart failure. 
Despite these limitations, these models are likely perform well in any group of hospitalised 
elderly patients with a clinical syndrome of heart failure, due to their general applicability 
and simplicity of use in the bedside. They will help to improve resource utilisation and to 
target high risk patients for intense monitoring and treatment. 
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CHAPTER 3. METHODS OF INVESTIGATIONS, DATA HANDLING AND 
STATISTICS 
In this thesis the various analyses were based on the results of clinical investigations in 
heart failure. This chapter describes those investigations, methods employed in handling 
the data and statistical analysis.  
3.1 CLINICAL INVESTIGATIONS 
These investigations included 12 lead ECG, signal averaged ECG (SAECG), 
echocardiography, Holter monitoring and blood tests comprising of routine biochemical 
and haematological tests. 
3.1.1 Electrocardiography (ECG) 
A standard 12 – lead ECG was recorded for all cohorts of patients described in this thesis. 
In the Academic Cardiology Department of University of Hull, a GE-MAC 5000 ECG 
machine was used to record surface ECGs using standard 12 leads and ECG intervals (PR, 
RR, QRS, QT, QTc) were automatically calculated by the machine’s inclusive software. QTc 
interval was calculated by Bazett’s method.[69] Abnormalities in the ECG were reported 
by the attending clinician. 
In the Euro Heart Failure survey, the ECGs were recorded at the participating hospitals and 
reported by the attending clinicians locally. All the ECGs were sent to the core lab at Hull 
and the ECG intervals were measured by a single observer who was blinded to other 
clinical data. ECG intervals were obtained from three non–infarct chest or limb leads using 
a digital ruler-calliper (ABSolute digimatic, Mitutoya, UK) and averaged. QTc was 
calculated by Bazett’s method.[69] QRS prolongation was defined as QRS > 120ms. QTc 
prolongation was defined as QTc > 440ms. 
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Figure 3.1 ECG intervals 
 
3.1.2 Signal Averaged ECG 
Signal-averaged electrocardiography (SAECG) is a special electrocardiographic technique, 
which enables detection of low amplitude bioelectric potentials at the end of QRS 
complex (late potentials) which are masked by the noise due to skeletal muscle activity in 
standard ECG. This is done by averaging many QRS signals to remove interference, amplify 
the complexes, and letting finer detail of the QRS complexes appear. Late potentials on 
SAECG are associated with an increased risk of ventricular tachycardia, sudden death and 
total mortality in patients after myocardial infarction.[70-76] 
 3.1.2.1 Recording and analysis of SAECG 
In addition to the usual 12 leads used for surface ECG, orthogonal XYZ leads are recorded 
by placing 4 additional electrodes at the following positions; H – back of neck, E – mid 
sternum (same level as V4), I – right mid axillary line (same level as V4) and M – centre of 
back (same level as V4). Then the recordings are averaged, filtered and combined into a 
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vector magnitude called the filtered QRS complex. Analysis of this filtered QRS complex 
includes a) the filtered QRS duration; b) the root – mean – square (RMS) voltage of the 
terminal 40 ms of the filtered QRS; and c) the duration that the filtered QRS complex 
remains < 40 µv.  
 In normal SAECGs, the filtered QRS duration is < 114 ms, RMS voltage is > 20 µv and the 
duration that the filtered QRS complex remains < 40 µv is < 38 ms. [77] 
3.1.2.2 Criteria for late potential 
Late potentials are due to delayed ventricular activation, in areas of myocardial scarring, 
which form the substrate for ventricular arrhythmias. Patients with sustained ventricular 
tachycardia during electrophysiological testing are more likely to have late potentials. 
Characteristics of a late potential (using a 40Hz high pass bidirectional filter) include a 
filtered QRS complex  duration of > 114 ms; RMS voltage of < 20 µv in the last 40 ms of the 
filtered QRS complex and the duration that the filtered QRS complex remains < 40 µv is > 
38 ms. 
SAECG was considered abnormal if filtered QRS is > 114 ms and fulfilled the other two 
criteria for late potential, provided it was recorded in sinus rhythm and there was no 
evidence of bundle branch block or marked intra-ventricular conduction delay. 
3.1.3 Holter monitoring 
Holter monitoring was performed for 24 hours with Life Card CF digital Holter recorder 
(Del Mar Reynolds Medical Inc.) and data were analysed with Reynolds Pathfinder II 
program (Del Mar Reynolds Medical Inc.). The predominant Holter rhythm was recorded. 
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For patients in sinus rhythm, the heart rate variability index SDNN (standard deviation of 
the average R – R intervals) was recorded. All arrhythmias were captured. Frequent 
ventricular ectopics (VE’s) were defined as > 10 VE’s /hour. Non sustained ventricular 
tachycardia (NSVT) was defined as 3 VE’s or more in succession, but less than 30 seconds 
in duration. Sustained VT was defined as VT occurring for more than 30 seconds. 
3.1.4 Echocardiography 
This was performed by the attending clinicians or technicians at the Academic Cardiology 
department using a GE vivid 5 machine by standard technique. Left ventricular 
dysfunction (LVSD) was qualitatively assessed as being none, mild, moderate and severe. 
Ejection fraction was measured by Simpson’s method.[78] 
 In the Euro Heart Failure Survey, the echocardiograms were performed and reported by 
the participating hospitals. Left ventricular systolic dysfunction, dilatation and mitral 
regurgitation (MR) were assigned qualitatively (by the investigator) to one of four 
categories; none, mild, moderate and severe.  
3.1.5 Biochemical and haematological investigations 
Routine tests were carried out for all patients at the local laboratories. Hyponatraemia 
was defined as Na < 135 mmol/l. Hyperkalaemia was defined as K > 5 mmol/l. Renal 
impairment was defined as a creatinine of > 127 μmol/l in men or > 107 μmol/l in women. 
Hypercholesterolemia was defined as > 5 mmol/l (193 mg/dl). Hyperuricaemia was 
defined as uric acid > 0.42 mmol/l in men or > 0.36 mmol/l in women. The presence of 
anaemia was defined as Hb < 13 g/dl in men or Hb < 12 g/dl in women. 
 43 
3.2 STATISTICAL METHODS 
The software used for statistical tests was SPSS v16 (SPSS Inc, Chicago, Illinois, USA). 
3.2.1 General data handling 
I have expressed all continuous data as means with standard deviations (SD) when they 
are normally distributed. When normal distribution could not be assumed, medians with 
inter quartile range (IQR) are given. Categorical data are expressed as frequency with 
percentage. Group means were compared by parametric (students ‘t’ test and analysis of 
variance – ANOVA) and non parametric tests (Chi-square) as applicable to the relevant 
data (i.e. continuous or categorical).  
3.2.2 Standard Normal Distribution 
In the Euro Heart Failure Survey, for the purpose of multivariable analysis, the continuous 
variables were transformed into a standard normal distribution (with a mean of 0 and SD 
of +/- 1). This was achieved by subtracting the individual values by the mean and then 
dividing by standard deviation. This was done so that the effect size could be directly 
compared with that of other continuous and categorical variables. 
3.2.3 Missing Values handling 
In the Euro Heart Failure Survey, I excluded those variables with > 10% missing values 
from multivariable models. For others, missing values were replaced with the series mean. 
For echocardiographic variables, another category of “no echo” was added when the 
patient had not had an echocardiogram, thus keeping sample size same for all variables 
included in the logistic regression models. 
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3.2.4 Logistic regression  
Logistic Regression is one of the most commonly used statistical techniques biomedical 
research.[79]  This technique was employed for both univariate and multivariable analysis 
in most of the studies described in this thesis.  
3.2.4.1 Predictive modelling 
Logistic regression is a type of predictive model that can be used when the target variable 
is a categorical variable with two categories (such as, alive/dead) and the independent 
variables are continuous, categorical, or both. The relationship between predictor 
variables and an outcome variable is estimated similar to linear regression, but the 
difference is that in logistic regression we estimate the probability that the outcome 
variable assumes a certain value (yes or no), rather than estimating the value itself. 
3.2.4.2 Output from Logistic Regression 
Logistic regression estimates odds ratios (OR) associated with each independent 
(predictor) variable with 95% Confidence Intervals (CI). A p value of < 0.05 (two–tailed) 
was considered statistically significant. The "odds" of an event is defined as the probability 
of the outcome event occurring divided by the probability of the event not occurring. The 
"odds ratio" is one set of odds divided by another. The odds ratio for a variable is defined 
as the relative amount by which the odds of the outcome increase (OR greater than 1) or 
decrease (OR less than 1) when the value of the predictor variable is increased by 1 unit. 
3.2.4.3 Advantages and limitations of Logistic Regression 
Unlike linear regression, logistic regression does not assume that the relationship between 
the independent variables and the dependent variable is a linear one.  Nor does it assume 
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that the predictor variables are distributed normally. However, the predictor variables 
should not be highly correlated with one another because this could cause problems with 
estimation. 
Although the choice of a statistical model generally depends on biological or clinical 
considerations in addition to statistical results, large sample sizes are required for logistic 
regression to provide sufficient numbers in both categories of the dependant variable.  If 
there are many independent variables, a proportionately larger sample size is needed for 
accurate estimation. 
3.2.5 Bootstrapping 
In the Euro Heart Failure survey, I used bootstrapping to validate the multivariable model 
predicting mortality. The bootstrap method is used to estimate the accuracy of an 
estimator such as the standard error, a confidence interval, or the bias of an estimator. 
This technique is useful for analysing expensive-to-collect data sets where prior 
information is sparse, distributional assumptions are unclear, and where further data may 
be difficult to acquire.[80]  
The bootstrap procedure involves choosing random samples with replacement from a 
dataset and analyzing each sample the same way. Sampling with replacement means that 
each observation is selected separately at random from the original dataset. So a 
particular data point from the original data set could appear multiple times in a given 
bootstrap sample. The number of elements in each bootstrap sample equals the number 
of elements in the original data set. The range of sample estimates obtained enables us to 
establish the uncertainty of the quantity we are estimating. In the Euro Heart Failure 
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survey, bootstrapping was done with re-sampling 1000 times to calculate the 95% 
confidence intervals. 
3.2.6 Log Linear Analysis 
Log linear analysis is an extension of the chi-square test of independence and it provides a 
sophisticated way of looking at cross tables. It not only tests the different factors included 
in the cross tables, but also tests their interactions for statistical significance. Hence, I 
have used this analysis in the study of ECG intervals from the Euro Heart Failure Survey. 
3.2.7 Poisson Regression[81] 
Poisson regression predicts not only the likelihood of an event, but also the number of 
events in a statistical model. I have used this model to predict the likelihood and incidence 
of inappropriate shocks in those patients who have heart failure and had an ICD 
implanted. 
3.3 SUMMARY 
I have used advanced statistical methods in this thesis to analyse data generated from 
simple clinical investigations. 
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CHAPTER 4. PREDICTORS OF SHORT TERM MORTALITY IN HEART FAILURE –  
INSIGHTS FROM THE EURO HEART FAILURE SURVEY. 
4.1 INTRODUCTION 
Data from large heart failure registries have demonstrated that simple clinical variables 
can predict mortality in patients hospitalised with heart failure.[66, 67] Some are 
modifiable, potential causes of deterioration and death and therefore possible targets for 
therapy. Others may just be markers of risk but nonetheless identify patients in need of 
intensive management or, palliative care. Standard treatment for heart failure includes 
ACE inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists and, 
in selected patients, cardiac resynchronisation therapy and implantable defibrillators.[82] 
These medication and devices have improved the prognosis of heart failure but are often 
not implemented correctly.[83] New treatments are being developed that target specific 
problems such as renal dysfunction and anaemia.  
4.2. EURO HEART FAILURE SURVEY 
The Euro Heart Failure survey investigated whether appropriate tests were being 
performed and therapeutic interventions done according to European Society of 
Cardiology guidelines in patients hospitalised with a diagnosis of or suspected heart 
failure.[4, 84, 85]   The Academic Cardiology Department at the University of Hull holds the 
core data collected from the Euro Heart Failure Survey. I had integrated these extensive 
data into a single dataset and analysed these data to identify factors that independently 
predicted short term mortality. 
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4.3 METHODS 
4.3.1 Study Population 
In the Euro Heart Failure survey, vital data were collected from 10,701 patients enrolled 
with suspected heart failure in 115 hospitals across Europe during 2000-2001. The 
detailed design of this study has been published.[4]  In short, consecutive  hospital 
discharges and deaths  were screened for 6 weeks and patients enrolled if they fulfilled at 
least one of the following: (1) a clinical diagnosis of heart failure during admission; (2) a 
diagnosis of heart failure recorded at any time in last three years; (3) administration of 
loop diuretic for any reason other than renal failure in the 24 hours prior to death or 
discharge; (4) pharmacological treatment for heart failure or ventricular dysfunction in the 
24 hours prior to death or discharge. Data were collected on co-morbid conditions and 
results of following investigations were recorded: ECG, echocardiogram, serum 
electrolytes, creatinine, haemoglobin (during this admission), uric acid and cholesterol 
(most recent results). Details of medication used any time during this admission were also 
recorded. Deaths within 12 weeks of admission, either in hospital or after discharge were 
recorded. 
4.3.2 Clinical Investigations 
4.3.2.1 ECG 
The 12 lead ECGs were analysed in the core laboratory at University of Hull by a single 
observer, blinded to other results. ECG intervals were measured from three non–infarct 
chest or limb leads using a digital ruler-calliper (ABSolute digimatic, Mitutoya, UK) and 
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averaged. QTc was calculated by Bazett’s method.[69] QRS prolongation was defined as 
QRS > 120ms. QTc prolongation was defined as QTc > 440ms. 
4.3.2.2 Echocardiography 
The echocardiograms were performed and reported by the participating hospitals. Left 
ventricular systolic dysfunction (LVSD), dilatation and mitral regurgitation (MR) were 
assigned qualitatively (by the investigator) to one of four categories; none, mild, moderate 
and severe.  
4.3.2.3 Blood Tests 
The results of routine blood tests were recorded and were considered abnormal if outside 
the laboratory reference range, as defined in the previous chapter. 
4.3.3 Statistical Analysis 
The clinical, laboratory, ECG and echocardiographic variables were subjected to univariate 
analysis by binary logistic regression to predict death within 12 weeks of admission and 
odds ratios (OR) with 95% confidence intervals (CI) were calculated. A p value of < 0.05 
(two–tailed) was considered statistically significant. Those variables with a p value of < 
0.001 on univariate analysis were included in a multivariable stepwise logistic regression 
model. The continuous variables were transformed into a standard normal distribution 
(with a mean of 0 and SD of +/- 1). Odds ratios were calculated per unit change in 
standard deviation. Those variables with > 10% missing values were excluded from 
multivariable model. For others, missing values were replaced with series mean. For echo 
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variables, another category of “no echo” was added, thus keeping sample size same for all 
variables. This model was validated by bootstrapping (resample = 1000). 
A risk score to predict mortality was derived by using the simple variables obtained from 
the multi variable model. Statistical analysis was carried out using SPSS v16 (SPSS Inc, 
Chicago). 
4.4 RESULTS 
4.4.1. Death 
Vital status was available for 10,701 patients at 12 weeks after admission. 1404 (13%) had 
died during this period. Most patients fulfilled three or more enrolment criteria, 84% of 
patients had a diagnostic label of heart failure and only 10% were enrolled solely because 
they received loop diuretics, as previously reported.[84] Of 1,603 patients who were not 
enrolled with a diagnostic label of heart failure, 145 (8.3%) died, compared to 1259 
(14.1%) of 7,694 patients with a reported diagnosis of heart failure (p<0.001 on univariate 
analysis).  
4.4.2 Clinical Investigations  
The results of routine laboratory tests were available for 92% (9833) of patients and 
abnormalities were common, especially anaemia and renal dysfunction (table 4.1). ECGs 
were available for 83% (n = 8863) of patients, 18% of which showed atrial fibrillation and 
27% of which showed a QRS interval >120msec. Echocardiography results were available 
for 65% (n = 6993) of patients, 71% of which showed LVSD and  27% showed moderate or 
severe MR. In the investigator’s opinion major valve disease was present in 23% of 
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patients. The mean (SD) ejection fraction in the four qualitative categories of LVSD were 
as follows: no LVSD – 62 (8) %, mild LVSD – 50 (7) %, moderate – 41 (7) % and severe 27 
(8) %. Most patients were treated with a diuretic with about two thirds of patients taking 
ACE inhibitors and one third on beta-blockers.  
4.4.3 Univariate analysis 
On univariate analysis (table 4.1), four variables were associated with an odds ratio >2.0 of 
dying, hyponatraemia, renal impairment, need for IV inotropic agents and hyperkalaemia, 
whilst the upper confidence limit was >2.0 for anaemia (1.9; 1.7-2.1) and severe MR (1.7; 
1.3 – 2.2).  Treatment with ACE inhibitors (0.4; 0.4-0.5), angiotensin receptor blockers (0.3; 
0.2-0.5), beta blockers (0.5; 0.4-0.5), nitrates (0.8; 0.7-0.9), anti-thrombotics (0.6; 0.5-0.7) 
and lipid lowering drugs (0.3; 0.3-0.4) were associated with a better prognosis. Patients 
who were on loop diuretics (1.5; 1.3 – 1.8) or intravenous inotropic agents (5.1; 4.4 – 6.0) 
had a worse prognosis. 
4.4.4 Multivariable analysis 
Multivariable analysis (table 4.2) was performed with the following variables, included in 
the model; sex, presence of severe LVSD, mitral regurgitation, major valvular disease, 
hypertension,  atrial fibrillation, treatment with ACEI, ARB,  beta-blockers, loop diuretic, 
thiazide diuretic,  calcium channel blockers, digitalis, nitrates, inotropic agents, anti 
thrombotic agents, anti arrhythmic drugs and lipid regulators  as categorical variables and 
age, sodium, potassium, cholesterol, Hb, urea, creatinine, urate, QTc & QRS durations as 
continuous variables. Odds ratios were given for a change of +/- 1 SD for continuous 
variables and odds ratios obtained by comparing Yes vs No for categorical variables. 
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TABLE 4.1: Univariate Analysis by binary logistic regression predicting mortality within 
12 weeks of admission with heart failure.  
Variable Descriptive 
Statistics 
 μ + SD / n (%) 
Wald 
Statistic 
Odds Ratio 
(95% CI) 
 
P value 
Demographic profile (n = 10701) 
Age (years) 71 + 13  234.0 1.7   (1.6 – 1.8) < 0.001 
Female Sex  5021 (47) 14.0 1.2   (1.1 – 1.4) < 0.001 
Hypertension 5679 (53) 17.5 0.8    (0.7 – 0.9) < 0.001 
Diabetes 2907 (27) 0.4 1.0    (0.9 – 1.2)  0.537 
Echocardiogram (n = 6993) 
LV dilatation 2771 (26) 0.8 1.1   (0.9 – 1.3) 0.369 
Severe LVSD 2087 (20) 32.5 1.6  (1.4 – 1.9) < 0.001 
Moderate or severe LVSD 3736 (35)  13.9 1.3   (1.2 – 1.6) < 0.001 
Major valve disease 2501 (23) 37.4 1.6  (1.4 – 1.9) < 0.001 
Mild MR 2525 (24) 1.2 0.9   (0.7 – 1.1) 0.274 
Moderate MR 1453 (14) 10.6 1.5   (1.2 – 1.8) < 0.001 
Severe MR 454 (4) 17.0 1.7   (1.3 – 2.2) < 0.001 
ECG (n = 8863) 
Heart rate (bpm) 83 + 22 231.2 1.6 (1.5 – 1.6) < 0.001 
QRS prolongation  
(> 120ms) 
2360 (22) 
8.2 
1.2   (1.1 – 1.4) 0.004 
QTc prolongation (>440ms) 4763 (45) 16.0 1.3   (1.1 – 1.4) < 0.001 
AF 1595 (15) 28.5 1.5   (1.3 – 1.7) < 0.001 
Ventricular Arrhythmias 239 (2) 1.2 1.2   (0.9 – 1.7) 0.275 
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Treatment profile (n = 10701) 
ACE or ARB 6995 (65) 241.3 0.4   (0.4 – 0.5)  < 0.001 
ACE (in those not on ARB) 6610 (62) 195.1 0.4   (0.4 – 0.5) < 0.001 
ARB(in those not on ACEI) 481 (5) 13.6 0.3   (0.2 – 0.5) < 0.001 
Beta Blocker 3944 (37) 122.3 0.5   (0.4 – 0.5) < 0.001 
Loop Diuretic 8627 (81) 26.2 1.5   (1.3 – 1.8) < 0.001 
Thiazide 1179 (11) 10.6 0.7  (0.6 – 0.9) 0.001 
Spironolactone 2197 (21) 2.5     0.9  (0.8 – 1.0) 0.115 
CCBlocker 2265 (21) 34.3 0.6  (0.5 – 0.7) < 0.001 
Digoxin 3825 (36) 7.3 1.2   (1.0 – 1.3) 0.007 
Nitrates 5069 (47) 9.2 0.8  (0.7 – 0.9) 0.002 
Anti Arrhythmic agents 1574 (15) 1.6 1.1  (0.9 – 1.3) 0.211 
Aspirin / Anti Platelet drugs 5593 (52) 99.7 0.6 (0.5 – 0.6) < 0.001 
Heparin 2682 (25) 69.5 1.7 (1.5 – 1.9) < 0.001 
Warfarin & other coumadin drugs 2450 (23) 56.3 0.6 (0.5 – 0.6) < 0.001 
IV Inotropic agents 767 (7) 408.9 5.1  (4.4 – 6.0) < 0.001 
Lipid Regulators 2187 (20) 128.4 0.3   (0.3 – 0.4) < 0.001 
Laboratory tests ( n = 9833) 
Sodium < 135 mmol/l 1477 (14) 150.1 2.4   (2.1 – 2.7) < 0.001 
Potassium > 5 mmol/l  997 (9) 96.9  2.2  (1.9 – 2.6) < 0.001 
Renal Impairment (Cr >127μmol/l 
in Male ; >107μmol/l in Female) 
3398 (32) 
220.6 
2.5   (2.2 – 2.8) < 0.001 
Cholesterol > 5mmol/l 2768 (26) 29.8 0.6   (0.5– 0.7) < 0.001 
Uric acid (>0.42-M 0.36-F mmol/l) 2355 (22) 0.03 1.0   (0.8 – 1.3) 0.861 
Anaemia (<13g/dl  M; <12g/dl  F) 4180 (39) 109.7 1.9   (1.7 – 2.1) < 0.001 
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The following factors provided independent prognostic information: increasing age, severe 
LVSD, serum creatinine, sodium, Hb and treatment with ACEI, beta blockers, statins, calcium 
channel blockers, warfarin, heparin, anti-platelet drugs and need for inotropic agents.  
The relation between mortality, cholesterol and its therapy was examined further (chapter 7) 
and I found that low cholesterol levels carry an adverse prognosis (figure 4.1). Among those on 
lipid lowering therapy, the mortality was higher in those with cholesterol in the lowest and 
highest quintiles (figure 4.2 - U shaped relation). 
4.4.5 Derivation of Risk Score 
A crude risk score was derived from the variables in the multivariable model, after examining 
their relative ability to predict mortality. The variables were then examined in various 
combinations by stepwise logistic regression and the best combination that predicted mortality 
with the least number of variables was chosen and a score assigned based on their odds ratios. 
A final risk score was obtained (0-11) with the following variables only:  Age: 71-75 (1), 76 – 80 
(2) and > 80 (3), LVSD: Mild (1), Moderate (2) and severe (3), Not on beta blocker (2), Not on 
ACEI/ARB (2) and elevated serum creatinine (1).  Increase in risk score was associated with a 
linear increase in mortality (table 4.3 and figure 4.3) throughout the range with R square = 
0.952. Other variables from multivariable analysis were excluded as they did not improve the 
predictive ability any further. 
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TABLE 4.2: Multivariable analysis predicting mortality within 12 weeks of admission with heart failure.  
Variable p 
Wald 
Statistic 
Odds 
Ratio 
95% CI 
Bootstrap 
p (97.5%) 
Age*  (SD = 13 years) < 0.001 127.2 1.5 1.4 – 1.6 < 0.001 
Haemoglobin*  (SD = 2.2 g/dl) < 0.001 27.9 0.9 0.8 – 0.9 0.003 
Creatinine*  (SD = 103 μmol/l) < 0.001 79.2 1.2 1.2 – 1.3 < 0.001 
Sodium* (SD = 5 mmol/l) < 0.001 19.8 0.9 0.8 – 0.9 0.035 
Severe LVSD (20% of all patients) < 0.001 35.7 1.8 1.5 – 2.1 < 0.001 
Atrial Fibrillation (15%)  0.001 10.9 1.3 1.1 – 1.6 0.205 
ACE therapy (62%) < 0.001 85.4 0.5 0.5 – 0.6 < 0.001 
ARB therapy (5%) 0.001 11.9 0.5 0.4 – 0.8 0.073 
Beta blocker therapy (37%) < 0.001 19.1 0.7 0.6 – 0.8 0.006 
Calcium channel blocker therapy 
(21%) 
< 0.001 
15.7 0.7 0.6 – 0.8 0.018 
Lipid lowering therapy (20%) < 0.001 24.8 0.6 0.5 – 0.7 0.001 
Aspirin and anti platelet drugs 
(53%) 
< 0.001 
69.1 0.6 0.5 – 0.6 < 0.001 
Warfarin (23%) < 0.001 54.5 0.5  0.4 – 0.6 < 0.001 
Heparin (25%) < 0.001 53.1 1.7 1.4 – 1.9 < 0.001 
Need for IV inotropic agents (7%) < 0.001 325.4 5.5 4.6 – 6.6 < 0.001 
 
 56 
Figure 4.1 Relation between cholesterol level and mortality 
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Figure 4.2. Mortality related to cholesterol level in patients on lipid lowering drugs. 
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Figure 4.3. Relation between Euro Heart Failure Risk Score and mortality at 12 weeks of 
hospital admission 
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Table 4.3 Euro Heart Failure Score and mortality 
 
Risk Score No (%) Died (%) 
0 306 (2.9) 6 (2) 
1 357 (3.3) 9 (2.5) 
2 1066 (10) 58 (5.4) 
3 1429 (13.4) 94 (6.6) 
4 1587 (14.8) 177 (11.2) 
5 1757 (16.4) 242 (13.8) 
6 1281 (12) 223 (17.4) 
7 956 (8.9) 209 (21.9) 
8 672 (6.3) 199 (29.6) 
9 157 (1.5) 47 (29.9) 
10 58 (0.5) 18 (31) 
11 27 (0.3) 12 (44.4) 
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4.5 DISCUSSION 
This analysis shows that simple clinical information acquired during hospitalisation in an 
international clinical survey can be used to risk-stratify patients with suspected heart failure. 
The scoring system was able to identify patients with a 12 week mortality risk as low as 2% and 
as high as 44%. This information may help with planning of care. Patients at higher risk may 
benefit from more intense monitoring and therapy during and after hospitalization. 
Alternatively, patients with poor scores and symptoms recalcitrant to conventional therapy 
might be selected for palliative care. Some markers of risk may also be targets for therapy.  
Treatment with established heart failure drugs such as ACEI and beta blockers were 
independently associated with a lower mortality. It is unclear whether the higher mortality in 
those who were not treated with these agents reflects important omissions of medical care or 
inability to tolerate therapy. However, important co-morbidities such as renal dysfunction that 
might contra-indicate such treatment were included in the model but did not eliminate 
treatment effects.  This suggests that the association between treatment with these agents and 
outcome may indeed reflect their therapeutic benefits. Many patients in this survey did not 
receive optimal treatment, even if they had documented LVSD.[86] This survey suggests that 
further efforts to ensure that patients are initiated on life-saving treatment during 
hospitalization are required to reduce the high mortality observed during this period. A similar 
association was observed with nitrates, consistent with the outcomes of the V-HeFT-I and A-
HeFT trials.[87, 88] It is difficult to explain the association between the use of thiazide diuretics 
and lower mortality as there have been concerns such as thiazide induced hypokalemia, 
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ventricular ectopics and elevation of uric acid levels.[89, 90] This could reflect use in younger 
patients with less severe LVSD or in those with hypertension, as supported by evidence from 
ALLHAT trial, although adjustment for these co-variates (age and hypertension) did not 
eliminate the effect.[91] The same could be true for calcium channel blockers, predominantly 
amlodipine, which were associated with lower mortality in this study.  
The relation between low cholesterol level and increased mortality observed in this study 
(figure 4.2) has been well recognized as part of “reverse epidemiology” when low body mass 
index, low blood pressure and low cholesterol are associated with adverse prognosis in HF. This 
is thought to be due to malnutrition and inflammation in severe heart failure. [92] The higher 
number of deaths observed in patients with high cholesterol despite being on lipid lowering 
therapy (figure 4.3) was probably due to increased risk of ischemic events due to refractory 
hypercholesterolemia. However, the association between lipid lowering therapy and better 
outcome was independent of cholesterol and might be due to the pleiotropic effects of 
statins.[93-95] But, two large randomised trials, CORONA and GISSI-HF did not find any 
mortality benefit with statin therapy in patients with ischaemic heart failure.[96, 97]  
Anti platelet drugs and warfarin were associated with good outcome, although two randomized 
controlled trials in this setting (WASH and WATCH) were unable to identify benefits.[98, 99] It is 
also not clear why heparin, which presumably was used mainly in patients confined to bed and 
only during hospitalization, was not associated with a favorable outcome. It is likely that 
heparin was used more often in patients who had an acute coronary syndrome, atrial 
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fibrillation, valve disease/replacements, factors which are associated with an independent risk 
of death and possibly the additional risk of bleeding contributed to increased mortality.  
The association of use of inotropic drugs with poor outcome observed in this survey is 
consistent with previous observations that inotropic agents are associated with increased 
mortality, although used in severe heart failure to improve cardiac output.[100] However, this 
may simply be a marker of end stage decompensated HF rather than having any independent 
mechanistic effect on increasing the mortality. The lack of association of ventricular 
arrhythmias with adverse outcome is probably due to the small number of patients (2%) with 
documented arrhythmias. It is highly likely that the true prevalence of non sustained ventricular 
arrhythmias was much higher and the detection rate was low as most of these patients would 
not have been on continuous ECG monitoring during their admission. 
Severe heart failure is commonly associated with electrolyte abnormalities such as 
hyponatraemia, hyperkalaemia, elevated urea and creatinine. These abnormalities can be made 
worse by treatment with loop diuretics. All these factors were associated with a higher 
mortality in this survey on univariate analysis and hyponatraemia and creatinine on the multi-
variable analysis. Arginine vasopressin receptor antagonists can improve hyponatraemia and 
cause weight loss by aquaresis with modest improvement in symptoms and quality of life.[101] 
However there is no evidence that these agents reduce either short or long term mortality. 
Renal impairment is an important marker of cardiovascular morbidity and mortality risk in 
patients with both systolic and diastolic heart failure, an observation to which this analysis 
provides additional support.[102-104] At present our understanding of the mechanism of this 
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cardio-renal syndrome is rudimentary and the question of whether renal dysfunction is a 
marker or mediator of death due to worsening heart failure awaits the outcome of effective 
therapies targeted at this problem. Adenosine is an important determinant of renal function in 
patients with heart failure and there were encouraging reports that adenosine A1 receptor 
antagonists may improve renal function in this setting.[105-109]  The PROTECT pilot study 
showed that in 301 patients, compared with placebo treatment with rolofylline, improved 
dyspnea over the first 48 hours, prevented increases in serum creatinine of 0.3 mg/dL or 
greater on days 7 and 14, and tended to reduce 60-day mortality or readmission for 
cardiovascular or renal causes in patients with ADHF.[110] However, the PROTECT clinical trial 
failed to confirm this and there was no difference in death or readmission due to cardiovascular 
or renal causes at 60 days between study and placebo groups (31 vs 32%).[111] Hence the 
search for effective agent to treat patients hospitalised with heart failure and renal dysfunction 
is still ongoing.  
Anaemia is common among patients with heart failure. The prevalence increases with age, 
increasing severity of heart failure and declining renal function, which themselves are 
independently associated with a poor prognosis.[112] Anaemia is consistently associated with 
increasing mortality and the more severe the anaemia, the higher the mortality.[113] 
Erythropoietin has been shown to improve the hemoglobin and exercise capacity in these 
patients.[114] It has been shown that that heart failure patients with persistent anemia have a 
worse prognosis when compared to those with resolved anemia.[115]   
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 Non modifiable risk factors such as increasing age and female sex (on univariate analysis) were 
associated with an unfavorable outcome as expected and this is significant, as frail elderly 
population is not adequately represented in randomized trials in heart failure. It is surprising 
that diabetes was not associated with a worse outcome in this study, as other observational 
studies have demonstrated poor outcome with diabetes in hospitalised patients in heart 
failure.[116, 117] However this has been observed in previous similar studies such as EFFECT, 
ADHERE and OPTIME-HF.[66-68] It is likely that adverse impact of diabetes is limited to those 
with ischemic etiology as shown in a previous study. [118] In this study of 1246 patients with LV 
systolic dysfunction by de Groote et al, diabetes was an independent predictor of 
cardiovascular mortality in ischaemic patients but it was associated with a statistically 
significant decrease in cardiovascular mortality in non-ischaemic patients. 
 The findings of the SHAPE (Study group on HF Awareness and Perception in Europe) study,  
showed that adherence of guideline management therapies in HF was quite low among 
internists, geriatricians and primary care physicians.[119] For example, in this study only 39% 
internists/geriatricians used a β-blocker in >50% of their patients (vs. 73% of cardiologists, p < 
0.0001). Hence findings from Euro Heart Failure Survey are truly relevant in contemporary 
medical practice, emphasising the need to prescribe therapies such as β-blocker and ACEI in 
patients with HF. 
4.6 LIMITATIONS 
I acknowledge that surveys, unlike randomised trials, cannot distinguish whether the 
association between treatment and better outcome reflects the likelihood that patients with an 
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intrinsically better prognosis will receive treatment or reflects a true therapeutic effect. In the 
survey, 16% of patients had markers of heart failure, such as use of loop diuretics, but were not 
given a diagnosis of heart failure and 29% of those who had echocardiograms had preserved LV 
systolic function. Data on physical signs such as blood pressure, admission BNP and other non 
conventional risk factors such as microalbuminaemia and fibrinogen were not collected in this 
survey and might have changed the predictive power of the variables included. 
Echocardiographic data were reported from individual hospitals and not validated. However 
any potential error due to these limitations has probably been overcome to some extent by the 
large patient numbers in this study. 
4.7 CONCLUSIONS 
Simple and readily available clinical variables and a risk score using this information may be 
useful to identify patients at high risk of dying during or soon after hospital discharge. 
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CHAPTER 5. VALIDATION OF EURO HEART FAILURE SCORE IN A CONTEMPORARY 
HEART FAILURE POPULATION 
5.1 INTRODUCTION 
The Euro Heart Failure Survey Score (table 5.1) was derived from the Euro Heart Failure Survey 
data as discussed in last chapter.[120] This simple score may be useful to predict short term 
mortality in patients hospitalised with signs and symptoms of heart failure and evidence of left 
ventricular systolic dysfunction. In this chapter, I have prospectively evaluated the usefulness of 
this score in a contemporary patient population with heart failure. 
5.2 AIM 
To assess the usefulness of Euro Heart Failure Survey score to predict 12 week mortality in 
patients admitted with symptoms or signs of heart failure associated with evidence of left 
ventricular systolic dysfunction on echocardiography. 
5.3 PATIENTS AND METHODS 
This is a prospective, observational study of consecutive patients admitted to Liverpool Heart 
Chest Hospital, Liverpool, UK between January – March 2010 with symptoms or signs of heart 
failure and found to have evidence of left ventricular systolic dysfunction. The study was 
prospectively approved by the R&D department of Liverpool Heart and Chest Hospital NHS 
Foundation Trust, Liverpool. 
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Baseline clinical characteristics, details of therapeutic intervention, laboratory test results and 
details of medication (once medical therapy has been optimised) were recorded. Vital status 
(alive or dead) was determined at 12 weeks, by reviewing the follow up data and a telephone 
call to the patient. 
Table 5.1. Euro Heart Failure Survey score 
Variable Risk Score 
Age (years) 
71 – 75 
76 – 80 
> 80 
 
1 
2 
3 
LVSD on echocardiogram 
Mild 
Moderate 
Severe 
 
1 
2 
3 
Elevated serum creatinine 1 
Not on ACEI /ARB 2 
Not on beta blocker 2 
 
Minimum score = 0; Maximum score = 11 
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5.4 RESULTS 
75 patients were enrolled during a study period of 8 weeks between 25th January 2010 and 18th 
March 2010. 61 (81%) were male. The mean age was 66 (SD 12) years. The primary reason for 
hospital admission is given in table 5.2. 69 (92%) had ischaemic heart disease, 51 (68%) had 
hypertension and 18 (24%) had diabetes. 19 (25%) had renal impairment. Details of medical 
therapy are given in table 5.3. 
Table 5.2: Reason for hospital admission 
Primary reason for hospital admission No (%) 
Worsening of heart failure 
Angina 
Acute coronary syndrome 
Myocardial Infarction 
Valvular heart disease 
Atrial Fibrillation 
Ventricular arrhythmia 
6 (8) 
5 (7) 
6 (8) 
53 (71) 
3 (4) 
1 (1) 
1 (1) 
Table 5.3: Details of medication 
Medication No (%) 
Beta blockers 
ACEI 
ARB 
Inotropes 
51 (68) 
55 (73) 
4 (5) 
7 (9) 
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47 patients (63%) underwent PCI and 10 (13%) had CABG. 3 (4%) had CRT implantation and 1 
(1%) had CRT-D implantation.  Two patients had previously undergone CRT device implantation.  
In-patient echocardiography was performed in all patients. 23 (31%) had mild LV systolic 
dysfunction, 34 (45%) had moderate LV systolic dysfunction and 18 (24%) had severe LV systolic 
dysfunction. 
9 (12%) patients died during the 12 week follow up period. The Euro Heart Failure Survey Score 
was calculated for all patients. The relationship between the score and risk of death before 12 
weeks from admission is given in table 5.4. None of the patients with a risk score below 5 died. 
In patients with a risk score of > 5, there was almost a linear relation between increasing score 
and increasing risk of death. 
Table 5.4. Frequency distribution of Euro Heart Failure Survey score and death in this study 
population 
Risk Score No (%) Died (%) 
1 11 (15) 0 (0) 
2 18 (24) 0 (0) 
3 6 (8) 0 (0) 
4 8 (11) 0 (0) 
5 9 (12) 2 (22) 
6 8 (11) 2 (25) 
7 10 (13) 2 (20) 
8 4 (5) 2 (50) 
9 1 (1) 1 (100) 
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5.5 DISCUSSION  
This validation study of the Euro Heart Failure Survey score shows that this score can predict 
the risk of death within 12 weeks of hospital admission with heart failure. A risk score below 5 
indicates good prognosis with a very low risk of death in the short term whereas a score of 5 or 
above indicates worse prognosis with a substantial risk of death within 3 months.  
This reiterates the observation from other large registries such as ADHERE, OPTIME-HF and 
EFFECT that a few simple clinical variables that are readily available can reliably predict short 
term mortality in hospitalised patients with heart failure.[66-68]  Although some variables such 
as age are non modifiable, other variables such as renal impairment can be modified by 
adjusting the fluid status and the dose of diuretic medication. Left ventricular impairment may 
be improved at least in some patients with appropriate medical or device therapy. 
While, some patients may be truly unable to tolerate beta blockers and ACE inhibitors due to 
severe hypotension caused by low-output cardiac state, most would be able to take these 
medication in at least small doses. It is still common to withhold beta blockers in patients with 
airways disease and decompensated heart failure. However the evidence is for the contrary. In 
the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization 
(ESCAPE) trial, consistent beta-blocker use during hospitalization of patients with 
decompensated heart failure was associated with a significant reduction in the rate of re-
hospitalization or death within six months after discharge (odds ratio 0.27, 95% confidence 
interval 0.10 to 0.71; p < 0.01).[121] The same observation was noted in the OPTIME-HF 
program and in addition withdrawal of beta-blocker therapy during hospitalisation for 
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decompensated heart failure was associated with worse risk and propensity-adjusted mortality. 
[122] 
 A study from University of Hull has shown that the majority of patients with heart failure and 
obstructive airways disease can safely tolerate low dose initiation and gradual up titration of 
beta blockers.[123] The population with true absolute contraindication for beta blocker therapy 
such as bronchial asthma is like to be very small. Hence we should endeavour to get everyone 
on these life saving medication prior to discharge from hospital. 
Finally the risk score may help us to identify those patients who are candidates for palliative 
therapy. As very elderly patients with severe left ventricular and renal impairment who are 
unable to tolerate beta blocker or ACE inhibitor therapy clearly have a grave prognosis, they are 
better managed by palliative therapy rather than referred for CRT or ICD therapy. 
5.6 LIMITATIONS 
The sample size for this study was small. However, the patient population is representative of a 
“real life” heart failure in-patient cohort seen every day in an average UK hospital. 
5.7 CONCLUSIONS 
The Euro Heart Failure Survey risk score is useful in predicting short term mortality in 
contemporary patients admitted to hospital with heart failure.  
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CHAPTER 6. CHOLESTEROL LEVEL AND RISK OF DEATH IN HEART FAILURE –A 
REVIEW OF LITERATURE ABOUT THE CHOLESTEROL PARADOX 
6.1 INTRODUCTION 
Heart failure is caused by left ventricular systolic dysfunction in more than half of the cases and 
this is usually due to coronary artery disease (CAD) or dilated cardiomyopathy. 
Hypercholesterolemia is a major risk factor for CAD.  Statins (3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase inhibitors) are highly effective in reducing Low Density Lipoprotein (LDL) 
cholesterol levels by reducing the endogenous synthesis of cholesterol. Statins have been 
shown to reduce mortality and morbidity in large randomised controlled trials in patients with 
CAD.[124-127] Retrospective analyses of data from clinical trials of other agents, database 
analysis and re-analysis of data from statin trials have suggested that there might be a benefit 
from statins in patients with heart failure.[128-133]  Statins have other biological effects apart 
from cholesterol lowering which are of potential benefit for patients with HF.[93, 94, 134-138]  
Paradoxically, however, low cholesterol level is an adverse prognostic marker in patients with 
chronic heart failure. [139-141] 
6.2 STATINS IN CORONARY HEART DISEASE 
Large randomised controlled trials such as Scandinavian Simvastatin Survival Study (4S), CARE 
and LIPD have demonstrated that statins can reduce the rate of vascular events in patients who 
have actual or circumstantial evidence of stable atherosclerotic vascular disease.[125-127] The 
Heart Protection Study (HPS) showed that adding simvastatin to existing treatments safely 
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produces substantial additional benefits for a wide range of high-risk patients, irrespective of 
their initial cholesterol concentrations.[142] However, the evidence for primary prevention of 
cardiovascular events by statin therapy is not as strong as for secondary prevention. The 
WOSCOPS study showed that in men with moderate hypercholesterolemia and no history of 
myocardial infarction, treatment with pravastatin significantly reduced the incidence of 
myocardial infarction and death from cardiovascular causes although there was no reduction in 
overall mortality.[143]  More recent trials have demonstrated that statins are effective in the 
treatment of patients presenting with acute coronary syndromes and statins are now part of 
standard treatment of acute coronary syndrome and stable CAD.[144, 145]   
6.3 STATINS IN HEART FAILURE  
Many patients with CAD have left ventricular systolic dysfunction, either symptomatic or 
asymptomatic, as a result of previous acute coronary events or chronic myocardial ischaemia. 
In these patients, statins may indirectly help to preserve left ventricular function by preventing 
further acute coronary events. However, all the major randomised controlled trials of statins in 
CAD have specifically excluded patients with heart failure by design. Retrospective analysis of 
4S study found that simvastatin reduced the occurrence of heart failure in a cohort of patients 
with coronary heart disease without previous evidence of congestive heart failure.[146]  
Analyses from PROVE IT-TIMI 22 and TNT studies suggested that intensive statin therapy 
reduced the risk of hospitalisations with HF,[147, 148] but there is no direct evidence that 
statins might be useful for patients with established heart failure. 
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6.4 PLEIOTROPIC EFFECTS OF STATINS IN PATIENTS WITH HEART FAILURE 
6.4.1 Beyond lipid lowering 
Statins have many effects beyond simply lowering cholesterol (the so called pleiotropic effects) 
including improvement in endothelial function, reduction in oxidative stress, anti inflammatory 
and anti thrombotic properties, regulation of autonomic function, anti arrhythmic effects, 
reduction of myocardial hypertrophy, reduction of angiotensin II mediated vasoconstriction, 
induction of angiogenesis and reduced apoptotic rate.[135]  
6.4.2  Anti-oxidant properties 
Statins interact with the nitric oxide (NO) pathway and increase NO bioavailability. There is 
evidence from animal experiments and a few human studies to support this hypothesis.[149, 
150] Oxidative stress by increased production of oxygen free radicals in patients with HF is 
linked with the development of myocardial hypertrophy and progression of heart failure in 
animal studies.[151]  Statins have antioxidant properties and reduce NADPH dependent 
superoxide formation which may contribute to the beneficial effect of statins in HF.[152] Statins 
also inhibit the synthesis of isoprenoids, thereby decreasing vascular and myocardial oxidative 
stress.[153]  
6.4.3 Anti-inflammatory actions 
Increased circulating levels of tumour necrosis factor alpha (TNF-α), interleukin-6, and the 
soluble TNF receptors have been shown to be independent predictors of higher mortality 
in patients with advanced heart failure.[154] In small studies, statins appear to interfere in
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Table 6.1: Trials of statins and heart failure 
Study Patients 
Follow-up & 
outcome 
Results 
Hazard Ratios (HR) for outcome with Statin 
therapy 
Horwich et al. [155] 
Observational 
A University centre 
N=551 
LVEF <= 40% 
Referred for HF treatment and/or transplant 
evaluation 
45% IHD 
Mean age 52 ± 13 years 
1 year 
All-cause 
mortality or 
urgent heart 
transplant 
 
HR 0.44 (95% CI 0.30 – 0.67), p=0.0001 
[All-cause mortality: HR 0.52 (95% CI 0.30 – 
0.90), p=0.017] 
 
Sola et al. [137] 
Observational 
N=446        Stable HF treatment 
LVEF <=35% 
NYHA II/III 
44% IHD 
Mean age (Statin) 55.4 ± 6.4 & (No statin) 53.8 ± 
5.7 years. 
2 years 
All-cause 
mortality  
 
 
HF hospitalisation 
 
Statin 38/255 (15%) vs No statin 63/191 
(33%), p<0.0001 
 
Statin 57/255 (22%) vs No statin 72/191 
(37%), p<0.0001 
Anker et al. [156] 
Observational 
1) N=3132 [397 (13%) on statin] in ELITE II Study 
Median FU 559 days 
1-year 
All-cause 
 
Statin 8% (5-10%) vs No Statin 12% (11-
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Analyses of 2 studies 
 
mean age 71.5 ± 6.8 yrs 
LVEF 31.1 ± 6.9% 
71.3% IHD 
 
 
2) N=2068 [from HF clinics in 5 EU tertiary centres, 
max. n=693 from Ludwigshafen, Germany; 705 
(34%) on statin] 
Median FU 742 (486-1331) days 
Age 61.7 ± 0.3 years 
LVEF 30.1 ± 0.3% 
58.1% IHD 
mortality 
 
 
 
 
 
1-year 
All-cause 
mortality 
 
 
3 year 
All-cause 
mortality 
 
13%), p<0.001 
HR 0.61, 95% CI 0.44-0.84, p=0.0028) 
corrected for age, sex, LVEF, cholesterol, 
beta-blockers (at baseline) and BMI. 
 
Statin 7% (6-9%) vs No Statin 14% (12-16%), 
(χ2 = 20.1, p < 0.0001) 
 
 
Statin 22% (16-29%) vs No statin (31-35%),  
(χ2 = 26.6, p < 0.0001) 
 
Foody et al. [130]  
Observational 
N=54960 (16.7% received statin) 
USA -Medicare beneficiaries Between 4/1998 & 
3/1999 and 7/2000 & 6/2001 
All-cause 
mortality 
1-year 
 
HR 0.80 (95% CI 0.76 – 0.84), p<0.001 
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Age >= 65 years 
Discharge from hospital with new HF diagnosis 
 
3-year 
HR 0.82 (95% CI 0.79 – 0.85), p<0.001 
Ray et al. [157] 
Observational 
N=28828 (4.0% received statin)    Ontario, Canada 
Age 66 – 85 yrs (mean 76.5 yrs) 
Survived > = 90 days following hospitalisation for 
newly diagnosed HF. 
7 years 
Death/AMI/Stroke 
 
 
Statin 13.6 vs No statin 21.8 per 100 person-
years. 
HR 0.72 (95% CI 0.63 – 0.83) 
 
Kjekshus et al. [146]  
Retrospective 
analysis of 4S 
 
N=4444 
All IHD 
 
 
Median 5.4 years 
New HF (n=412) 
[mean age 61 yrs] 
 
 
New HF and died 
Simvastatin 184/2221 (8.3%) vs Placebo 
228/2223 (10.3%), p<0.015 
 
Simvastatin 47/2221 vs 73/2223, RR 0.63 
(95% CI 0.44 – 0.91, p=0.014) 
For the 412 who developed new HF, 
simvastatin was associated with 19% 
reduction in mortality. 
Mozaffarian et al. 
[158] 
Retrospective 
analysis of PRAISE 
N=1153 
LVEF <= 30% & NYHA IIIB/IV 
134 (12%) had statin at baseline or during follow-
up 
Mean 15 months 
All-cause 
mortality 
 
Statin 12 vs No statin 31 deaths/100 person-
years, p<0.001 [HR 0.38 (95% CI 0.23 – 0.65, 
p<0.001)]Statin was also associated with 
lower sudden death and pump failure death 
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Scirica et al.[148]  
PROVE IT – TIMI 22 
Randomised trial 
N = 4162 
North America, Europe and Australasia. 
Age 58 +/- 11 yrs 
Recent hospitalisation with ACS 
2 years 
HF admission 30 
days after 
randomisation 
Atorvastatin 80 mg od: 1.6% vs.  
Pravastatin 40 mg od: 3.1%,  
HR (Atorvastatin 80 mg) 0.55, (95% CI 0.35 
to 0.85), p = 0.008 
Khush et al.[147] 
TNT study 
Randomised trial 
N = 10,001 
Age 35 – 75 yrs; mean = 61 yrs 
Stable coronary artery disease 
4.9 years 
Hospitalization for  
HF  
Atorvastatin 80 mg: 2.4% vs 10 mg: 3.3%  
HR (Atorvastatin 80 mg) 0.74, (95% CI 0.59 
to 0.94), p=0.0116 
CORONA trial[96] N = 5011 
Age = 73 + 7 (at least 60 years) 
NYHA II – IV 
LVSD secondary to IHD (EF = 0.31 + 0.07) 
32.8  months 
Death from CV 
causes, non fatal 
MI or stroke 
Death 
 
HR (Rosuvastatin)  0.92 (95%CI 0.83 – 1.02) 
p = 0.12 
HR (Rosuvastatin)  0.95 (95%CI 0.86 – 1.05) 
p = 0.31 
GISSI-HF trial [97] N = 4574 
Age = 68 + 11 (at least 18 years) 
Chronic heart failure of NYHA II – IV, irrespective 
of cause and LV ejection fraction 
3.9 years 
Death 
Death or 
hospitalisation for 
CV causes 
 
HR (rosuvastatin) 1·00 (95% CI 0·9 1·1), 
p=0·943. 
HR (rosuvastatin) 1·00 (95% CI 0·9 1·1), 
p=0·903 
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the inflammatory pathway leading to reductions in serum levels of high sensitivity C-
reactive protein, IL-6, brain natriuretic peptide and TNF-α receptor II.[93, 153] Statins may 
have an antithrombotic effect.[159] It is also postulated that statins might reduce the 
vasoconstrictor effect of angiotensin II by downregulating the AT1 receptors in vascular 
smooth muscle cells.[135]  
6.4.4 Statins and apoptosis 
Animal studies suggest that statins can decrease the rate of apoptosis, thereby reducing 
the development of cardiac hypertrophy and fibrosis.[160] Statins may also modulate the 
remodelling process of heart failure through effects on matrix metalloproteinases.[161]  
Whether these experimental data will translate into a clinical effect is not yet clear. Sola et 
al showed that atorvastatin improved left ventricular function and serum markers of 
inflammation in non ischaemic heart failure.[162] However in the UNIVERSE trial, high 
dose rosuvastatin did not beneficially alter LV remodelling in patients with HF. [163] 
6.4.5 Left ventricular function 
Several observational studies and retrospective analyses of randomised controlled trials 
have suggested that statins might be beneficial in patients with heart failure (table 6.1) 
with and without CAD.  In observational short term studies, statin use was associated with 
improvement in left ventricular ejection fraction, peak oxygen consumption and 
attenuation of adverse left ventricular remodelling even in patients who had dilated 
cardiomyopathy.[153, 164] 
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6.4.6 Anti-arrhythmic properties 
Vrtovec et al showed that in a group of 40 patients who received atorvastatin 10 mg od 
for a period of 3 months, statin therapy increased heart rate variability (HRV), decreased 
QT variability, and shortened QTc interval as compared to the control group. Several small 
studies and analyses of the MADIT -2 and DEFINITE trials done in post MI patients have 
suggested that statins have anti-arrhythmic properties leading to reduction in sudden 
death due to arrhythmias in both ischemic and non ischemic cardiomyopathy.[165-167]  
However, the majority of the evidence suggesting the benefit of statin therapy in heart 
failure was derived from studies with small number of patients. It is also possible that in 
all these observational studies, statins might have been prescribed to younger patients 
with less severe disease and an apparently better prognosis and statin prescribing may be 
a marker of better access to healthcare systems.[168] 
6.5 ADVANCED HEART FAILURE AND CHOLESTEROL 
Chronic heart failure may lead to a catabolic state and eventually cachexia in advanced 
cases.[169] The mechanisms underlying cachexia are poorly understood but appear to 
reflect increased resting energy consumption. There is preferential loss of fat but also a 
decline in lean body mass. This can only partially be explained by increased myocardial 
work, increased work of breathing or sympathetically mediated increases in 
thermogenesis by brown fat. Reduced efficiency of ATP production by mitochondria, 
reduced appetite, malabsorption and reduced levels of anabolic steroids may play a role. 
[169]  
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Patients with advanced heart failure have severe symptoms, a high mortality and a  low 
cholesterol.[139] This may be due to inflammation, endotoxins, adrenergic activation, 
oxidative stress, tissue injury, hepatic dysfunction and cachexia.[134, 138] A similar 
constellation of factors is likely to be responsible for low cholesterol and the catabolic 
state. Higher cholesterol levels were noted to be associated with better survival in 
patients with chronic heart failure (figure 6.1).[139]   
6.5.1 Reverse Epidemiology 
In patients with advanced heart failure, the traditional risk factors of poor clinical outcome 
and mortality in the general population such as obesity, hypercholesterolemia, and high 
values of blood pressure have been associated with greater survival.[92, 170] The 
association between low cholesterol and increased mortality in HF is part of this “reverse 
epidemiology”, which is also seen in other patient populations such as those with end 
stage renal disease. [171] However, the mechanism is not clear. Malnutrition, 
immunologic reaction and inflammation have been postulated as causes of low 
cholesterol and adverse prognosis.[92] Circulating lipoproteins help to neutralize bacterial 
lipopolysaccarides (LPS) and endotoxins which may be sources of inflammatory activation. 
[139] 
However, low cholesterol might simply reflect more advanced illness and thus be a marker 
of worse prognosis rather than be a mediator. The low cholesterol may reflect reduced 
food intake, reduced intestinal absorption due to bowel oedema and as a result of 
increased metabolic stress.[172] This is supported by the observation that the possible 
benefit of statin therapy in heart failure may be independent of cholesterol levels.[156]  
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Figure 6.1: Relation between cholesterol level and mortality in a cohort of 114 patients 
with chronic heart failure, followed up to 3 years.  
(Reproduced with permission: Rauchhaus M, Clark AL et al.  JACC 2003;42:1933-40) 
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6.6 STATINS AND COENZYME Q10 
 Theoretically, statins might have adverse effects in patients with heart failure for 
several reasons. Further reductions in cholesterol and lipoproteins could have adverse 
consequences as noted above. Statins can affect coenzyme Q10 (CoQ10). This is a 
component of the mitochondrial electron transport chain and participates in aerobic 
cellular respiration, generating energy as ATP. The heart and the liver have high CoQ10 
concentrations under normal circumsatnces.  Statins reduce circulating levels of 
CoQ10, as this is transported in lower-density lipoproteins.[173, 174]   COQ10 levels in 
serum and the myocardium have been shown to be low in HF patients, with potential 
for further decrease in these levels with a statin, particularly in the elderly.[175, 176] 
Coenzyme Q10 deficiency may exacerbate the poor contractility of myocardial cells in 
CHF patients because, in the setting of LV dysfunction, the myocardium demonstrates 
oxidative stress and coenzyme Q10 can reduce this oxidative stress and improve 
energy production in the mitochondria. [176-179]  There have been claims that CoQ10 
supplementation could improve LV function, but other studies were neutral.[179-183] 
CoQ10 reduction with statin therapy has been postulated as one of the mechanisms 
for the neutral outcome of UNIVERSE trial, where rosuvastatin did not improve 
adverse cardiac remodelling in chronic heart failure.[184]  
6.7 DRUG INTERACTIONS 
Several drug interactions have been noted between statins and other heart failure 
drugs. In experimental studies in humans, atorvastatin has decreased the inhibitory 
effect of clopidogrel on platelet aggregation.[185] Most statins have been reported to 
increase the anticoagulant effect of warfarin, requiring slight warfarin dosage 
reduction.[185] High doses of some statins (eg, simvastatin and atorvastatin) can 
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slightly increase the plasma concentrations of digoxin (up to 20%).[185] The 
mechanism of these interactions is poorly understood, but the clinical significance of 
these interactions is likely to be limited in routine clinical practice. 
6.8 RECENT RANDOMISED TRIALS OF STATIN THERAPY IN HEART FAILURE 
CORONA was a large, multi- centre trial of 5011 patients of at least 60 years of age 
(mean = 73 + 7) with NYHA II-IV class symptoms and heart failure due to left 
ventricular systolic dysfunction (mean ejection fraction = 0.31 + 0.07) secondary to 
underlying ischaemic heart disease.[96] Patients were randomised to rosuvastatin 10 
mg or placebo. Median follow up was 32.8 months. Rosuvastatin did not reduce the 
number of deaths from any cause or the primary outcome, a composite endpoint 
comprising death from cardiovascular causes, non fatal myocardial infarction or stroke. 
As expected with a potent lipid lowering drug, there was a substantial reduction in the 
levels of low density lipoprotein (LDL) cholesterol and high sensitivity C reactive 
protein in the rosuvastatin group. There was no reduction in the number of patients 
hospitalised, but a significant reduction in the total number of hospitalisations was 
noted in the rosuvastatin group. There was no excess of muscle related or other 
adverse events observed with rosuvastatin. 
Although the results of CORONA were neutral, a number of questions remain 
unanswered. A class effect of statins cannot be assumed, as learnt from experience 
with cerivastatin, which did not lower LDL cholesterol to the same extent as other 
statins, but higher incidence of rhabdomyolysis was observed.[186, 187]  CORONA was 
limited to patients with ischaemic heart failure, already on evidence based therapy 
with beta blockers and angiotensin converting enzyme blockers or angiotensin 
receptor blockers. It is possible that some beneficial effect of rosuvastatin might be 
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more important in patients with non ischemic heart failure or those with heart failure 
and preserved left ventricular function. It is also possible that there might be a small 
benefit of rosuvastatin  in younger patients with a better prognosis who are hence 
going to be followed up for a longer time, such that there was no benefit in older 
patients with a shorter follow up. 
GISSI-HF is a multicenter, randomized, double-blind clinical trial examining the effect of 
n-3 polyunsaturated fatty acids and rosuvastatin at a dose of 10 mg versus placebo on 
the cardiovascular morbidity and mortality of patients with chronic symptomatic 
HF.[97]  In this trial, patients  with heart failure of NYHA class II-IV, irrespective of 
cause and left ventricular ejection fraction, were randomly assigned to rosuvastatin 10 
mg daily (n=2285) or placebo (n=2289) and followed up for a median of 3.9 years. 
Primary endpoints were time to death, and time to death or admission to hospital for 
cardiovascular reasons. 29% died in rosuvastatin group and 28% died in placebo group. 
Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart 
failure of any cause. 
6.9 CONCLUSIONS 
Statin therapy to lower LDL cholesterol is established in the treatment of coronary 
artery disease. The assumption that statins will also be useful in treatment of heart 
failure, for which coronary artery disease is the main contributing factor, is supported 
by only a number of small studies. However the mechanisms for the potential benefit 
of statin therapy in heart failure seem different as advanced heart failure is a highly 
catabolic state and is associated with adverse prognostic factors such as cardiac 
cachexia, elevated inflammatory markers and low cholesterol levels. These studies 
have shown evidence of beneficial pleiotropic effects of statins in heart failure, beyond 
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lipid lowering.  However this hypothesis was not proven in large randomised 
controlled trials such as the CORONA and GISSI-HF. It is still possible that statins may 
have role in the treatment of heart failure in patient populations different to those 
recruited in these trials, but they are currently not included as standard therapy in the 
guidelines for treatment of heart failure. 
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CHAPTER 7. CHOLESTEROL LEVEL AND RISK OF DEATH IN HEART FAILURE 
– THE FINDINGS FROM EURO HEART FAILURE SURVEY 
7.1 INTRODUCTION 
7.1.1 Cholesterol levels in heart failure 
As reviewed in the last chapter, patients with heart failure often have low cholesterol 
and this is usually associated with more advanced symptoms and increased 
mortality.[188] It is not clear whether low cholesterol is a marker or mediator of 
adverse prognosis. On the other hand many patients with heart failure may have 
hypercholesterolemia, as this is an important cause of ischemic heart disease, the 
most common etiology of heart failure. 
7.1.2 Causes of low cholesterol in heart failure 
Low cholesterol level in heart failure may be due to reduced food intake or due to 
metabolic stress caused by factors such as inflammation, endotoxins, adrenergic 
stimuli, oxidative stress and tissue injury due to cachexia.[134, 138, 172, 189] 
7.1.3. Role of statin therapy in heart failure 
Statin therapy has been advocated in both ischemic and non-ischemic heart 
failure.[155, 156, 190] This apparent paradox of recommending a treatment that 
lowers cholesterol for a condition where low cholesterol is an indicator of poor 
prognosis is supported by the evidence for the beneficial pleiotropic effects of statins. 
These include reduction of inflammatory factors, improvement of endothelial function, 
nitric oxide potentiation, angiogenesis, improvement in autonomic function and anti 
arrhythmic effects.[94, 95, 149, 159, 160, 164, 166] However statins could cause harm 
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by diminishing the ability of lipoproteins to bind endotoxins and can reduce levels of 
coenzyme Q10, an important factor in mitochondrial electron transport chain.[176] 
7.2. AIMS 
In this study, the following were examined in a patient population hospitalised with or 
suspected heart failure. 
1. Relation between cholesterol level and short term (12 week) mortality  
2. Relation between statin therapy, cholesterol level and mortality. 
7.3 METHODS 
The data from Euro Heart Failure Survey, held at the University of Hull were used for 
this analysis. This survey was conducted on 10,701 patients, hospitalised with or 
suspected heart failure in 115 hospitals from 24 ESC countries during 2000-2001. Data 
on clinical profile, investigations and treatment were collected and vital status 
determined at 12 weeks after admission. Lipid lowering therapy was assumed as statin 
therapy in view of contemporary practice at the time of survey. 
7.4 RESULTS 
7.4.1 Cholesterol levels 
Serum total cholesterol level (mmol/l) was available for 5729 patients. Hence this 
study population consists of these 5729 patients. The mean cholesterol was 5.04 
mmol/l (SD 1.44). The cholesterol levels were normally distributed (figure 7.1). 1506  
(26%) patients were on lipid lowering therapy, assumed with statins. Patients on lipid 
lowering treatment were likely to have a higher cholesterol (5.2 mmol/l vs 5.0 mmol/l; 
p < 0.001) than those who were not on treatment (table 7.1). 
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Figure 7.1. Distribution of cholesterol level in Euro Heart Failure Survey 
 
 
Table 7.1 Cholesterol levels (mmol/l), treatment and survival 
Group N (%) Mean (mmol/l) SE p 
Alive vs Dead  
Alive 5123 (89) 5.1 0.02 
< 0.001 
Dead 606 (11) 4.7 0.06 
Lipid lowering treatment  
No 4223 (71) 5.0 0.02 
< 0.001 
Yes 1506 (29) 5.2 0.04 
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7.4.2 Mortality and cholesterol level 
606 patients (11%) had died by 12 weeks from admission. These patients had lower 
cholesterol when compared to those who were alive at 12 weeks after admission (4.7 
vs 5.1 mmol/l; p < 0.001) (table 7.1). Patients who died had lower cholesterol 
irrespective of whether they were on lipid lowering therapy or not (table 7.2). The 
difference was statistically significant in those not on lipid lowering therapy (p < 0.001) 
but not in the group which was on lipid lowering therapy (p = 0.526). 
TABLE 7.2 Survival vs Lipid lowering treatment and mean cholesterol levels 
Status 
Total 
N 
(cholesterol) 
Lipid Regulators 
No Yes 
Total 
5729 
(5.0 mmol/l) 
4223 
(5.0 mmol/l) 
1506 
(5.2 mmol/l) 
Alive 
5123 
(5.1 mmol/l) 
3688 
(5.0 mmol/l) 
1435 
(5.2 mmol/l) 
Dead 
606 
(4.7 mmol/l) 
535 
(4.6 mmol/l) 
71 
(5.1 mmol/l) 
P value < 0.0001 < 0.0001 0.526 
 
When the cholesterol level was divided into quintiles, I found a linear association 
between the level of cholesterol and risk of death. The lower the cholesterol, the 
higher the risk of death (table 7.3.A and figure 7.2). Among those on lipid lowering 
therapy, the relationship was “U” shaped (table 7.3.B and figure 7.3), as higher rates of 
death were observed in those with a very low cholesterol level and in those with a high 
cholesterol level despite lipid lowering therapy. 
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TABLE 7.3. Relation between cholesterol levels in quintiles and mortality 
A: All patients 
 
 B: Patients on lipid lowering drugs 
Vital Status Cholesterol - mmol/l (mg/dl) - Quintiles 
Total 
< 3.91 
(<151) 
3.91 - 4.64 
(151 - 179) 
4.65 - 5.30 
(180 – 205) 
 5.31 - 6.09 
(206 – 235) 
> 6.09 
(> 235) 
Alive Count 1001 978 1090 1019 1046 5134 
% of total survivors 19.5% 19.0% 21.2% 19.8% 20.4% 100% 
Survivors within quintile  83.4% 89.2% 91.1% 91.0% 92.6% 89.4% 
Dead Count 199 119 106 101 83 608 
% of total deaths 32.7% 19.6% 17.4% 16.6% 13.7% 100% 
Deaths within quintile  16.6% 10.8% 8.9% 9.0% 7.4% 10.6% 
Vital Status Cholesterol - mmol/l (mg/dl) - Quintiles 
Total 
< 3.91 
(<151) 
3.91 - 4.64 
(151 - 179) 
4.65 - 5.30 
(180 – 205) 
 5.31 - 6.09 
(206 – 235) 
> 6.09 
(> 235) 
Alive Count 262 253 285 253 385 1438 
% of total survivors 18.2% 17.6% 19.8% 17.6% 26.8% 100.0% 
Survivors within quintile  94.2% 94.8% 96.0% 96.9% 94.8% 95.3% 
Dead Count 16 14 12 8 21 71 
% of total deaths 22.5% 19.7% 16.9% 11.3% 29.6% 100.0% 
Deaths within quintile  5.8% 5.2% 4.0% 3.1% 5.2% 4.7% 
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Figure 7.2. Relation between cholesterol level in quintiles and mortality within each 
quintile. 
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Figure 7.3. Mortality related to cholesterol level in patients on lipid lowering drugs.  
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On univariate analysis, a cholesterol level of > 5mmol/l was associated with a lower 
risk of death (OR 0.6, 95%CI 05 – 0.7; p < 0.001) and statin therapy was also associated 
with a better prognosis (OR 0.3, 95%CI 0.3 – 0.4; p < 0.001). 
In a multivariable model, predicting mortality (chapter 4), statin therapy was 
independently associated with mortality. The following factors were included in the 
model; sex, presence of severe LVSD, mitral regurgitation, major valvular disease, 
hypertension, atrial fibrillation, treatment with ACEI, ARB,  beta-blockers, loop diuretic, 
thiazide diuretic,  calcium channel blockers, digitalis, nitrates, inotropic agents, anti 
thrombotic agents, anti arrhythmic drugs and lipid regulators  as categorical variables 
and age, sodium, potassium, Hb, urea, creatinine, cholesterol, urate, QTc & QRS 
durations as continuous variables.  
7.4.3 Cholesterol level and left ventricular systolic dysfunction. 
Echocardiogram results were available for 4213 patients (out of a total study 
population of 5729 patients). Among these, 702 (17%) had mild LV systolic dysfunction, 
1009 (24%) had moderate LV systolic dysfunction and 1320 (31%) had severe LV 
systolic dysfunction.  
Those patients who had significant (moderate or severe) LV dysfunction had slightly 
lower cholesterol as compared to those without significant LV dysfunction (4.98 
mmol/l vs 5.08 mmol/l; p = 0.046) (figure 7.4). When the population was divided into 
two groups, alive and dead, this relation with LV function was still observed (figure 
7.5). 
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Figure 7.4. Relation between cholesterol level and LV systolic dysfunction 
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Figure 7.5 Relation between cholesterol level, LV systolic dysfunction and mortality 
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7.5 DISCUSSION 
The findings from this large international survey demonstrate an inverse association 
between cholesterol level and risk of death but a better prognosis with statin therapy, 
thus showing the “cholesterol paradox”. 
The linear association between cholesterol level and risk of death contributes further 
evidence to the “reverse epidemiology” in heart failure. This is most likely a part of 
general cardiac cachexia, such that low cholesterol is simply a marker rather than 
mediator of poor prognosis.  
The beneficial effect of statin therapy could be explained in two ways. As discussed in 
the last chapter, statin therapy has been shown to have pleiotropic beneficial effects in 
heart failure independent of lipid lowering. The other possibility is that statins 
contributed to reduction in ischemic events mediated by lipid lowering in patients with 
hypercholesterolemia and atherosclerotic plaque stabilisation. This is supported by the 
observation that patients who had hypercholesterolemia despite taking statin therapy 
had a higher risk of death (figure 7.3 and table 7.3B). However it should be noted that 
only a quarter of all patients were on lipid lowering therapy as the mean cholesterol 
level in this population was not high (5 mmol/l). 
Two large randomised trials (CORONA and GISSI-HF) did not show evidence of benefit 
from statin therapy in patients with heart failure, thus contradicting evidence from 
observational studies, including this one.[96, 97] However there remains a possibility 
that a statin therapy might be beneficial in some select groups, not well represented in 
these randomised trials. 
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A weak relation between cholesterol level and severity of left ventricular dysfunction 
has been observed, Again, it is likely that low cholesterol in patients with significant LV 
dysfunction is simply a marker of higher risk group. 
7.6 LIMITATIONS 
I acknowledge that this analysis has several limitations. This is an observational study 
and only total cholesterol levels were studied with no differentiation between random 
and fasting lipid levels. The lipid regulator therapy had been assumed as statins. 
However the large patient numbers would have offset some of these limitations. 
7.7 CONCLUSIONS 
In the Euro Heart Failure survey, there was an independent inverse association with 
cholesterol level and risk of death. This relationship was linear as those with the lowest 
cholesterol levels appear to be at the highest risk of death. A weak association was 
observed between cholesterol level and severity of LV systolic dysfunction.  
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CHAPTER 8. ECG AS A PREDICTOR OF SEVERITY OF HEART FAILURE -  
RELATIONSHIP BETWEEN REPOLARISATION ABNORMALITIES ON THE 
SURFACE ELECTROCARDIOGRAM AND SEVERITY OF LEFT VENTRICULAR 
SYSTOLIC DYSFUNCTION – A REPORT FROM THE EURO HEART FAILURE 
SURVEY. 
8.1 BACKGROUND 
Electrocardiography (ECG) is a simple investigation, routinely performed in all cardiac 
patients. It may be useful to risk stratify patients suspected to have heart failure since 
those without an abnormal ECG are less likely to have left ventricular dysfunction. ECG 
abnormalities such as evidence of previous myocardial infarction, left ventricular strain 
and bundle branch block can suggest presence of left ventricular dysfunction. Other 
ECG abnormalities such as QT prolongation are known to be associated with increased 
risk of coronary heart disease and cardiovascular death.[191-193].  
8.2 QT PROLONGATION 
The QT interval, which represents the duration of ventricular electrical systole, i.e., the 
time required for completion of both ventricular depolarisation and repolarisation, has 
been a variable of particular interest in cardiology and may provide information about 
ventricular function. Although a high prevalence of QT prolongation has been reported 
in patients with heart failure, its mechanism and significance are uncertain.[194] 
Whether QT interval is related to the severity of left ventricular dysfunction or poor 
prognosis in patients with heart failure remains controversial.[194-198] However, as 
the QT interval includes the duration of activation as well as repolarisation of the left 
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ventricle, it will be influenced by QRS width, which has already been shown to predict 
both increased mortality and sudden death in patients with heart failure.[199]  In this 
study, I have examined the relationship between ECG intervals and the presence and 
severity of LV dysfunction. 
8.3 AIMS 
In this study I have examined the following hypotheses using the data from Euro Heart 
Failure Survey.  
1. The QT interval is prolonged in patients with left ventricular systolic dysfunction 
(LVSD). 
2. The degree of QT prolongation is related to the severity of LVSD. 
3. QRS prolongation and QT prolongation are independently associated with 
LVSD. 
 
8.4 METHODS 
In the Euro Heart Failure survey, data were collected from 10,701 patients with 
suspected heart failure in 115 hospitals across 24 European countries during 2000-
2001, over 6 weeks. The detailed design of this study has been published previously.[4] 
In short, all consecutive discharges and deaths in the departments of cardiology, 
cardiovascular surgery, general internal medicine and care of the elderly were 
screened for 6 weeks and patients were enrolled if they fulfilled at least one of the 
following criteria: (1) a clinical diagnosis of heart failure during the admission; (2) a 
diagnosis of heart failure recorded at any time in the last three years; (3) 
administration of a loop diuretic for any reason other than renal failure in the 24 hours 
prior to death or discharge; (4) pharmacological treatment for heart failure or 
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ventricular dysfunction in the 24 hours prior to death or discharge. Data were collected 
on co-morbid conditions including hypertension, diabetes and renal impairment. 
Investigations included a 12 lead ECG, echocardiogram and routine blood tests. Vital 
status (dead or alive) was determined at 12 weeks after discharge. 
8.4.1 ECG analysis 
The PR, RR, QT, QRS and JT intervals (figure 8.1) were measured from the original 12 
lead ECGs with a digital ruler-calliper (ABSolute digimatic, Mitutoya UK Ltd) by a single 
observer (my coworker, Dr Nasrin Khan), who was blinded to the patients’ clinical 
characteristics and the results of other investigations including echocardiography. 
Bazett’s method of correction for heart rate was used to calculate the QTc interval.[69] 
JTc interval was defined as QTc minus QRS duration.[200]  
Figure 8.1 ECG intervals 
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The normal QTc is generally accepted to be less than or equal to 440 milliseconds (ms). 
However the ARIC study, which included 14,672 healthy middle aged men and women, 
suggested that many apparently healthy people have values > 440 ms and that QTc 
and JTc durations are greater in women than in men.[192] Accordingly, I identified sex-
specific cut-off values for QTc (men; 464 ms and women; 481 ms) and JTc (men: 365 
ms and women: 387 ms) of 2SD above the mean of a large population (n=14,240) study 
of healthy subjects without QRS prolongation.[192]  
8.4.2 Echocardiography 
The echocardiograms were performed in the participating hospitals to assess left 
ventricular function and reported by the local cardiologists. Left ventricular systolic 
dysfunction was classified qualitatively into one of four categories; none, mild, 
moderate and severe. 
The data from 12 lead ECGs analysed as described above and echocardiographic data 
were available in the University of Hull. I had integrated these data by matching the 
ECG and Echocardiographic findings. I included 5934 patients who had both 12 lead 
ECG and echocardiogram results available for this analysis. 
8.4.3 Data Analysis 
I examined the relation between the ECG variables and the degree of LV systolic 
function. The group means were compared for significant differences by analysis of 
variance (ANOVA) or its non parametric equivalent, depending on the distribution of 
the data. The interaction of beta blocker treatment with LVSD was examined by log 
linear analysis. Correlation coefficients were calculated for interrelationship between 
QT variables and for any relation between QT variables with age and heart rate. Each 
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QT variable was arbitrarily divided into 5 categories of 20 ms intervals (QRS: < 100, 
100-120, 121-140, 141-160 and >160 ms. QTc: < 440, 441-460, 461-180, 481-500 and 
>500 ms. JTc < 330; 331-350, 351-370, 371-390 and >390 ms) and each category was 
examined by a multivariable logistic regression model to predict the severity of left 
ventricular systolic dysfunction. From this model, odds ratios (predicting moderate or 
severe LVSD) with 95% confidence intervals were obtained by comparing each 
category to the average effect of previous categories. A nominal level of 5% statistical 
significance was assumed (two-tailed). SPSS v16 software (SPSS Inc, Chicago, IL, USA) 
was used for statistical analysis. 
8.5 RESULTS 
The detailed patient characteristics and treatment profile have been published 
previously.[84, 85] In the present study group (n = 5934), the mean age was 69 (SD: 13) 
years; 41% (n = 2445) were women; 65% (n = 3874) had coronary disease; 26% (n = 
1572) had diabetes; 47% (n = 2784) had hypertension and 16% (n = 962) had renal 
dysfunction. 44% (n=2598) were treated with beta blockers. The patient characteristics 
were similar to that of the whole study population. 
The mean (SD) QT interval was 389 (55) ms; QTc = 447 (41) ms; QRS = 112 (29) ms; JT = 
277 (50) ms; JTc = 334 (37) ms; RR = 774 (189) ms and PR = 178 (36) ms. In 55% 
(n=3236) of patients the QTc was more than 440 ms.  32% of men and 17% of women 
had QTc prolongation 2SD above that of a healthy population. The higher proportion 
of men with QTc prolongation reflected the higher proportion with LVSD (81% of men 
versus 57% of women). 17% of men and 9% of women had JTc values 2SD above that 
of the healthy population.  29 % (n=1709) had QRS > 120 ms. 20 % (n = 1200) had LBBB 
pattern.  
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LVSD was present in 71% (n=4213); mild in 17% (n=1012), moderate in 23% (n=1374) 
and severe in 31% (n=1827). Patients with LVSD had prolonged QT (392 v 383 ms; p < 
0.001), QTc (449 v 439 ms; p < 0.001) and QRS (117 v 102 ms; p < 0.001) but not JT 
intervals. The QT, QTc and QRS intervals were longer with increasing severity of LVSD 
(see table 8.1 and figures 8.2 and 8.3). The JT and JTc intervals were shorter as LVSD 
increased in severity (figure 8.4). 
 
Table 8.1: ECG variables related to severity of LVSD 
Interval 
Median (IQR) 
No 
LVSD 
(n = 1721) 
Mild 
LVSD 
(n = 1012) 
Moderate 
LVSD 
(n = 1374) 
Severe 
LVSD 
(n = 1827) 
p value 
QT 384 (70) 390 (72) 391 (70) 395 (73) < 0.001 
QTc 437 (45) 439 (46) 442 (49) 453 (52) < 0.001 
QRS 95 (23) 101 (30) 104 (31) 118 (43) < 0.001 
JT 281 (66) 280 (69) 279 (69) 269 (61) < 0.001 
JTc 339 (43) 333 (42) 334 (45) 331 (47) < 0.001 
RR 778 (248) 820 (258) 796 (247) 761 (246) 0.824 
PR 168 (45) 172 (44) 172 (47) 179 (44) 0.213 
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Figure 8.2: Relation between QRS and severity of left ventricular systolic dysfunction 
(LVSD) 
 
 
Figure 8.3: Relation between QTc and severity of left ventricular systolic dysfunction 
(LVSD) 
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Figure 8.4: Relation between JTc and severity of left ventricular systolic dysfunction 
(LVSD) 
 
Patients treated with beta-blockers (n=2598; 44%) had a shorter QRS interval (110 v 
114 ms; p < 0.001) but a longer QT interval (396 v 384 ms; p < 0.001). When corrected 
for heart rate, beta-blocker treatment was associated with shorter QTc (443 v 449 ms; 
p < 0.001) and JTc intervals (333 v 336 ms; p = 0.005). This difference was consistent 
within all categories of LV systolic dysfunction (figures 8.2, 8.4 and 8.4). Patients 
treated with beta blockers were younger (66 v 70 years; p < 0.001) and had a lower 
heart rate (78 v 86 bpm; p < 0.001) than those who were not on them. On log linear 
analysis there was no significant interaction between the severity of LVSD and beta 
blocker treatment. QRS duration did not show any association with age (r = 0.04) or 
heart rate (r = -0.12). QRS interval was strongly correlated with QTc (r = 0.42; p < 
0.001), but the association of QRS interval with JTc (r = - 0.25) and RR (r = 0.12) 
intervals were weak. 
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When the QT variables were subjected to multivariable logistic regression analysis 
(that also included age, sex and beta blocker effect), I found that only QRS 
prolongation was an independent predictor of moderate to severe LV dysfunction. 
There was a “dose-response” effect with QRS interval prolongation, so that the odds of 
having moderate or severe LVSD increased with increasing QRS interval (table 8.2). No 
such effect was seen for QTc interval prolongation. 
Table 8.2: QRS and QTc prolongation predicting moderate or severe LVSD  
                            QRS   (ms) Odds Ratio 95 % CI 
< 100    (n=2509) Reference category 
100-120   (n=1716) 1.6 1.4 - 1.8 
121-140    (n=694) 2.1 1.7 - 2.3 
141-160   (n=551) 2.3 1.7 – 2.6 
> 160     (n=441) 3.5 2.6 – 4.4 
 
QTc  (ms) Odds  Ratio 95 % CI 
< 440  (n=2698) Reference category 
441-460  (n=1207) 1.1 0.9 – 1.2 
461-480  (n=866) 1.1 1.0 – 1.4 
481-500  (n=566) 1.0 0.9 – 1.3 
> 500  (n=594) 0.8 0.8 – 1.2 
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8.6.DISCUSSION 
This analysis from a large epidemiologic study shows that there is a relationship 
between QT prolongation and the presence and severity of LVSD, but this relationship 
is due to QRS prolongation. Indeed, the JT interval shortened with increasing severity 
of LVSD. This could reflect heightened sympathetic activity or it may be an artifact due 
to extension of the QRS interval into the start of the repolarisation phase.  
The QRS interval reflects the duration of ventricular electrical activation and increased 
QRS width indicates prolonged or delayed activation and is an approximate guide to 
cardiac dyssynchrony. There are several possible interconnected reasons for the 
association between QRS width and the severity of LVSD: (1) an increase in myocardial 
mass, (2) dilated ventricles, leading to longer activation pathways and (3) altered 
electrical conduction through the His-Purkinje system and/or myocardium. 
Dyssynchrony is more common in patients with longer duration of QRS, and may lead 
to worsening of the pre existing LVSD.[201] Thus, QRS prolongation may reflect both 
the cause and consequence of LVSD. In the presence of cardiac dyssynchrony, cardiac 
resynchronisation therapy (CRT) improves synchrony, left ventricular ejection fraction, 
symptoms, morbidity and mortality. [52, 202] 
Use of beta blockers was associated with shorter QRS and QTc intervals, the 
mechanism of which is not clear. Beta blocker toxicity is associated with prolonged 
QRS duration, and it is generally believed that beta blockers have no effect on QRS 
duration at therapeutic doses.[203] Hence this finding is surprising, and it is not known 
whether this is one of the mechanisms for the prognostic benefit observed with beta 
blockers in heart failure. However studies have shown that beta-blockers improve 
cardiac dyssynchrony, although the effect may be modest compared to CRT.[204, 205] 
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It is also possible that those patients with severe heart failure (and marked QRS 
prolongation) might not have tolerated beta blocker therapy and those on beta 
blockers were relatively healthy and hence had a shorter QRS interval. However, it 
should be noted that the association of shorter QRS interval with beta blocker therapy 
was seen independent of the severity of LV dysfunction.  To date, no randomized 
controlled trial has reported a shortening of QRS with beta-blocker therapy. However, 
the effect is modest (about 4 ms) and could very easily have been missed. 
8.7 CONCLUSIONS 
The ECG is useful in identifying the presence of left ventricular dysfunction and 
estimating its severity in patients suspected to have heart failure. The QRS interval 
appears to be the main determinant of QT interval in patients with heart failure and 
the best electrocardiographic marker of the severity of LV systolic dysfunction.  
The relationship between beta blocker treatment with QRS duration and dyssynchrony 
needs further study. 
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CHAPTER 9. THE UTILITY OF SIGNAL AVERAGED ECG IN RISK 
STRATIFICATION OF HEART FAILURE PATIENTS 
9.1 INTRODUCTION 
Randomised clinical trial data have shown that in general, sudden death constituted 
around 50% of all deaths in patients with heart failure.[14-22] Patients who have only 
minimal symptoms (NYHA 2) are those more likely to die from sudden death than 
those with severe symptoms (NYHA 3/4) in whom death from progressive heart failure 
is more common.[22] Thus patients with heart failure who are apparently quite well 
are those who may be at risk from sudden death. Hence it is important to accurately 
identify these patients in order to prevent sudden cardiac death in heart failure. 
Sudden cardiac death in patients with heart failure is commonly due to ventricular 
tachycardia (VT) or ventricular fibrillation (VF), as patients with heart failure are more 
prone to these arrhythmias.. Most life-threatening ventricular arrhythmias are due to 
re-entry phenomena which require an area of slow conduction to allow the 
perpetuation of an arrhythmia.[206] Following myocardial infarction, fibrosis results in 
areas of delayed ventricular activation which form the substrate for ventricular 
arrhythmias. The delayed ventricular activation may extend beyond the end of the QRS 
complex on the surface ECG forming so called “late potentials”. Patients with sustained 
monomorphic ventricular tachycardia during electrophysiological testing are more 
likely to have late potentials.[207]  
 There is “noise” in surface ECGs generated by skeletal muscle activity ranging in 
amplitude from 8 to 10 µv. This noise may mask the presence of late potentials which 
appear after the end of the QRS complex, as detected on the surface ECG. Signal-
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averaged electrocardiography (SAECG) allows the detection of low amplitude 
bioelectric potentials which are masked on surface ECG by averaging many QRS signals 
to remove interference, amplify the complexes, and letting finer detail of the QRS 
complexes appear. 
Abnormalities in the signal-averaged ECG are detected rarely in normal subjects, in 
only a small percentage of patients who have had myocardial infarction but not 
ventricular tachycardia and in up to 93% of patients with a history of sustained 
monomorphic VT[208]. The presence of late potentials is also associated with inducible 
sustained VT during electrophysiological testing.[209, 210] In contrast, late potentials 
are detectable in only 21% to 65% of patients with ischemic heart disease and a history 
of previous ventricular fibrillation.[208] Late potentials on SAECG are associated with 
an increased risk of ventricular tachycardia, sudden death and total mortality in 
patients after myocardial infarction.[70-76] The SAECG might thus be a useful tool for 
risk stratification in predicting sudden death in patients with chronic heart failure 
(CHF). However it may be limited to those at risk of monomorphic VT, as the 
association of late potentials with VF was not strong as with monomorphic VT. 
9.2 HYPOTHESES 
1. SAECG provides information on left ventricular systolic function. 
2. Abnormal SAECG is independently associated with higher risk of death in 
patients with heart failure. 
9.3 PATIENTS AND METHODS 
Consecutive patients with clinical symptoms and/or signs of chronic heart failure, 
being seen in a community heart failure clinic serving the population of Hull and the 
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East Riding of Yorkshire were recruited into the study. Fully informed written consent 
was obtained. The study was approved by the local ethics committee and by the Hull 
and East Yorkshire NHS Trust board.  
A total of 845 patients who were in sinus rhythm were recruited. SAECG recordings 
were made in every patient on one of two GE Mac 5000 machines during 2004-2005.  
315 patients were excluded due to the presence of bundle branch block or marked 
intra-ventricular delay with QRS duration > 150 ms, leaving 530 patients in the study. 
This was necessary to reduce the number of false positives that can occur in these 
patients, for whom standard criteria for late potentials are not applicable and different 
criteria have been proposed.[211] 
 Left ventricular function was qualitatively assessed. Significant LV systolic dysfunction 
was defined as moderate or severe LV impairment. Any deaths (all cause mortality) 
were recorded during the follow up period. Follow up was censored on 01 April 2010. 
The status of all patients was known at this date. This status was cross checked with 
the national database.   
9.3.1 12 Lead ECG 
Standard 12 lead ECG intervals were calculated automatically by the ECG machine’s 
included software. The QTc interval was derived by Bazett’s method.[69] 
9.3.2 Signal Averaged ECG  
9.3.2.1 Recording Technique 
In addition to usual 12 leads used for surface ECG, orthogonal XYZ leads were recorded 
by placing 4 additional electrodes at the following positions; H – back of neck, E – mid 
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sternum (same level as V4), I – right mid axillary line (same level as V4) and M – centre 
of back (same level as V4). At least 100 consecutive QRS complexes were recorded and 
the recordings averaged, filtered and combined into a vector magnitude termed the 
filtered QRS complex. Analysis of the filtered QRS complex included a) unfiltered QRS 
duration; b) filtered QRS duration  c) root – mean – square (RMS) voltage of the 
terminal 40 ms of the filtered QRS; and d) duration that the filtered QRS complex 
remains < 40 µv. These variables were measured automatically by the software of the 
ECG machines. 
9.3.2.2 Criteria to define presence of late potentials 
Characteristics of an abnormal late potential include the following [208] 
 a filtered QRS complex duration > 114 ms;   
 a signal  < 20 µv in the last 40 ms of the filtered QRS complex and  
 voltage  < 40 µv in the terminal QRS complex for > 38 ms. 
Late potential was considered present when all the above three criteria were fulfilled. 
9.3.3 Statistical analysis 
Continuous variables were expressed as mean with standard deviation or median with 
inter quartile range, depending on their distribution. Categorical variables were 
expressed as frequency with percentage. Difference between groups was tested with 
independent samples “t” test for continuous variables or chi square test for categorical 
data. All the clinical variables were tested by univariate logistic regression to predict 
mortality, after excluding those who had an ICD. Those predictor variables with a 
significance level of < 0.05 on univariate analysis were included in the multivariable 
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analysis. In addition, QRS duration on 12 lead ECG, filtered QRS duration, late 
potentials on SAECG, beta blocker and amiodarone therapy were also entered. 
Statistical software used was SPSS v 16 (SPSS inc, Chicago, IL, USA). 
9.4 RESULTS 
The patients were followed up for a median of 65 (IQR = 8) months. All survivors were 
followed for a minimum of 5 years. A total of 135 patients (25%) died during follow up. 
Crude mortality rate at 5 years was 51 per 1000 per year. All were in sinus rhythm. 
None had a pacemaker or cardiac re-synchronisation device. Significant (moderate or 
severe) left ventricular impairment was present in 138 patients (26%). 
33 (6%) had an ICD in situ, but none was paced at the time of assessment. 7 (21%) 
patients had died despite having an ICD and there was no difference in the rate of 
death between those with or without an ICD (p = 0.562).  
The detailed patient characteristics of those who died during follow up as compared to 
the survivors, are shown in table 9.1. The clinical factors associated with death on 
univariate and multivariable analysis by logistic regression are shown in tables 9.2 and 
9.3. Those who had an ICD were excluded from the model, to avoid the confounding 
effect of appropriate potentially life-saving therapy from the device. The benefit of 
aspirin therapy was observed only in patients with ischaemic heart disease. 
9.4.1 12- lead ECG  
The mean heart rate was 67 (15) bpm. The mean QRS duration was 95 (13) ms and 
mean QTc interval was 437 (52) ms. 205 patients (39%) had presence of Q waves on 12 
lead ECG, consistent with previous myocardial infarction.  
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Table 9.1 Patient characteristics of survivors compared with those who had died by 5 
years of follow up. 
Patient characteristic  
N (%) 
Vital status at 5 years 
Alive 
395 (75%) 
Dead 
135 (25%) 
p value 
Age (yrs) – Median (IQR) 67 (14) 75 (10) < 0.001 
Sex  
Male 
Female 
 
273 (79%) 
122 (67%) 
 
74 (21%) 
61 (33%) 
 
0.003 
Ischaemic Heart Disease  
PCI 
CABG 
273 (74%) 
52 (84%) 
79 (79%) 
95 (26%) 
10 (16%) 
21 (21%) 
0.829 
0.087 
0.308 
Hypertension  178 (74%) 62 (26%) 0.920 
Diabetes  72 (65%) 39 (35%) 0.010 
NYHA 
I 
II 
III 
IV 
 
128 (86%) 
193 (73%) 
67 (63%) 
7 (78%) 
 
21 (14%) 
73 (27%) 
39 (37%) 
2 (22%) 
 
< 0.001 
0.296 
0.003 
0.821 
Smoking  
Never smoked 
Ex smoker  
Current 
 
113 (75%) 
230 (74%) 
52 (74%) 
 
38 (25%) 
79 (26%) 
18 (26%) 
 
0.919 
0.953 
0.960 
Renal Impairment 
(serum creatinine of > 127 μmol/l in 
men or > 107 μmol/l in women) 
 
83 (60%) 
 
56 (40%) 
 
< 0.001 
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Left ventricular impairment  
Mild (or less) 
Moderate 
Severe 
 
312 (80%) 
73 (60%) 
10 (59%) 
 
80 (20%) 
48 (40%) 
7 (41%) 
 
< 0.001 
<0.001 
0.131 
Medication  
Loop diuretic  
Aspirin  
Warfarin  
Beta blocker 
Amiodarone 
Digoxin 
ACEI   
ARB 
Thiazide  
Spironolactone  
Statin  
 
197 (64%) 
238 (79%) 
43 (71%) 
271 (77%) 
24 (73%) 
13 (57%) 
250 (75%) 
63 (72%) 
37 (80%) 
55 (62%) 
266 (77%) 
 
109 (36%) 
63 (21%) 
18 (29%) 
81 (23%) 
9 (27%) 
10 (43%) 
82 (25%) 
24 (28%) 
9 (20%) 
34 (38%) 
80 (23%) 
 
< 0.001 
0.007 
0.438 
0.073 
0.837 
0.051 
0.073 
0.592 
0.381 
0.003 
0.095 
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Table 9.2. Univariate predictors of mortality 
Variable Wald 
statistic 
Odds 
Ratio 
95% CI P value 
Age (years) 45.7 1.1 1.1 – 1.1 < 0.001 
Use of loop diuretic 35.9 4.5 2.8 – 7.4 < 0.001 
Haemoglobin (g/dl) 34.8 0.7 0.6 – 0.8 < 0.001 
Urea (mmol/l) 19.3 1.1 1.1 – 1.2 < 0.001 
Elevated  serum creatinine (> 
127 μmol/l in men or > 107 
μmol/l in women) 
18.3 2.6 1.7 – 3.9 < 0.001 
Significant (moderate/severe) 
LVSD 
17.8 2.6 1.7 – 4.0 < 0.001 
QTc interval (ms) 14.4 1.01 1.004 – 1.012 < 0.001 
NT-pro BNP (log) 14.2 3.3 1.8 – 6.1 < 0.001 
Heart rate (bpm) 12.5 1.02 1.01 – 1.04 < 0.001 
Spironolactone 7.5 2.0 1.2 – 3.3 0.006 
NYHA III/IV 7.0 1.9 1.2 – 3.0 0.008 
Aspirin 7.0 0.6 0.4 – 0.9 0.008 
Diabetes 6.1 1.8 1.1 – 2.9 0.014 
Filtered QRS duration on SAECG 
(ms) 
0.7 1.0 0.9 – 1.0 0.42 
QRS duration on ECG (ms) 0.7 1.0 0.9 – 1.0 0.39 
Presence of late potentials on 
SAECG 
0.04 1.0 0.7 – 1.6 0.83 
 
*OR (odds ratio) calculated per unit change for continuous variables. 
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Table 9.3. Multivariable predictors of mortality*  
Variable Wald OR^ 95% CI P value 
Age (years) 16.3 1.1 1.04 – 1.11 < 0.001 
Heart rate (bpm) 7.2 1.03 1.01 - 1.05 0.007 
NT-pro BNP (log) 6.6 2.5 1.2  – 5.1 0.010 
Use of loop diuretic 6.0 2.3 1.2 – 4.4 0.015 
 
*by stepwise logistic regression model that included all variables shown in table 9.2 
and in addition, ischemic heart disease, beta blocker and amiodarone therapy. 
^ OR (odds ratio) calculated per unit change for continuous variables. 
 
The relation between the 12 lead ECG intervals and presence of significant left 
ventricular systolic dysfunction (LVSD) on echocardiography is given in table 9.4. The 
QRS duration was significantly longer in patients with LVSD. Similar association with 
LVSD was noted with QTc interval but this was weaker than QRS duration. 
The relation between 12 lead ECG variables and vital status at 5 years is shown in table 
9.5. The heart rate was higher and QTc interval was longer in those who had died 
within 5 years, but there was no significant difference in the QRS duration. When the 
QRS duration was divided into tertiles and examined in relation to survival at 5 years, 
no significant difference was detected (figure 9.1). 
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Table 9.4. Relation between ECG intervals and presence of significant LVSD on 
echocardiography. 
Variable  
Mean (SD) 
Significant LVSD on echo 
No Yes p value 
12 – lead ECG  
Heart rate  
QRS (ms)  
QTc (ms)  
 
67 (14) 
92 (13) 
434 (54) 
 
68 (15) 
102 (12) 
444 (47) 
 
0.423 
< 0.001 
0.045 
SAECG 
Unfiltered QRS (ms) 
Filtered QRS (ms) 
Late potentials – N (%) 
 
95 (13) 
114 (25) 
107 (27%) 
 
106 (15) 
129 (31) 
57 (41%) 
 
< 0.001 
< 0.001 
0.002 
 
Table 9.5. Relation between ECG intervals and survival at 5 years. 
 
Variable  
Mean (SD) 
Vital Status at 5 years 
Alive Dead p value 
12 – lead ECG  
Heart rate  
QRS (ms)  
QTc (ms)  
 
66 (14) 
95 (13) 
432 (45) 
 
71 (17) 
96 (14) 
452 (60) 
 
0.001 
0.483 
0.001 
SAECG 
Unfiltered QRS (ms) 
Filtered QRS (ms) 
Late potentials – N (%) 
 
97 (14) 
117 (27) 
121 (31%) 
 
99 (17) 
119 (29) 
43 (32%) 
 
0.239 
0.424 
0.791 
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Figure 9.1. Kaplan – Meier curve showing the relation between QRS duration (in 
tertiles) on 12 lead ECG and survival. 
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9.4.2 SAECG  
9.4.2.1 QRS duration on SAECG 
The mean (SD) unfiltered QRS duration was 98 (14) ms and the mean filtered QRS on 
SAECG was 118 (28) ms. There was modest correlation between standard QRS duration 
on 12 lead ECG and unfiltered QRS duration on SAECG (Pearson’s coefficient r = 0.69; p 
< 0.001). However, there was only weak correlation between standard QRS duration 
on 12- lead ECG and filtered QRS duration on SAECG (r = 0.33; p < 0.001). The Bland-
Altman plot demonstrating this correlation between QRS duration on ECG and filtered 
QRS duration on SAECG is shown in figure 9.2.  
The relation between QRS intervals on SAECG and presence of significant left 
ventricular systolic dysfunction (LVSD) on echocardiography is given in table 9.4. Both 
filtered and unfiltered QRS durations were significantly longer in patients with 
significant LVSD. The filtered QRS duration was also progressively longer with 
increasing severity of LVSD (figure 9.3). 
There was no significant difference in the filtered or unfiltered QRS duration between 
those who were alive and those who were dead at 5 years of follow up (table 9.5). 
When the filtered QRS duration was divided into tertiles and examined in relation to 
survival at 5 years, no significant difference was detected (figure 9.4). 
Patients with an ICD (6%) had a longer QRS (103 vs 94 ms), unfiltered QRS (109 vs 97 
ms) and filtered QRS durations (138 vs 116 ms) when compared to those without an 
ICD and the difference was statistically significant (p < 0.01) for all three comparisons. 
This is probably due to the fact that patients with an ICD had a higher prevalence of 
moderate or severe LV impairment (52% vs 24%). 
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Figure 9.2. Bland – Altman plot showing correlation between QRS measured from 12 
lead ECG and filtered QRS measured from SAECG 
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Figure 9.3. Relation between severity of LV dysfunction and filtered QRS duration on 
Signal Averaged ECG.  
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Figure 9.4. Kaplan – Meier survival graph showing the relation between filtered QRS 
duration (in tertiles) and mortality within 5 years. 
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9.4.2.2 Late potentials on SAECG 
164 patients (31%) had late potentials detected on SAECG. There was no significant 
difference in the frequency of late potentials between those who were alive and those 
who were dead at 5 years of follow up (table 9.6) and the presence of late potentials 
on the SAECG was not associated with increased risk of death on either univariate or 
multivariable analysis. There was no difference in the survival between those who did 
or did not have late potentials on SAECG (figure 9.5). The positive predictive value of 
presence of late potentials on the SAECG in predicting death within 5 years was only 
26%, although the specificity was 69%. The sensitivity was only 32% but the negative 
predictive value was 75%.  There was also no association between any of the individual 
criteria for defining late potentials and the risk of death.  
 
Table 9.6. Relation between death and presence of late potentials on Signal 
Averaged ECG. 
Vital Status (at 5 years) 
Late Potentials on SAECG 
No Yes 
Alive 274 121 
Dead 92 43 
p = 0.791 
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Figure 9.5. Kaplan – Meier plot showing lack of association between presence of late 
potentials on SAECG and survival 
 
 
 
 
 
 
 
 127 
However, there was a significant association between presence of significant left 
ventricular systolic dysfunction  (LVSD) on echocardiography and the presence of late 
potentials on SAECG, as a linear increase in the prevalence of late potentials was 
observed with increasing severity of LVSD (figure 9.6).  
9.4.3 NT –pro BNP 
NT-pro BNP level was significantly higher in patients with LVSD and there was an 
almost linear relation with increasing severity of LVSD (figure 9.7). When the NT-pro 
BNP was divided into tertiles and examined in relation to survival, there was a 
significant association, as those with NT-pro BNP in the highest tertile had the worst 
survival (figure 9.8). Patients with late potentials on SAECG had higher level of NT-pro 
BNP when compared to those who did not have late potentials (figure 9.9). However 
there was no correlation between filtered QRS duration on SAECG and NT-pro BNP 
levels (figure 9.10). 
9.5 DISCUSSION  
This study has assessed the usefulness of Signal Averaged ECG as a tool for predicting 
significant left ventricular dysfunction and for risk stratification in predicting mortality 
in the medium term, in a contemporary population with heart failure. 
Previous studies have demonstrated that late potentials on SAECG had a low sensitivity 
in predicting sudden death, but high negative predictive value. In this study, there was 
no statistically significant association with death and the negative predictive value was 
only modest (75%). This supports the view that SAECG can no longer be recommended 
as a risk stratification tool in predicting death in heart failure.[212] 
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Figure 9.6. Relation between severity of LVSD and prevalence of late potentials on 
SAECG 
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Figure 9.7. Relation between NT-pro BNP level and severity of LV systolic dysfunction 
on echocardiography. 
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Figure 9.8. Kaplan - Meier survival graph showing the relation between NT pro – BNP 
level (in tertiles) and mortality within 5 years.  
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Figure 9.9. Relation between presence of late potentials on SAECG and NT-pro BNP 
level.   
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Figure 9.10. Correlation between filtered QRS duration on SAECG and NT-pro BNP 
level. 
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In an earlier study from the Euro Heart Failure survey data, I had demonstrated that 
increasing QRS duration on standard 12-lead ECG was associated with presence of 
significant LV dysfunction on echocardiography.[213] In the present study group where 
patients with gross QRS prolongation on 12 lead ECG were excluded, SAECG was able 
to identify patients with significant LV dysfunction on the basis of prolonged filtered 
QRS duration. The prevalence of late potentials increased with increasing severity of 
LV systolic dysfunction. Hence it could be used in settings where echocardiography is 
not immediately available (such as outpatient clinics) as recording SAECG does not 
usually require additional hardware (in modern equipment) and takes only an extra of 
2 - 3 minutes. Nevertheless, SAECG can obviously not replace echocardiography as only 
41% of those with moderate or severe LVSD were found to have late potentials. 
Further, 27% of patients without significant LVSD had late potentials. Thus, whilst 
there was a statistically significant relation between abnormal SAECG and LVSD, SAECG 
is not clinically useful as a screening test to either diagnose or exclude LVSD.  
In addition to evaluating the SAECG variables, several other important observations 
were noted from this study. Elevated level of NT-pro BNP was associated with the 
presence of late potentials in this study, indicating a higher risk. It was also associated 
with presence of significant LV systolic dysfunction and increased risk of death in the 
medium term. In 1994, a seminal paper by Davis et al found that plasma BNP was 
raised in dyspnoeic patients with heart failure but not in acutely breathless patients 
with primary lung disorder.[214]  Since then, numerous publications have confirmed 
the relation between raised BNP and left ventricular systolic or diastolic dysfunction 
and its prognostic significance.[215, 216] This study also found that raised NT-pro BNP 
predicted increased risk of death in the medium term. This would be consistent with 
the well-known ability of BNP to predict prognosis, thus increasing the confidence in 
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the results of this study, even though the number of patients recruited was relatively 
small. 
The heart rate was higher in those who had died within 5 years. The relation between 
heart rate and prognosis in heart failure has been well established, explaining at least 
in part why beta blocker therapy would have prognostic benefit patients with all 
degrees of heart failure. [20, 22] The BEAUTIFUL study assessed the morbidity and 
mortality benefits of the heart rate-lowering agent ivabradine.[217] The placebo arm 
of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery 
disease and LV dysfunction. Patients with heart rates of 70 beats per minute (bpm) or 
more had increased risk for cardiovascular death, admission to hospital for heart 
failure or MI, and coronary revascularisation.[218]  Subsequently, the large SHIFT study 
confirmed the prognostic value for using ivabradine in addition to beta blocker therapy 
in patients whose heart rate exceeds 70 bpm.[219] Ivabradine reduced cardiovascular 
death, death from heart failure and hospitalisation for heart failure.  The present study 
has found heart rate to be a significant predictor of all-cause mortality after heart 
failure, independent of beta blocker use. Thus, if a patient attends the heart failure 
clinic and is found to have a relatively fast heart rate despite beta blocker use, one 
should consider additional therapy for better heart rate control, such as with 
ivabradine, provided they are in sinus rhythm.  
Use of loop diuretic therapy to control heart failure symptoms had been associated 
with increased risk of death in both univariate and multivariable analysis. This may be 
partially explained by the fact that patients with severe symptoms are more likely to 
be on loop diuretic therapy. However, the dose dependent association between loop 
diuretic therapy and adverse prognosis has been well recognised.[220-222] The 
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potential mechanisms are deterioration in renal function and severe electrolyte 
abnormalities leading to arrhythmias.[223, 224] 
QTc interval was longer in patients who died within 5 years in univariate but not 
multivariate analysis in this study. It has long been known that QT dispersion predicts 
cardiac death in heart failure.[225] QTc dispersion reduction may be one of the 
mechanisms why ACE-inhibitor therapy improves prognosis in heart failure.[226] Long 
QTc per se has also been shown to predict cardiac death in other populations, such as 
stroke survivors.[227] Long QTc may identify silent but potentially lethal cardiac 
abnormalities which are often treatable.[228] In the present study, QTc was longer in 
patients with significant LV systolic dysfunction. This observation was noted previously 
(chapter 8) in the Euro Heart Failure survey data, but it was found to be mainly driven 
by the QRS prolongation.[213] 
By comparison, QRS duration did not appear to predict 5-year survival, despite my 
observation that patients with increasing severity of LV systolic dysfunction had 
progressively longer QRS duration. This is intriguing especially since cardiac 
resynchronisation therapy is particularly effective in patients with prolonged QRS 
duration, although there is an ongoing debate about whether cardiac imaging (such as 
with echocardiography) may be superior in the selection of patients for CRT. [52, 229] 
However, this could be explained by the fact that in my cohort, patients with bundle 
branch block and gross QRS prolongation due to marked intra-ventricular conduction 
delay were excluded, as SAECG in these patients are known to have severe 
abnormalities mimicking late potentials, leading to a high false positive rate. If these 
were included in the study, it is likely that the relation between QRS duration and 
survival would have reached statistical significance. 
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One of the most important findings of this study is the observation that the QRS 
duration measured from a 12-lead ECG was only weakly correlated with QRS duration 
derived from signal averaged ECGs. In current clinical practice, if a patient has lots of 
ventricular ectopics, occasionally SAECG would be used to obtain a “filtered” QRS, 
which may over-estimate the true QRS duration. This is important because trials 
demonstrated the importance of QRS duration in selecting patients for CRT and 
implantable defibrillator therapies, and subsequently NICE guidelines recommended 
their use based on QRS duration measured from the 12-lead ECG. It can be argued that 
instead of using the filtered QRS duration, one should examine the 12-lead ECG for 
QRS duration from beats which are not ventricular in origin (and excluding beats which 
immediately follow a compensatory pause). 
9.6 LIMITATIONS 
The major limitation of this study is that SAECG was examined to predict all cause 
mortality, rather than only sudden cardiac death. However the fact that late potentials 
on SAECG were equally prevalent in those who died and in those who were alive, 
suggests that the role of SAECG in predicting death is very limited, if any.  
9.7 CONCLUSIONS 
The QRS duration measured from a 12-lead ECG is only weakly correlated with QRS 
duration derived from signal averaged ECGs. Late potentials on signal averaged ECG 
are associated with the presence of left ventricular systolic dysfunction, in patients 
presenting with symptoms and signs of heart failure.  However SAECG is not useful in 
predicting all-cause mortality in patients who suffer from heart failure. 
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CHAPTER 10. RELATION BETWEEN PREVALENCE OF ARRHYTHMIAS ON 
HOLTER MONITORING AND RISK OF DEATH IN PATIENTS WITH HEART 
FAILURE 
10.1 BACKGROUND 
The prognosis of heart failure remains poor. Approximately one half of deaths are 
classified as sudden and cardiac (SCD) and are presumed to be due to arrhythmias. 
Although these deaths could be prevented by Implantable Cardioverter-Defibrillators 
(ICD), it is necessary to identify patients at risk of SCD, as ICDs are expensive and are 
associated with significant adverse events. Primary ICD prevention studies suggest that 
less functionally impaired patients with HF have the greatest gain in overall survival 
from prophylactic ICD placement.[54] This reflects the high mortality from causes 
other than SCD in patients with advanced heart failure or important co-morbidities 
such as lung or renal diseases. Although an ICD may prevent SCD in such cases the 
patient may survive only for a short period before dying of something else. Also, it is 
possible that ICD shocks accelerate deterioration in myocardial function.[230] This fact 
underscores the need for accurate risk profiling. 
The search for accurate risk stratification methods to predict SCD is ongoing. Reduced 
left ventricular ejection fraction is universally accepted as a marker of the risk of SCD 
as is more severe symptoms of heart failure. Historically, Holter monitoring has been 
an important clinical diagnostic test for the recording of cardiac tachy and brady 
arrhythmias and it has evolved over the last three decades. It can now provide 
additional information including ST segment changes (to assess ischaemia providing 
the ECG is not significantly abnormal under non-ischaemic conditions), R-R interval 
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changes (to assess heart rate variability, as a marker of autonomic function), QRS 
measurements and signal averaged ECG (for late potentials).  
10.2 HOLTER MONITORING IN HEART FAILURE 
In patients with heart failure, Holter monitoring is useful in four situations; diagnosis 
and assessment of symptoms (such as palpitations or dizziness), evaluate chronotropic 
competence, prognostic assessment and risk stratification and evaluation of 
therapeutic interventions (such as changes in drug therapy, assessment of paroxysmal 
AF or ventricular rate control etc.).  
Trials such as ESVEM (Electro physiologic Study Versus Electro cardiographic 
Monitoring) compared Holter monitoring with invasive methods such as  electro 
physiologic studies to assess drug efficacy in patients with ventricular 
arrhythmias.[231] This trial demonstrated that Holter monitoring yielded more 
information at a much smaller cost. Later studies showed that variables obtained from 
Holter such as heart rate, heart rate variability, heart rate turbulence and presence of 
arrhythmias such as atrial fibrillation, ventricular premature beats, non-sustained 
ventricular tachycardia have prognostic value in heart failure.[34, 37] 
And yet Holter monitoring is not routinely recommended in professional guidelines 
(such as National Institute of Clinical Excellence – NICE, in the UK) as part of routine 
management of heart failure (except for risk stratification for ICD therapy) which is 
logically inconsistent. 
It should be noted that these studies on Holter monitoring were done some years ago 
and great progress has been made in treatment of heart failure since then. At present 
Holter monitoring is not widely performed as a routine investigation in patients with 
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heart failure. Hence I have attempted in this study to answer the question of 
usefulness of Holter monitoring in the contemporary era in providing prognostic 
information in patients with heart failure. 
10.3 AIMS 
1. To study the prevalence of arrhythmias in patients with chronic heart failure. 
2. To study the relation between the abnormalities on Holter monitoring and 
mortality. 
10.4 STUDY POPULATION AND METHODS 
Patients being regularly followed up in a community heart failure clinic with stable 
heart failure symptoms and on optimal medical therapy were invited to participate. 
Patients were recruited after written informed consent.  
Data were collected on history, NYHA status, clinical examination, medication, ECG, 
routine blood tests, echocardiogram. Holter monitoring was performed for 24 hours 
with Life Card CF digital Holter recorder (Del Mar Reynolds Medical Inc.) and data were 
analysed with Reynolds Pathfinder II program (Del Mar Reynolds Medical Inc.). Heart 
Rate Variability (HRV) parameters were also recorded. Vital status was recorded for all 
patients at the end of the follow up period. 
The predominant Holter rhythm was recorded. All arrhythmias were captured. For 
patients in sinus rhythm, heart rate variability index of SDNN (standard deviation of 
the average R – R intervals) was recorded. Frequent ventricular ectopics (VE’s) was 
defined as > 10 VE’s /hour.[232] Non sustained ventricular tachycardia (NSVT) was 
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defined as 3 VE’s or more in succession, but less than 30 seconds in duration. 
Sustained VT was defined as occurring   more than 30 seconds in duration. 
10.5 STATISTICAL METHODS 
Both clinical variables and Holter variables were subjected to univariate analysis 
predicting mortality by binary logistic regression. A p value of < 0.05 was considered 
statistically significant. Those variables which were significant on univariate analysis 
were then included in a multivariable logistic regression model to predict mortality. 
Statistical analysis was done with SPSS v16 software. 
10.6 RESULTS 
194 patients were recruited over a 2 year period. The patient characteristics are given 
in table 10.1. On echocardiography, 67 (34%) had mild LVSD, 63 (33%) had moderate 
LVSD and 18 (9%) had severe LVSD. 
The mean follow up period was 32 (9) months and 27 (14%) patients died during this 
period. 11 (41%) had sudden cardiac death, 11 (41%) died due to worsening heart 
failure and 5 (18%) died due to mainly non cardiac causes. The prevalence of 
arrhythmias is given in table 10.2. Six patients received an ICD in this period and were 
censored for analysis. Of those that received an ICD none died during the follow up 
period. 
Of the 27 patients who died, 20 had moderate or severe LVSD and 12 had NSVT on 
Holter. Patients who died were older, had a longer QRS duration, more likely to have 
severe LV impairment or renal impairment, and had higher prevalence of AF, DM, 
frequent VEs and NSVT (table 10.3). Patients who died suddenly were more likely to 
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Table 10.1.  Patient characteristics and LV function 
Characteristic All 
(n = 194) 
LVSD (n) 
None 
(n=46) 
Mild 
(n=67) 
Mod/Severe 
(n=81) 
Age (yrs) - Median (IQR) 69 (13) 67 (17) 72 (11) 72 (14) 
Male Sex (%) 138 (71) 26 50 62 
Ischaemic Heart Disease (%) 138 (71) 29 44 65 
Dilated Cardiomyopathy (%) 15 (8) 1 7 7 
Hypertension (%) 89 (46) 24 32 33 
Diabetes  Mellitus (%) 31 (16) 5 12 14 
Persistent Atrial Fibrillation (AF) at 
Assessment 
40 (21) 3 18 19 
Never smoked 
Ex smoker  
Current 
50 (26) 
108 (56) 
29 (15) 
15 
22 
7 
11 
44 
11 
24 
42 
11 
Renal Impairment (%)(serum 
creatinine of > 127 μmol/l in men 
or > 107 μmol/l in women) 
27 (14) 3 10 14 
Medication (%) 
Aspirin  
Warfarin  
Beta blocker 
Amiodarone 
Digoxin 
ACEI  or ARB 
Thiazide  
Loop diuretic  
Spironolactone  
Statin  
 
113 (58) 
36 (19) 
140 (72) 
14 (7) 
31(16) 
157 (81) 
9 (5) 
95(49) 
29 (15) 
106 (55) 
 
26 
4 
24 
1 
4 
22 
7 
12 
3 
26 
 
41 
11 
52 
2 
9 
56 
1 
32 
3 
33 
 
46 
21 
64 
11 
18 
79 
1 
51 
23 
47 
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Table 10.2. Prevalence of arrhythmias on holter monitoring. 
 
Arrhythmias Overall 
No (%) 
LVSD 
None Mild Mod/Severe 
Atrial fibrillation 40 (21) 3 (7) 18 (27) 19 (23) 
Frequent VE’s 47 (24) 3 (7) 16 (24) 28 (35) 
NSVT 35 (18) 3(7) 11 (16) 21 (26) 
Sustained VT 6 (3) 0 3 (4) 3 (4) 
 
 
have had significant arrhythmias on Holter monitoring; frequent VE’s in 73%, NSVT in 
73%and AF in 64%. On univariate analysis, the same factors (except age and QRS 
duration) predicted higher mortality (table 10.4).  On multivariable analysis, presence 
of NSVT on Holter monitoring predicted increased mortality along with the clinical 
factors such as AF, diabetes, renal impairment and severe left ventricular dysfunction 
(table 10.5). SDNN, the measure of heart rate variability did not predict outcome. 
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Table 10.3: Differences in clinical characteristics between patients who survived or 
died at 2 years 
 
Variable Alive Dead P value   
Age in years (median) 68 75 0.014 
QRS duration in ms 
(median) 
98 126 0.089 
VE count (median) 98 1789 0.008 
Couplet count (median) 0 13 0.001 
Frequent VE’s (%) 20 48 0.002 
NSVT (%) 14 44 < 0.001 
Renal impairment (%) 10 37 < 0.001 
AF (%) 16 52 < 0.001 
No LVSD (%) 28 0 0.002 
Mild LVSD (%) 36 26 0.311 
Moderate LVSD (%) 30 48 0.061 
Severe LVSD (%) 7 26 0.001 
Diabetes (%) 13 30 0.008 
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Table 10.4. Univariate predictors of mortality 
Variable OR 95% CI P value 
Frequent VE’s 3.6 1.6 – 8.5 0.003 
VE count > 1.0  0.013 
NSVT 5.0 2.1 – 12.0 < 0.0001 
Couplet count >1.0  0.031 
Renal impairment 5.1 2.1 -13.1 0.001 
AF 5.8 2.5 -13.8 < 0.0001 
Severe LVSD 5.0 1.7 – 14.3 0.003 
DM 3.3 1.3 – 8.3 0.011 
 
 
Table 10.5. Multivariable predictors of mortality 
 
Variable OR 95% CI P value 
NSVT 3.3 1.1 – 10.0 0.032 
Renal impairment 6.8 2.2 – 20.9 0.001 
AF 5.3 1.9 – 15.1 0.002 
Severe LVSD 4.3 1.2 – 15.4 0.025 
Diabetes 3.2 1.1 – 9.8 0.039 
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10.7 DISCUSSION 
This analysis of Holter monitoring shows that arrhythmias remain extremely common 
in patients with chronic heart failure despite modern pharmacological therapy and 
that NSVT remains an important predictor of prognosis. This suggests that NICE 
guidelines should be made consistent and perhaps all patients with heart failure, 
unless they are clearly not a candidate for an ICD due to frailty and co-morbidity, 
should undergo Holter monitoring. The current NICE guidelines mention Holter 
monitoring only in the context of patient selection for an ICD. This analysis suggest that 
Holter monitoring may provide additional prognostic information. The duration of 
monitoring and how often this should be repeated are unknown.  
Although arrhythmias are common, their prevalence may be lower than previously 
reported, when more than 85% of patients with heart failure were reported to have 
frequent VEs.[233] This may reflect improvement in treatment of heart failure such as 
widespread use of beta blockers but could also reflect differences in case selection, 
since previous studies tended to focus on patients with severe LVSD. 
 Those patients who had arrhythmias such as atrial fibrillation and non sustained 
ventricular tachycardia had a poorer prognosis, independent of other traditional risk 
factors such as diabetes, renal impairment and severity of left ventricular systolic 
dysfunction. This is in line with previous studies and a recent meta-analysis of 16 
studies involving 53 969 patients suggesting that the presence of AF is associated with 
an adverse prognosis in CHF irrespective of LV systolic function.[234] My study 
supports this observation. 
Previous studies have suggested that non sustained VT in patients after myocardial 
infarction was associated with a higher mortality,[37] but it was inferior to other 
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markers such as left ventricular dysfunction in its predictive value. On the other hand 
an epidemiological study of heart failure conducted before the widespread use of 
beta-blockers (UK-HEART) suggested that presence of symptomatic non sustained VT 
on Holter monitoring was associated with higher risk of sudden death.[34] A recent 
analysis of DYNAMIT trial found that patients with non sustained VT experienced 
higher rates of both arrhythmic and non arrhythmic death.[235] A meta analysis which 
included 11 prognostic studies with > 100 patients with good quality data and 
multivariate analysis of predictors of sudden cardiac death found that absence of NSVT 
was associated with a low probability of sudden cardiac death in patients with left 
ventricular impairment.[236] It is possible that higher prevalence of arrhythmias 
reflect sicker ventricles and therefore imply higher risk of both arrhythmic and non 
arrhythmic death. 
Severe left ventricular dysfunction, diabetes and renal impairment are well established 
markers of high risk in patients with heart failure and several studies have 
demonstrated their association with poor prognosis. However, these are generally non 
modifiable risk factors and their presence simply imply a worse prognosis since any 
therapeutic interventions are unlikely to modify these risk factors in the majority of 
the patients. Obviously, more accurate assessment of risk is unlikely to be useful in the 
absence of effective therapeutic interventions to target these adverse prognostic 
factors. In contrast, the arrhythmic markers revealed by Holter monitoring can be 
modified by intense medical therapy with maximum tolerated dose of beta blockers 
and ACE inhibitors which may reduce both incidence and prevalence of arrhythmias, 
thereby altering the risk profile favourably. Patients with silent paroxysmal AF may 
benefit from anticoagulation with warfarin and patients with poorly controlled AF may 
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benefit from amiodarone therapy or newer treatments such as AF ablation, thereby 
preventing tachycardia mediated deterioration in LV function.  
Although not demonstrated in this study, a small proportion of elderly heart failure 
patients would be of high risk of sudden death due to silent bradyarrhythmias that 
may be unmasked by Holter monitoring. Those patients with heart failure and 
relatively few symptoms but high risk arrhythmias on routine Holter monitoring could 
be considered for device therapy with ICDs (or CRT-D). Thus Holter monitoring can 
identify additional prognostic indicators that can be modified by effective therapeutic 
interventions. 
10.8 LIMITATIONS 
The patient numbers are small in this analysis, as I had included only those patients for 
whom I was responsible for arranging the Holter monitor. 
10.9 CONCLUSIONS 
In summary, Holter monitoring is useful in the management of patients with heart 
failure as it can provide prognostic information in addition to its value in evaluating 
arrhythmias. Hence it should be considered routinely in all patients with heart failure, 
even in the absence of symptoms suggestive of arrhythmias and it may aid selection 
for ICD as suggested by the NICE guidelines. 
 
 
 
 
 148 
11. PREDICTORS OF SHOCKS AND MORTALITY IN HEART FAILURE PATIENTS WITH 
IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS (ICDS) – ALL INDICATIONS 
11.1 INTRODUCTION 
The incidence of sudden cardiac death is 100,000 / year in the UK.[237] Implantable 
Cardioverter Defibrillators (ICD) represent a major advance over the last decade in the 
fight against sudden cardiac death.[238] ICDs are used for both primary and secondary 
prevention of sudden cardiac death in high risk populations such as those with heart 
failure or inherited cardiomyopathies and as a bridge to heart transplant.[239-241] 
ICDs have been shown in many clinical trials to be effective in aborting sudden 
arrhythmic death.[242] [60, 166] 
Only limited data exist about the determinants of long term outcome after ICD 
implantation.[243] A proportion of patients do not benefit and experience adverse 
effects such as infection, unnecessary shocks, potential for pro-arrhythmia, device 
malfunction, highly publicized manufacturer advisories, and procedural complications, 
which can adversely affect morbidity and quality of life.[244-251] Patients get no 
benefit in terms of heart failure symptoms or quality of life with an ICD and indeed 
there is some evidence that they make symptoms worse.[252] ICDs do reduce the risk 
of dying from a lethal arrhythmia but may reprogram the mode of death from sudden 
arrhythmic death into death due to worsening heart failure. In the Sudden Cardiac 
Death in Heart Failure Trial (SCD-HeFT), seven more people were alive after 5 years for 
every 100 devices implanted, but 29 had died despite an ICD implant.[54] In a meta-
analysis that showed a significant difference in mortality in favour of ICD with a 
combined follow-up period of 6 years, patients with defibrillators lived only 4.4 months 
longer than those treated with anti-arrhythmic therapy, and all statistically significant 
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differences were non-sustained, narrowing at 4 years towards negligible after 6 
years.[253] ICDs are expensive (total cost probably in excess of 30,000 euros for 
purchase, implantation and programming). A critical appraisal by an expert group 
considering all the published evidence concluded that the major clinical trials have 
overestimated the clinical benefits and underestimated the risks and cost 
effectiveness.[254] Hence patient selection is a major issue in the absence of reliable 
risk stratification methods for primary prevention.[255] I believe that longitudinal 
follow up data from those patients who had ICDs implanted will help in better patient 
selection and to find out those interventions which will minimise the risk of adverse 
events due to the ICD. 
11.2 AIMS 
1. To identify predictors of mortality after ICD implantation.  
2. To identify predictors of appropriate shocks due to malignant ventricular 
arrhythmias. 
3. To estimate the incidence of adverse effects and inappropriate shocks. 
11.3 STUDY POPULATION 
I invited 211 patients who were being seen in a tertiary centre ICD clinic to participate 
in the Heart Care (comprehensive heart failure assessment and follow up) programme 
of the academic department of cardiology at the University of Hull. 165 patients 
agreed to participate and they were included in the study after written consent. 
11.4 METHODS 
Patients were seen at regular intervals (at least twice a year) and a comprehensive 
assessment was done at each visit. In addition to detailed history and clinical 
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examination, investigations included 12 lead ECG, signal averaged ECG, 2D 
echocardiogram, routine blood tests, NT pro BNP, six minute walking test, regular ICD 
interrogation and review of medical therapy. ICD interrogation was done by expert 
technicians and all arrhythmia episodes were reviewed by attending physicians. All 
therapies by the device were reviewed by the attending physician and deemed 
appropriate or inappropriate. 
The relationship between the likelihood of experiencing an appropriate shock, 
mortality and the predictor variables was investigated by binary univariate and 
multivariable logistic regression and odds ratios calculated.  The relation between the 
number of inappropriate shocks and the predictor variables was examined by Poisson 
regression from which incidence rate ratios (IRR) were estimated.  
11.5 RESULTS 
165 patients were enrolled in this study. Mean age was 67 + 10 (range 31 – 84) years 
and 83% were men. Most (76%) had history of coronary artery disease and 72% had 
history of previous myocardial infarction. Among patients with CAD, 56% had previous 
coronary revascularisation (percutaneous in 11%, bypass surgery in 41% and 3% had 
both). The indications for ICD and the type of ICD in this study population are given in 
table 11.1. The most frequent indication was ischemic heart disease with impaired left 
ventricular function (75%). 89% of ICDs were implanted for secondary prevention. The 
baseline characteristics are given in table 11.2. 
The mean follow up period was 68 (34) months. A significant complication related to 
implant and necessitating extended hospital stay or re-admission, occurred in 26 
patients (16%). 45 patients (28%) were readmitted due to an arrhythmia. 
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Table 11.1 Indications for ICD 
Indication No (%) 
Coronary artery disease and impaired LV function – primary 
prevention 
8 (5) 
Coronary artery disease and impaired LV function – secondary 
prevention 
115 (70) 
Dilated cardiomyopathy – primary prevention 7 (4) 
Dilated cardiomyopathy – secondary prevention 32 (19) 
Heart failure due to hypertrophic cardiomyopathy 3 (2) 
ICD device type  
Single chamber 96 (58) 
Dual chamber 52 (32) 
Bi ventricular 11 (7) 
 
Device interrogation showed episodes of supra ventricular tachycardia in 36 (22%) 
patients, non-sustained ventricular tachycardia in 61 (37%) and frequent ventricular 
ectopics in 28 (17%) patients. 51 (31%) patients had a generator or lead change during 
the follow up period (5 ½ years). Sustained ventricular arrhythmias occurred in 59 
patients (36%) during this period. Anti tachycardia pacing was activated in 63 (38%) 
patients and was successful in terminating the arrhythmia in 38 (60%) patients on at 
least one occasion.  27 patients (16%) died. 46% had shocks from the ICD, appropriate 
in 32%, inappropriate in 22%.  9% had both appropriate and inappropriate shocks. The 
time to first shock was 20 (23) months. Those who had appropriate shocks were alive 
for a median period of 34 months after the first shock and those who had 
inappropriate shocks were alive for a median of 26 months after the first shock. 
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Table 11.2. Baseline patient characteristics (n = 165) 
Age (yr) 
Median 
Interquartile range 
 
68 
62 - 72 
Male Sex (%) 137 (83) 
NYHA (%) 
I 
II 
III 
IV 
 
12 (7) 
49 (30) 
84 (51) 
7 (4) 
Ischaemic Heart Disease (%) 
MI pre implant 
MI post implant 
123 (75) 
118 (72) 
3 (2) 
Coronary revascularisation (%) 
PCI 
CABG 
Both PCI & CABG 
 
14 (9) 
51 (31) 
4 (2) 
Dilated cardiomyopathy (%) 39 (24) 
Hypertension (%) 56 (34) 
Diabetes (%) 27 (16) 
Smoking (%) 
Never smoked 
Ex smoker (> 12 m) 
Current 
 
56 (34) 
89 (54) 
18 (11) 
ECG Rhythm (%) 
Sinus 
Paced 
Atrial Fibrillation (all types)  
 
117 (71) 
37 (22) 
59 (36) 
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QRS duration (ms) 
Median 
Interquartile range 
 
118 
100 - 152 
Left ventricular ejection fraction (%) 
Median 
Interquartile range 
 
30 
20 – 40 
Hyponatraemia (%) 
(Na < 135 mmol/l) 
15 (9) 
Hyperkalaemia (%) 
(K > 5 mmol/l) 
26 (16) 
Renal Impairment (%) 
(serum creatinine of > 127 μmol/l in men or  
> 107 μmol/l in women) 
67 (41) 
Anaemia (%) 
(Hb < 13 g/dl in men or Hb < 12 g/dl in women) 
46 (28) 
Medication (%) 
Anti platelet drugs  
Warfarin  
Beta blocker 
Amiodarone 
Digoxin  
ACEI   
ARB 
Thiazide  
Loop diuretic  
Spironolactone  
Statin  
Nitrate 
              Nicorandil      
 
100 (61) 
52 (32) 
150 (91) 
77 (47) 
13 (8) 
116 (70) 
19 (12) 
5 (3) 
110 (67) 
43 (26) 
111 (67) 
21 (13) 
11 (7) 
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The overall rate of adverse events, including implant or device complications and 
inappropriate shocks, was 32%. 20% of patients did not derive an explicit benefit from 
ICD (i.e. appropriate shocks or ATP), but experienced an adverse event related to the 
ICD. 43% received no explicit benefit but had no adverse event (table 11.3). 
Table 11.3: Details of benefit and harm from ICD 
Neither Benefit nor Harm 
71 (43%) 
Benefit Only 
(Appropriate shock or successful ATP) 
38 (23%) 
Harm Only:  26 (16%) 
Inappropriate Shock: 14 (9%) 
Other complications: 12 (7%) 
Benefit & Harm 
28 (17%) 
 
11.5.1 Shocks 
11.5.1.1 Appropriate shocks 
The univariate predictors of appropriate shocks are given in table 11.4. When 
examined as continuous variables, increasing QRS duration and lower ejection fraction 
were both associated with increased risk of appropriate shocks. When examined as 
categorical variables, presence of bundle branch block on ECG, paced rhythm on ECG 
and severe left ventricular impairment on echocardiography were both associated with 
increased risk of appropriate shocks. Prevalence of arrhythmias such as frequent 
ventricular ectopics, non sustained ventricular tachycardia and supraventricular 
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tachycardia (SVT) were also associated with appropriate shocks.  Patients with more 
severe symptoms, as those in NYHA class 3 or on Spironolactone were also more likely 
to experience an appropriate shock.  
On multivariable analysis, three variables were independently associated with an 
increased risk of experiencing an appropriate shock; severe LVSD (OR 2.2; 95% CI 1.1 – 
4.8; p = 0.035), paced rhythm on ECG (OR 2.5; 95% CI 1.1 – 5.9; p = 0.032) and SVT (OR 
2.7; 95% CI 1.2 – 6.3; p = 0.019). 
11.5.1.2 Inappropriate shocks 
The factors associated with inappropriate shocks are given in table 11.5. The IRRs 
derived from Poisson regression indicate the association with not only the risk but also 
the number of inappropriate shocks. Atrial fibrillation and supraventricular tachycardia 
were the strongest predictors. The paucity of variables did not allow a multivariable 
analysis. Patients who had dual chamber ICDs had lower incidence of inappropriate 
shocks when compared to those with single chamber ICDs (18% vs 25%), but this did 
not reach statistical significance. 
11.5.1.3 NYHA class and outcome 
84 (51%) patients were in NYHA class 3 status at the time of ICD implantation. Among 
this group, 19  (23%) died, 46 (56%) experienced shocks, 32 (39%) appropriate and 21 
(26%) inappropriate. NYHA class 3 was significantly associated with increased risk of 
shocks (OR 2.3; 95%CI 1.2-4.3; p = 0.01). When analysed separately for appropriate 
and inappropriate shocks, there was a tendency for increased risk of both types of 
shocks (tables 11.4 and 11.5). 
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Table 11.4 Univariate predictors of appropriate shocks 
Variable OR 95% CI P 
QRS    0.048 
BBB 2.2 1.1 – 4.4 0.019 
Paced rhythm on ECG 3.0 1.2 – 7.1 0.015 
Severe LVSD 2.7 1.3 – 5.6 0.010 
EF 0.97 0.94 – 0.99 0.017 
VEs 3.1 1.3 – 7.0 0.009 
SVT 2.5 1.2 – 5.5 0.019 
NSVT 2.5 1.3 – 5.0 0.007 
Spironolactone 2.2 1.1 -4.6 0.033 
NHYA class III 2.0 1.0 – 3.8 0.05 
 
Table 11.5. Univariate predictors of inappropriate shocks (Poisson regression 
models) 
Variable OR 95% CI P value 
Atrial fibrillation 3.5 1.5 – 8.2 0.004 
Supra ventricular 
tachycardia 
5.8 2.8 – 11.9 < 0.0001 
Non sustained VT 1.9 1.0 – 4.0 0.08 
NYHA 3 at 
implantation 
2.3 1.0 – 5.4 0.06 
BMI 0.9 0.86 – 0.99 0.03 
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11.5.2 Mortality 
Univariate associations for all-cause mortality are presented in Table 11.6. Increasing 
age, body mass index and QRS duration were associated with increased risk of death. 
Patients in paced rhythm, those with diabetes, anaemia, renal impairment, 
hyponatremia, hyperkalemia and patients with severe LVSD were more likely to die.  
Patients in sinus rhythm and those on beta blocker treatment were less likely to die. 
There was a significant relationship between death and appropriate shocks. NYHA class 
3 was again associated with adverse prognosis. In a multivariable model, adjusted for 
age, three variables were significantly associated with all-cause mortality. Two 
variables were associated with a favourable prognosis; sinus rhythm (OR 0.1; 95%CI 
0.1-0.6; p = 0.015) and beta blocker treatment (OR 0.1; 95%CI 0.1-0.6; p = 0.020). 
Patients who had renal impairment were more likely to die (OR 8.4; 95%CI 1.2-60.6; p 
= 0.034). 
11.6 DISCUSSION 
This study suggests that presence of non sustained arrhythmias, increased QRS 
duration and lower left ventricular ejection fraction increased the risk of having an 
appropriate shock. SVT and atrial fibrillation predicted the rate and number of 
inappropriate shocks.  Renal impairment increased the risk of all-cause mortality in 
patients who have received an ICD. ECG rhythm was a major factor affecting the 
outcome and beta blocker treatment was beneficial. 
Severe LV impairment and non sustained VT have previously been shown to be 
associated with higher risk of death in heart failure patients.[256-258] In the TOVA 
study, an EF < 20% was associated with higher risk of appropriate shocks (OR 3.9; 
95%CI 1.3 – 11.2).[258] 
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Table 11.6. Univariate predictors of mortality  
Variable OR 95% CI P value 
Age (years) 1.1 1.0 – 1.4 0.038 
BMI 1.1 1.0 – 1.1 0.025 
NYHA class III 2.7 1.1 – 6.5 0.031 
Diabetes 2.6 1.0 – 6.8 0.05 
Sinus rhythm 0.4 0.2 – 0.9 0.02 
Paced rhythm 3.0 1.2 – 7.1 0.015 
Filtered QRS on 
SAECG 
1.01 1.0 – 1.02 0.014 
Broad QRS (> 120 
ms) on 12 lead ECG 
2.4 1.0 – 6.0 0.049 
Severe LVSD 3.3 1.4 – 7.8 0.006 
Renal impairment 7.0 2.6 – 18.5 < 0.001 
Hyperkalaemia 2.8 1.1 – 7.4 0.036 
Hyponatraemia 4.1 1.3 – 12.7 0.015 
Anaemia 2.4 1.0 – 5.7 0.04 
Spironolactone 2.8 1.2 – 6.5 0.02 
Beta blocker  0.2 0.1 – 0.5 0.002 
Appropriate shocks 2.8 1.2 – 6.5 0.018 
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In this study NSVT was associated with higher risk of appropriate shocks and severe LV 
impairment was associated with death. However, NSVT did not predict death 
suggesting that ICDs do indeed manage this mortality risk factor effectively. This was 
also shown in the previous analysis of Holter monitoring in which NSVT predicted 
death but none of the ICD recipients died during the follow up period. 
QRS duration is a marker of cardiac dyssynchrony and in my study increased QRS 
duration was associated with worse prognosis. This supports the argument that 
patients with heart failure needing an ICD should be considered for more aggressive 
management with a CRT-D device, if they have a broad QRS duration since CRT has 
been shown to reduce mortality in patients with symptomatic heart failure and broad 
QRS duration.[52, 259] However, it should also be noted that those patients in paced 
rhythm did not do well. 
Atrial fibrillation and SVT were strong predictors of inappropriate shocks. As most of 
the ICDs were programmed to detect VT by rate algorithm, any supraventricular 
rhythm with a high rate above the VT threshold is likely to be misinterpreted by the 
device. Atrial fibrillation has been shown previously to be associated with an increased 
risk of mortality or appropriate device therapy and increased the risk of inappropriate 
device therapy by three fold.[260, 261]  
It is known that patients in NYHA class 3 are likely to get more shocks than those in 
NYHA class 2.[262] This study supports this observation as those in this group were at a 
significantly higher risk of death or experiencing a shock. It is also known that patients 
with NYHA class 4 are more likely to get appropriate shocks very soon after 
implant.[263] Some cardiologists believe that patients with severe heart failure should 
not have ICDs implanted as benefit vs risk ratio is likely to be small. But a recent 
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analysis of published literature has found no evidence for this argument, as no 
attenuation of benefit of ICD implantation was found in patients with higher NYHA 
class or lower LVEF.[264] This study also supports this observation as patients in NYHA 
class 3 had a higher incidence of death and appropriate shocks. Patients on 
spironolactone in this study were more likely to get an appropriate shock as 
spironolactone is usually prescribed for those patients in NYHA class 3 or worse 
symptoms. 
In the MADIT II study and SCD-HeFT, inappropriate shock occurrence was associated 
with increased probability of mortality in follow-up. Coupled with potential effects on 
quality of life, this association with increased mortality heightens the importance of 
efforts to reduce the occurrence of inappropriate shocks. The main strategy to avoid 
inappropriate shocks has been to implant a dual chamber ICD (DC-ICD), but the extent 
to which DC-ICD devices confer advantage is controversial. Some studies found no 
benefit whereas others have shown a modest reduction.[265, 266] In my study there 
was trend towards lower incidence of inappropriate shocks with DC-ICDs.  
Advanced age was a predictor of death as expected. This is an important observation 
as there are no clear criteria for ICD implantation in very elderly, since this group was 
excluded in trials. Despite this, approximately one fifth of devices are implanted in this 
age group. This was demonstrated in a recent multivariate analysis of data from a large 
registry of 26,887 patients (73% male with a median age of 70). The in-hospital 
mortality increased from 0.7% among patients younger than 80 years to 1.2% among 
those aged 80 to 85 years and 2.2% among those older than 85 years (P < .001).[267] 
Hence more studies should address the benefit of ICD in very elderly. 
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Higher body mass index was associated with increased risk of death in this study. In 
MADIT II, BMI > 30 was associated with increased risk for appropriate ICD therapy for 
VT, VF, or death.[268] In this trial obese patients who comprised 25% of the study 
population had appropriate ICD therapy in 39% as compared to 24% in non obese 
patients at 2 years of follow up.  However in some heart failure studies, increased BMI 
was in fact associated with better prognosis.[92, 170] This is thought to be a part of 
“reverse epidemiology” whereby traditional risk factors such as high blood pressure, 
high cholesterol and obesity are associated with a better survival in advanced HF. My 
findings are however in line with MADIT II analysis with regards to BMI. This may be 
due to a selection bias, as thin cachectic patients with advanced heart failure are less 
likely to have received an ICD on the basis that their prognosis is so poor that an ICD is 
unlikely to alter it favourably.  
Renal impairment has been consistently associated with adverse outcome in both 
acute and chronic heart failure. In this study population renal impairment was the 
strongest predictor of death. This questions the value of ICD implantation in those with 
established renal impairment, as ICD may not prevent premature death in this high risk 
population. 
Beta blocker therapy has been proven to be the most valuable pharmacological 
treatment along with ACE inhibitors in heart failure. Hence it is not surprising that it’s 
beneficial effects extend to those who have had ICD therapy. This also proves that 
pharmacological and device therapy in heart failure are complimentary to each other 
with incremental benefit. 
Over a quarter of all ICD recipients needed rehospitalisation following the implant for 
reasons including arrhythmias, inappropriate shocks and device related factors. This 
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highlights the significant morbidity associated with the device, the need for long term 
medical intervention and the associated cost. This situation is unlikely to change as 
evident from recent manufacturer recalls of defective ICD generator and leads. [269-
271] 
11.7 LIMITATIONS 
ICD therapies may not be a surrogate for sudden cardiac death, as many episodes may 
have been non-sustained non-fatal events. Hence all appropriate shocks might not be 
“necessary” shocks. This study population included patients from pre “Care-HF” period 
and hence had a low rate of BiV –ICD implants.  
11.8 CONCLUSIONS 
In summary, ICDs may prevent arrhythmic death by delivering appropriate shocks in a 
significant proportion of patients and the rest may be benefitting indirectly by the 
reassurance of having ICD protection. However, this comes with a price of significant 
adverse events and inappropriate shocks. Renal impairment is associated with a high 
risk of death in ICD recipients and beta blocker treatment favourably affects the 
outcome. 
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CHAPTER 12. ICDS FOR PRIMARY PREVENTION – FACTORS ASSOCIATED WITH 
SHOCKS AND MORTALITY IN CONTEMPORARY HEART FAILURE POPULATION. 
12.1 INTRODUCTION 
Increasing numbers of ICDs have been implanted over the last few years for primary 
prevention of sudden cardiac death in patients with heart failure after publication of 
MADIT II and SCD-HeFT trials. With increasing survival after myocardial infarction the 
population eligible for ICD for primary prevention is large.[272, 273]   With limited 
health resources, it is not possible for most economies to afford an ICD to everyone 
who is eligible based on these trial data. Currently less than 10% of eligible patients 
(based on trial data) receive an ICD in the USA.[274] Thus it is necessary to understand 
the factors which influence the clinical outcome after ICD implantation and establish 
that risk benefit ratio in these patients is favourable in order to justify the enormous 
cost involved. Hence I undertook this study examining those patients who have heart 
failure and received the ICD for primary prevention of sudden cardiac death. 
12.2 STUDY POPULATION 
Consecutive patients who had received an ICD for primary prevention indications in 
heart failure, at a large tertiary centre in the UK (Liverpool Heart and Chest Hospital, 
Liverpool) during 2007-2008.  
12.3 AIMS 
1.  To describe the incidence of shocks and mortality. 
2. To identify factors that predicted shocks and mortality. 
3. To describe the device related complications. 
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12.4 METHODS 
Approval for this study was obtained from the R&D department of the Liverpool Heart 
& Chest Hospital. Patients who had an ICD for primary prevention in heart failure 
during 2007 – 2008 were identified by the clinical audit department. I then retrieved 
the patients’ clinical records, ICD implantation details, follow up clinical and ICD 
interrogation data. Those who had a primary prevention ICD for non heart failure 
related indications such as channelopathies or adult congenital heart disease were 
excluded.  The vital status (alive or dead) was determined from the case records and 
this was cross checked with the patient administration system linked to national 
deaths database.  
Patients’ baseline clinical characteristics, NYHA functional status, left ventricular 
ejection fraction, details of medication, QRS duration on ECG, urea, creatinine and 
haemoglobin were recorded. The type of ICD, device complications and any system 
change during follow up were also recorded. The incidence of appropriate shocks and 
inappropriate shocks were obtained from the ICD follow up records. The prevalence of 
any non sustained arrhythmias detected during ICD interrogation was also recorded.  
12.5 RESULTS 
105 patients were enrolled in this study. All of them had objective evidence of left 
ventricular systolic dysfunction and had ICD implantation for primary prevention. The 
baseline clinical characteristics are given in table 12.1. More than 90% were men and 
88% were in NHYA class II/III. 75% had suffered previous myocardial infarction. 
Approximately one-fourth of them had diabetes. 94% of patients were treated with 
ACE inhibitors and 71% with beta blockers.  
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Biv-ICD was the most common type of device implanted (56%). 21 (20%) had a device 
related complication, 11 (10%) of which needed a reoperation (table 12.2). Others 
were managed conservatively (table 12.3).  Two patients needed a device 
enhancement at a later date (table 12.2). 
The median follow-up was 25 months (inter-quartile range 18 – 30 months). During 
this period 21 (20%) patients died, 6 (6%) patients experienced at least 1 appropriate 
shock and 7 (7%) experienced inappropriate shocks. The relation between ECG rhythm 
(prior to ICD implantation), beta blocker therapy and outcome is shown in table 12.4.   
There was a trend for better survival in patients who were in sinus rhythm when 
compared to those in atrial fibrillation, but this was not statistically significant (p = 
0.134). There was also trend for better survival in those on beta blocker therapy, again 
not statistically significant (p = 0.134). Patients with diabetes had a higher rate of 
death (26% vs 18%), but the difference was not statistically significant (p = 0.409). 
Only one patient experienced appropriate shocks on four occasions and another 
patient experienced three inappropriate shocks before death. The only variable 
associated with increased risk of death was elevated serum creatinine; > 127 μmol/l in 
men or > 107 μmol/l in women (OR 4.1; 95%CI 1.4 – 11.7; p=0.008). The relationship 
between serum creatinine level (in quartiles) and mortality is shown in table 12.5. 
Patients who had their creatinine in the lowest or highest quartiles had worse 
outcome than those who had creatinine in the mid two quartiles (figure 12.1). 
No specific variables predicting appropriate shocks were identified. The causes of 
inappropriate shocks were given in table 12.6. 
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Table 12.1 Baseline clinical characteristics (n = 105) 
Age (yr) 
Median 
Inter-quartile range 
 
68 
61 – 73 
Male Sex (%) 98 (93) 
NYHA (%) 
I 
II 
III 
IV 
 
9 (9) 
35 (33) 
58 (55) 
3 (3) 
Ischaemic Heart Disease (%) 
Previous MI 
86 (82) 
79 (75) 
Coronary revascularisation (%) 
PCI 
CABG 
Both PCI & CABG 
 
9 (9) 
43 (41) 
5 (5) 
Dilated cardiomyopathy (%) 12 (11) 
Hypertension (%) 50 (48) 
Diabetes (%) 23 (22) 
Smoking (%) 
Never smoked 
Ex smoker (> 12 m) 
Current 
 
17 (16) 
73 (70) 
9 (9) 
ECG Rhythm (%) 
Sinus 
Paced 
Atrial Fibrillation  
 
 
83 (79) 
 3(3) 
19 (18) 
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QRS duration (ms) 
Median 
Inter-quartile range 
 
136 
112 – 162 
Left ventricular ejection fraction (%) 
Median 
Inter-quartile range 
 
27 
20 – 30 
Renal Impairment (%) 
(serum creatinine of > 127 μmol/l in men or  
> 107 μmol/l in women)* 
22 (21) 
Anaemia (%) 
(Hb < 13 g/dl in men or Hb < 12 g/dl in women)* 
27 (26) 
Medication (%) 
Aspirin 
Clopidogrel 
Warfarin  
Beta blocker 
Amiodarone 
Digoxin  
ACEI /ARB 
Loop diuretic  
Spironolactone  
Statin    
 
52 (50) 
23 (22) 
47 (45) 
74 (71) 
25 (24) 
17 (16) 
99 (94) 
81 (77) 
49 (47) 
89 (85) 
Device Type (%) 
Single 
Dual chamber 
Bi ventricular 
 
26 (25) 
20 (19) 
59 (56) 
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Table 12.2 Details of reoperation after ICD implantation 
Intervention No 
Epicardial lead ( as unable to position a endocardial LV lead) 5 
Replacement of a faulty lead 1 
Replacement of a faulty generator 1 
Lead repositioning 4 
Upgrade to a BiV device 1 
Addition of SVC coil 1 
 
 
Table 12.3 Complications managed conservatively 
Complication No 
Severe anxiety 1 
Muscle twitching 1 
Wound sepsis 1 
Wound discharge 1 
Hematoma 1 
Chronic pain over the site 1 
RV lead malfunction (settings readjusted) 1 
Lead fracture (device switched off) 1 
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Table 12.4 Relation between ECG rhythm (prior to ICD implantation), beta blocker 
therapy and outcome 
 No BB BB SR AF Paced 
Alive 22 (71%) 62 (84%) 67 (81%) 14 (74%) 3 (100%) 
Dead 9 (29%) 12 (16%) 16 (19%) 5 (26%) 0 (0%) 
 
 
Table 12.5 Relation between creatinine level (in quartiles) and mortality 
Status 
Serum Creatinine (µmol/l) in quartiles  
Q1 
< 83 µmol/l 
Q2 
83.1 – 101.5 
µmol/l 
Q3 
101.6 – 119.5 
µmol/l 
Q4 
> 119.5 µmol/l 
Alive 20 (80%) 23 (92%) 23 (92%) 18 (72%) 
Dead 5 (20%) 2 (8%) 2 (8%) 7 (28%) 
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Figure 12.1 Kaplan – Meier survival plot showing the relation between serum 
creatinine and survival after ICD implantation. 
 
Table 12.6: Causes of inappropriate shocks 
Cause of inappropriate shock No 
Atrial Fibrillation 2 
Supra ventricular tachycardia 1 
Non sustained ventricular tachycardia 1 
“T” wave over sensing 2 
Lead fracture (sprint fidelis) 1 
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12.6 DISCUSSION 
This study was performed on contemporary patient population who were well treated 
with evidence proven therapies (ACE inhibitors and beta blockers). Despite ICD 
implantation a high annual rate of 10% death was observed and relatively few patients 
(6%) had a potentially life-saving defibrillation. This reiterates the fact that ICDs do not 
abolish the risk of premature death.  
One fifth of the patients had a device related complication of which half of them 
needed a second procedure. This indicates that there is significant peri-operative 
morbidity. The commonest technical problem was inability to position the LV lead 
during BiV-ICD implantation, thus needing an epicardial lead. This was mainly due to 
unfavourable coronary venous anatomy. 
This study shows that there is still a strong gender bias, as women get ICDs less 
frequently than men. However, women who do get an ICD may also gain less direct 
benefit from them. A meta-analysis by Santangeli et al showed that women enrolled in 
primary prevention ICD trials have the same mortality compared to men but 
experience significantly less appropriate ICD interventions.[275] 
Renal impairment was a strong predictor of death. This was consistent with the 
findings of the previous chapter in which the study was done mainly in patients who 
had ICDs for secondary prevention. It is interesting to note that patients who had the 
serum creatinine in the lowest and highest quartiles had higher risk of death. As serum 
creatinine correlates with the lean body mass, it is likely that patients who had a low 
body mass index had worse outcome due the “reverse epidemiology” phenomenon in 
heart failure, in which traditional risk factors of poor clinical outcome and mortality in 
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the general population such as obesity, hypercholesterolemia, and high values of blood 
pressure have been associated with greater survival.[92, 170]  
The association between renal impairment and poor outcome has been observed in 
many studies [67, 120]. The interaction between renal impairment and heart failure is 
complex.[276] Although there were earlier reports of benefit with adenosine receptor 
antagonists such as rolophylline in patients with heart failure and renal impairment, 
the PROTECT clinical trial failed to confirm this and there was no difference in death or 
readmission due to cardiovascular or renal causes at 60 days between rolophylline and 
placebo groups (31 vs 32%).[111] Hence the search for effective agents to treat 
patients hospitalised with heart failure and renal dysfunction is still ongoing.  
Until a proven therapy emerges, this observation of increased mortality with renal 
impairment in heart failure raises the question whether renal impairment should be a 
contraindication for ICD implantation, since the ICD is unlikely to alter the prognosis in 
these high risk patients. 
12.7 LIMITATIONS 
This was a retrospective study. The body mass index was not recorded and hence the 
relationship between serum creatinine and death could not be explained in full. 
12.8 CONCLUSIONS 
Patients who have received an ICD for primary prevention continue to experience high 
rates of mortality. Renal impairment is associated with poor outcome. 
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CHAPTER 13. IMPROVING PROGNOSIS IN HEART FAILURE – A REVIEW OF 
THE MULTI-DISCIPILINARY APPROACH TO REDUCE MORTALITY 
13.1 BACKGROUND 
 Heart failure is a common medical condition with high mortality. One third or more of 
patients with heart failure will die within 6 months of diagnosis and the annual 
mortality amongst 6 month-survivors is 10-15%.[7] Most patients with heart failure will 
die either suddenly or from progressive heart failure. However, not all sudden deaths 
in patients with left ventricular systolic dysfunction (LVSD) and heart failure are due to 
cardiac problems and a few will die from non cardiac causes. The causes of sudden 
death are varied and include ventricular arrhythmias, cerebro-vascular events, 
pulmonary embolism and ruptured aortic aneurysms. Aortic aneurysms are common in 
patients with heart failure and deep venous thrombosis is a common complication in 
hospitalised patients. Thus sudden death may be neither arrhythmic nor cardiac even 
in patients at risk of arrhythmias. 
13.2 POST-MORTEM STUDIES IN SUDDEN DEATH 
Studies of patients with LVSD either in the setting of chronic heart failure or after 
myocardial infarction suggest that many sudden deaths are associated with 
pathological evidence of acute coronary occlusion and/or myocardial infarction (Fig. 
13.1).[277, 278] A thorough post-mortem can exclude a pulmonary embolism, 
cerebrovascular accident and a ruptured aorta, but these do not seem common in 
clinical trials, although typically only 10–15% of deaths result in a post-mortem so 
there may be selective reporting. It is likely that many episodes of ventricular 
arrhythmias causing sudden death occur outside the setting of acute myocardial 
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infarction (scar related). Thus, it may not always be possible to establish an accurate 
cause in all cases. 
13.3 HOSPITALISED PATIENTS WITH ACUTE DECOMPENSATION OF HEART FAILURE 
The mortality in hospitalised patients with acute decompensation of heart failure is 
high in the short term, as demonstrated in the Euro Heart Failure survey, in which 13% 
died within 12 weeks of hospital admission.[120]  This is generally predictable, as most 
deaths in this group are likely to be due to progressive heart failure, rather than 
sudden and unexpected. The risk of dying from progressive heart failure is particularly 
high in the early period after diagnosis with over half of all progressive heart failure 
deaths in the first six months occurring within one month after diagnosis.[12] These 
patients are usually in NYHA class III or IV and hence at a higher risk of death due to 
progressive heart failure as demonstrated by the CONSENSUS-1 and RALES studies. 
[24, 25] Patients with advanced age, severe left ventricular impairment, renal 
impairment and those unable to tolerate optimal medical therapy are clearly at a very 
high risk of death.[120] 
13.4  MECHANISTIC APPROACHES TO THE PREVENTION OF COMMON CAUSES OF 
SUDDEN DEATH 
The most common causes of sudden death appear to be due to vascular events or 
arrhythmias. Both mechanisms of sudden death can be addressed. Vascular events 
might be prevented, either by stabilising plaque or preventing the propagation of 
occlusive thrombus, or the effects of the vascular event can be reduced.[279] 
Arrhythmias might be suppressed, their substrate may be corrected or they can be 
treated when they occur. It is unlikely that one strategy will be successful in all cases. 
The risks, benefits and, in the context of a public health service, the costs of each 
intervention needs to be weighed carefully. 
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Fig.13.1a Adjudicated causes of death in autopsied patients with a sudden mode of 
death (n=88) before and after autopsy was used to determine cause of death. [278] 
13.1b Relation of acute coronary findings to mode of death and presence of CAD is 
shown (168 patients). + Indicates presence of; –, absence of. CAD patients with sudden 
death had highest prevalence of acute coronary findings [14] 
 
(Reproduced with permission from Cleland J, et al[280]) 
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13.4.1 Reducing sudden vascular death 
ACE inhibitors, ARBs and beta-blockers are the mainstay of treatment for heart failure 
as they are proven therapies to prevent sudden death in heart failure. There is some 
evidence that intense statin therapy can cause plaque regression, as shown by the 
ASTEROID trial.[281] It is also possible that pharmacological therapy with these agents 
may prevent acute coronary events by altering plaque composition and reducing 
hemodynamic stress. 
The other approach to the reduction in sudden death is revascularisation. There is no 
convincing evidence that percutaneous coronary intervention can reduce the risk of 
sudden death.[282, 283] This may reflect the fact that percutaneous coronary 
intervention deals with tight coronary lesions which are responsible for angina but not 
for sudden death. There is little evidence that CABG reduces the risk of a myocardial 
infarction but it may reduce its extent.[284] However, there is no good evidence that 
CABG reduces the risk of death in patients with LVSD.[285] Both HEART and STITCH 
trials failed to show any evidence of benefit from revascularisation in patients with LV 
systolic dysfunction.[286-288] 
13.4.2 Reducing sudden arrhythmic death  
Trials of agents primarily to suppress arrhythmias have generally met with failure. 
[289, 290] However beta-blockers and ACE inhibitors may also be considered anti-
arrhythmic agents. These agents may reduce ventricular stress, protect from 
myocardial ischaemia, reduce general or episodic hypokalaemia, improve global 
ventricular function and reduce myocardial fibrosis. The same is also true of 
aldosterone antagonists. In addition beta blockers have direct anti-arrhythmic effects. 
The decline in the use of digoxin and its use in lower doses (when used) may also 
reduce arrhythmogenic substrate.[291] Indeed, aldosterone antagonists and beta-
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blockers appear to exert a greater reduction in mortality in the presence of 
digoxin.[292] 
13.4.3 Cardiac Resynchronisation therapy (CRT) 
Cardiac resynchronisation therapy reduces the risk of sudden death as demonstrated 
by the CARE-HF trial.[52] In this study, in patients with severe symptomatic HF from 
systolic dysfunction and left ventricular dyssynchrony in normal sinus rhythm, CRT 
decreased the incidence of both SCD and pump failure death.[293] The absolute 
percentage-point decrease in all-cause mortality for the CRT group was 7 at eight years 
of follow up. The predictors of SCD using multivariate analysis were limited to 
randomization to CRT and the severity of mitral regurgitation (MR) at 3 months. Thus 
by anatomical remodelling (thereby reducing the degree of MR) CRT could reduce the 
incidence of death. It has also been demonstrated that in CRT responders, anatomic 
remodelling leads to electrical remodelling resulting in significant reduction of 
premature ventricular beats and runs of non sustained ventricular tachycardia.[294] 
13.4.4 Implantable Cardioverter-Defibrillators (ICD) 
If there is reason to believe that the risk of sudden death remains high for an individual 
patient despite the above treatments, then consideration should be given to an 
implantable device that can treat the arrhythmia either using anti-tachycardia pacing 
or defibrillator therapy. Defibrillators are associated with substantial morbidity and are 
expensive. Current trials indicate that fewer than 10% of patients recommended for 
such treatment in existing guidelines will benefit from them directly (i.e. have their life 
saved) and a substantial proportion may be harmed (i.e. inappropriate shocks and 
worse heart failure). In addition, device discharge may not be an accurate surrogate 
for sudden death as randomised controlled trials suggest that the rate of sudden death 
in the control group of randomised trials may be much lower than the overall rate of 
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ICD device therapy. For instance, of the 720 patients with a defibrillator in MADIT-II, 
169 (23.5%) received device treatment that was considered appropriate by the 
investigator including 138 patients (19.2%) who received a shock. [252, 295] This 
compares with 48 (9.8%) sudden deaths in the control group. In addition, about one 
third of ICD therapies in this study were considered inappropriate, indicating that the 
total therapy delivered by an ICD may be five times higher than is strictly necessary. 
Also, in SCD-HeFT, 259 patients received a shock from their device, 177 of them 
considered appropriate.[60] However, there were only 244 deaths in the control group 
of which, based on contemporary trials, only 30% or about 80 should have been 
sudden. Hence, a shock, whether considered appropriate or not cannot be equated 
with sudden death. Also, it is likely that a proportion of these shocks were delivered to 
patients who were dying for other reasons. Clearly, ICDs are a blunt instrument and 
careful patient selection is required to ensure that the benefit of this therapy exceeds 
the potential for harm and that the cost of this relatively expensive treatment is 
justified. 
13.5 PREVENTION OF SUDDEN DEATH IN PATIENTS WITH ASYMPTOMATIC LVSD 
(ALSVD) 
Most patients who have substantial LVSD will not have symptoms or signs of heart 
failure and will be recognised as a consequence of assessing LV function in the 
aftermath of a myocardial infarction or in patients with angina. Accordingly, studies of 
post-infarction LV systolic dysfunction are highly relevant. Long-term follow-up 
indicates that these patients have an adverse prognosis. More patients die suddenly 
without developing heart failure than develop heart failure and then die.[292, 296] Of 
course, many of the patients who do develop heart failure will also die suddenly.  
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Adequate evidence that ACE inhibitors reduce mortality in patients with ALVSD is 
provided by the SOLVD prevention and SOLVD-extension reports.[297] This is made 
robust by the repeated ability of ACE inhibitors to reduce overall mortality and sudden 
death in post-infarction studies, studies of patients at high risk of vascular events or 
with heart failure.[298] There is reasonable evidence that these benefits can be 
achieved or are replicated by angiotensin receptor blockers (ARBs) although no 
adequate evidence of an additive effect of these agents on overall mortality or sudden 
death in this setting.[299, 300]  
 Clinical trials on beta blockers (BB) had included patients with very mild heart failure 
and there are many reports of the effects of BB on post-infarction LVSD.[301, 302] In a 
subgroup analysis of the asymptomatic patients from CAPRICORN trial, the use of 
carvedilol resulted in a risk reduction of 31% in all-cause mortality. These provide 
adequate evidence of a beneficial effect on re-infarction and mortality. It is likely that 
this reflects a reduction in sudden death.[303]  
The EPHESUS study provides evidence that the aldosterone receptor antagonist 
eplerenone reduces overall mortality and sudden death in patients with post-infarction 
LVSD.[18] There was 21 percent reduction in the rate of sudden death from cardiac 
causes in this trial. In addition, there was 15 percent reduction in the risk of 
hospitalization for heart failure and a 23 percent reduction in the number of episodes 
of hospitalization for heart failure. Most of these patients did not require long-term 
diuretic therapy and so the study may be considered predominantly one of 
asymptomatic LVSD post myocardial infarction.  
Studies of ICDs suggest that patients with asymptomatic LVSD obtain as great or 
greater benefit in relative terms than patients with heart failure.[252, 295] However, 
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the absolute risk and risk reductions have not been reported and therefore no clear 
recommendation can yet be made.  
The MADIT – CRT trial was published recently.[304] In this trial A total of 1,820 patients 
who were relatively asymptomatic (NYHA class I/II), were enrolled. The use of CRT-D 
was associated with a significant reduction (0.66; 95% CI, 0.52 to 0.84; P=0.001) in 
death or heart failure events when compared to traditional ICDs, during an average 
follow up of 2.4 years. The benefit was driven by a 41% reduction in the risk of heart-
failure events and the benefit of CRT was seen in both ischemic and non ischemic 
cardiomyopathy. The death rate was however very low in both groups (3%) suggesting 
that this trial was done in highly selected low risk patients. This trial has provided 
strong evidence for advocating CRT-D implantation in patients with reduced LVEF, 
wide QRS and minimal or no symptoms. This is reinforced by the recently published 
RAFT trial in which, patients in NYHA class II or III with a wide QRS complex, and left 
ventricular systolic dysfunction experienced reduced rates of death and hospitalization 
for heart failure with the addition of CRT to an ICD.[305]  
13.6 HEART FAILURE WITH A NORMAL LEFT VENTRICULAR EJECTION FRACTION 
Few studies have focussed on heart failure with a normal LV ejection fraction. Data 
from the CHARM study showed that overall mortality rate and the rate of sudden 
death are lower than in patients with LVSD.[299] The proportion of deaths that are 
cardiovascular is also lower than in patients with LVSD. However, the proportion of 
cardiovascular deaths that are sudden deaths is similar in patients with or without 
LVSD. 
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13.7 REDUCING MORTALITY IN HOSPITALISED PATIENTS WITH ACUTE 
DECOMPENSATED HEART FAILURE 
13.7.1 Medical therapy 
These patients are clearly at extremely high risk and hence should be targeted for 
intense medical management. Symptomatic benefit is derived from diuretics and 
vasodilator therapy along with agents such as dopamine which helps to relieve the 
fluid overload. Prognostic benefit is obtained by initiation or continuation of beta 
blockers and ACEI during hospitalisation. As shown by the Euro heart failure survey 
data, patients not on beta blocker or ACE inhibitor for whatever reason are at a very 
high risk of death. [120] 
Evidence for prognostic benefit from other medication such as antithrombotics and 
statin therapy had been conflicting and remains to be proven beyond doubt. 
Randomised trials of statin therapy in heart failure such as CORONA and GISSI-HF have 
been negative.[96, 97] However in a large registry of 54,960 Medicare beneficiaries 
who were hospitalised with a primary discharge diagnosis of heart failure, discharge 
statin therapy was associated with significant improvement in 1 year and 3 year 
mortality irrespective of cholesterol level or coronary artery disease status.[130] 
Close follow up of these patients after discharge by nurse led heart failure teams have 
been shown to be effective in reducing repeat hospitalisation episodes and improving 
the quality of life.[306-308] 
13.7.2 Other devices in heart failure management (excluding CRT/CRT-D) 
A small group of patients with acute decompensated heart failure may benefit from 
non-conventional device therapy. Left ventricular assist devices (LVAD) have been 
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shown to benefit patients in refractory heart failure, not only as bridge to cardiac 
transplant but also as destination therapy. In future, miniaturization, increased 
durability, and complete implantability may render LVADs an option in earlier stages of 
heart failure, as a bridge to myocardial recovery or even as an alternative to 
transplantation.[309] Implant-based monitoring of intra-thoracic impedance to detect 
fluid overload early before clinical symptoms, is undergoing clinical evaluation.[310] 
Left atrial pressure sensors and pulmonary artery pressure sensors have been shown 
feasible to predict decompensation in small pilot studies.[311, 312] They help to 
prevent hospitalisations by physician directed self management therapy, guided by the 
pressure measurements, as demonstrated by the HOMEOSTASIS study.[313]  However 
in the randomised COMPASS-HF trial, the implantable continuous hemodynamic 
monitor-guided care did not significantly reduce total heart failure related events 
compared with optimal medical management.[314] 
13.8 DEVELOPING THE MOST EFFECTIVE STRATEGY TO REDUCE MORTALITY 
Ultimately, a heart failure physician, leading a well-trained multi-disciplinary health-
care team including specially trained nurses, pharmacists, experts in rehabilitation and 
geriatric medicine as well as device-electro physiologists, interventional cardiologists 
and cardiac surgeons, is most likely to deliver the optimum care for patients. 
Investment in this strategy, which can best judge which of the many treatments for 
sudden death are used and when, is more likely to be effective and cost-effective than 
a blunderbuss approach in which no patient is allowed to die without treatment, 
whether or not it is effective. Further research is required to help ensure that patients 
get the treatment they need and avoid the treatment they don’t.  
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CHAPTER 14. CONCLUSIONS 
Heart failure is a common clinical condition encountered in every day clinical practice 
for physicians. It causes high mortality and morbidity. The mode of death can be 
sudden and unexpected or preceded by progressive deterioration of heart failure 
symptoms. Some of the contributing clinical factors can be modified and some may 
just be markers of high risk patients. If identified early, some of the high risk patients 
can be protected from death by appropriate medical therapy with or without device 
therapy such as ICDs. 
I have examined the data collected by the Euro Heart Failure Survey in patients 
hospitalised with or suspected heart failure to identify factors that predict short term 
mortality (within 12 weeks of hospital admission) using statistical models, as described 
in chapter 3. This analysis showed that advanced age, anemia, renal impairment, 
hyponatraemia, severe left ventricular impairment on echocardiography and the 
presence of atrial fibrillation were independently associated with an increased risk of 
death. Almost all of the standard medication used in these patients were 
independently associated with a better outcome. These included beta blocker, ACEI, 
ARB, calcium channel blockers, statins, warfarin and anti platelet therapy. However 
heparin and intravenous inotropes were associated with a worse outcome. I believe 
that this simply reflects the fact that patients on these medication were of high risk 
before the initiation of these medication due to acute coronary syndromes or 
cardiogenic shock. 
I have proposed a risk scoring system based on few simple variables from these data. 
These variables were age, degree of LV systolic dysfunction on echocardiography, 
presence of elevated creatinine and treatment with beta blockers and ACEI/ARB. This 
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risk scoring system was able to identify patients with a risk of death ranging from 2% 
to 44%. This was comparable to other published risk scoring systems based on EFFECT, 
ADHERE and OPTIME-HF models, which were reviewed in chapter 2.  
This risk score was validated in a contemporary in-patient population with heart failure 
in chapter 5. In this study, none of the patients with a risk score below 5 died. In 
patients with a risk score of > 5, there was almost a linear relation between increasing 
score and increasing risk of death. 
The relation between cholesterol and mortality in patients with heart failure was 
reviewed in detail. I have looked at the possible mechanisms explaining the so called 
“cholesterol paradox” – the association between low cholesterol and high mortality in 
heart failure. I have also reviewed the published literature with regard to the potential 
benefit of statin therapy in heart failure and the probable mechanisms. I found that 
although small non randomised studies have demonstrated benefit, the two large 
randomised trials (CORONA and GISSI-HF) failed to show any benefit of statin therapy 
in patients with heart failure. 
The relation between cholesterol and risk of death in patients enrolled on the Euro 
Heart Failure Survey was examined in detail in chapter 7. This showed the well known 
pattern of “reverse epidemiology” as low cholesterol level was associated with a 
higher risk of death. Statin therapy was associated with a better prognosis. However it 
should be noted that this has not been confirmed by randomised trials. 
Examination of the Euro Heart Failure Survey data has also revealed very interesting 
findings with regards to the utility of the simplest test in cardiology, the ECG, in 
predicting the presence and degree of LV systolic dysfunction. I found that QT interval 
in heart failure patients was prolonged and this was due to widening of QRS in interval. 
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The longer the QRS interval, the more likely that LV systolic dysfunction was present 
with a dose response effect. The patients with severe LVSD had longer QRS intervals 
than those with milder degree of LV systolic dysfunction. I also noted that patients on 
beta blockers tended to have shorter QRS intervals when compared with those with 
the same degree of LV systolic dysfunction but not on beta blocker therapy. The exact 
significance of this is not clear and merits further studies in the future. 
The utility of Signal Averaged ECG, a special ECG technique which removes 
interference on the standard ECGs to reveal late potentials was examined in patients 
with heart failure. Late potentials had been believed to markers of predisposition to 
sudden arrhythmic death. I found no association between presence of late potentials 
on SAECG and all cause mortality in patients with heart failure. However SAECG was 
useful in predicting the presence of LV systolic dysfunction, as increasing prevalence of 
late potentials was noted with increasing severity of LV systolic dysfunction. This 
finding was similar to the observation from my earlier analysis done on the ECG data 
from Euro Heart Failure survey. 
Holter monitoring is currently not routinely performed in all patients with chronic 
heart failure. I had assessed the utility of holter monitoring in a cohort of chronic heart 
failure patients attending a heart failure clinic. This showed that arrhythmias such as 
atrial fibrillation and non sustained ventricular tachycardia were very common, despite 
contemporary medical therapy and both were independently associated with a higher 
risk of mortality. Hence I believe holter monitoring should be considered as a routine 
investigation in all patients with heart failure to identify those at higher risk. 
Implantable Cardioverter Defibrillators (ICD) have been used widely to reduce death in 
patients with heart failure based on the evidence from large randomised trials. The 
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factors associated with death after ICD implantation in patients with heart failure were 
examined in two cohorts. The first cohort comprised those who mainly received an ICD 
for secondary prevention indications. In this group, approximately one fourth of 
patients derived explicit benefit and one third had some benefit but also experienced 
an adverse event. 43% had no explicit benefit. Patients with renal impairment had a 
higher risk of death whereas patients in sinus rhythm and those on beta blocker 
therapy had a lower risk of death. 
The second cohort comprised of ICD recipients for primary prevention in heart failure. 
The majority were men, indicating a strong gender bias.  Although this cohort was well 
treated by beta blockers and ACE inhibitors, there was a 10% annual risk of death and 
only 6% received a life saving defibrillation from the device during the 2 year follow up. 
One fifth of patients experienced a complication. As in the previous study group, 
presence of renal impairment was strongly associated with an increased risk of death. 
In summary, in this thesis, I have examined the various clinical factors which help to 
identify those patients with heart failure and at a higher risk of death. I believe that 
these analyses have provided some insights for better understanding of risk 
stratification in patients with heart failure and in those with Implantable Cardioverter 
Defibrillators. 
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